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Influenza A viruses (IAVs) cause occasional pandemics and seasonal epidemics,
thus presenting continuous challenges to public health. Vaccination is the primary
strategy for the prevention and control of influenza outbreaks. The antigenicity matched
high-yield seed strain is critical for the success of influenza vaccine. Currently, there are
several limitations for the influenza vaccine manufacture: 1) the conventional methods
for generating such strains are time consuming; 2) egg-based vaccines, the predominant
production platform, have several disadvantages including the emergence of viral
antigenic variants that can be induced during egg passage; 3) vaccine seed viruses often
do not grow efficiently in mammalian cell lines. Previous studies suggested that
mutations in the receptor binding site (RBS) that locates at the globular head of the HA1
can change IAVs’ binding specificity, antigenicity, and yield and thus RBS would be an
potential target for engineering vaccine seed strain. However, systematic analysis of the
mutations on RBS affecting those viral phenotypes is lacking. Specifically, this
dissertation has following aims: Firstly, we developed a novel method to rapidly generate
high-yield candidate vaccine strains by integrating error-prone PCR, site-directed

mutagenesis strategies, and reverse genetics. The error-prone PCR- based reverse genetic
system could also be applied to gain-of-function studies for influenza virus and other
pathogens; Secondly, in this dissertation, we identified an Y161F mutation in the
hemagglutinin (HA) that enhanced the infectivity and thermostability of virus without
changing its original antigenic properties which would prompted the development of cellbased vaccines; Thirdly, the molecular mechanisms underlying host adaption of equineorigin influenza A(H3N8) virus from horses to dogs are unknown. This dissertation
identified that a substitution of W222L in the HA of the equine-origin A(H3N8) virus
facilitated its host adaption to dogs. This mutation increased binding avidity of the virus
specifically to sialyl Lewis X motifs, which were found abundantly in the submucosal
glands of dog trachea but not in equine trachea. To summary, this dissertation
investigated the role of RBS in IAVs biology and expanded the current knowledge
toward IAV vaccine strain engineering, IAV host adaption and evolution.
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CHAPTER I

INTRODUCTION
Influenza Virus classification
Influenza causes substantial threats to human and animal health globally.
Influenza viruses, members of the Orthomyxoviridae family, are enveloped viruses with
segmented single-stranded negative-sense RNA genomes. Influenza viruses are
categorized into four known genera, namely A, B, C, and D, based on the antigenic
difference of the nucleoprotein (NP) and matrix protein (MP)(1). Influenza A and B
viruses are responsible for pandemic (type A), epidemic and seasonal outbreaks (type A
and B) in humans, whereas influenza C and recently discovered influenza D viruses do
not cause epidemic or pandemic outbreaks in humans (2).
In addition to humans, influenza A viruses (IAVs) can infect a wide range of
animals including birds (i.e. both domestic poultry and wild birds), pigs, horses, dogs,
and marine mammals (i.e. seals and whales). IAVs are classified based on the antigenic
properties of the surface glycoproteins hemagglutinin (HA) and neuraminidase (NA). To
date, there are 18 known HA subtypes (H1-H18) and 11 known NA subtypes (N1-N11)
(3). However, only H1N1, H3N2, and H2N2 subtypes have been reported to cause
pandemics (H1N1 for the 1918 and 2009 pandemics; H2N2 for the 1957 pandemic; and
H3N2 for the 1968 pandemic) or seasonal outbreaks in humans (4).
1

IAVs’ genome structure
The IAVs’ genomes consist of eight negative-sense, single-stranded RNA
segments with a total size of approximately 13,500 nucleotides (nt). The size of the
segments (1-8) varies between 890 nt and 2,341 nt. Segment 1, 4, 5 and 6 of IAV each
encodes one protein per segment: polymerase subunit 2 (PB2), hemagglutinin (HA),
nucleoprotein (NP), and NA, correspondingly. Segment 2 encodes the polymerase
subunit 1 (PB1). In some IAV strains, when the ribosomal scanning passes the main start
codon, the segment 2 also encodes PB1-F2, an 87- amino acid protein with apoptotic
activity (5), and PB1-N40, an N-terminal 39 amino acid truncated form of PBS with
unknown function (6). The regulation of the translation initiation of PB1-F2 and PB1N40 may be due to the interaction with the ribosome using the pseudoknot at nucleotides
65-126 in segment 2 of IAV (7). Segment 3 encodes the polymerase acidic (PA) subunit
and PA-X, proteins made by a ribosomal frame shifting of PA to modulate the virulence
of IAV(8). Newly identified N-truncated proteins of PA, PA-N155 and PA-N182, that are
translated from the 11th and 13th in-frame AUG of PA were found universally expressed
among IAVs (9). Compared to that with truncated PAs, the virus lacking truncated PAs
shows an impaired replication efficiency in Madin-Darby canine kidney (MDCK) cells
and have lower pathogenicity in mice; however, the detailed function of those PAs in the
IAV life cycle remains unknown. The segment 7 of IAV encodes the matrix 1 (M1)
protein and the matrix 2 (M2) iron channel through RNA alternative splicing (10).
Segment 8 encodes the interferon antagonist protein NS1 and the NS2 through mRNA
splicing (11, 12).
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IAV virion structures
IAVs have a lipid bilayer envelope and could exhibit a spherically morphology on
the order of 80-120 nm in diameter or a filament morphology with a length over 1 µm
under electron microscopy (13). The outer layer lipid envelope of an IAV is spiked with
HA and NA proteins in a ratio of approximately four to one, and a small number of M2
proteins serving as ion channels (14). M1 proteins play an important role in determining
the filamentous or spherical morphology of influenza viruses (15-17). It has been
suggested that the increased levels of influenza virus production by spherical strains
increase the efficiency of influenza virus transmission (18). The inner layer of the lipid
envelope is attached with matrix 1 (M1) protein, which is associated with the nuclear
export protein 2 (NEP or NS2) and the ribonucleoprotein (RNP) complex and is
responsible for the association of the RNP complex with the inner layer of the envelope.
Each IAV virion has eight well-organized ribonucleoprotein (RNP) complexes, each
consisting of one of the eight negative sense RNA segments wrapped on the
nucleoprotein (NP) and RNA-dependent RNA polymerases, which contains two
polymerase basic (PB2 and PB1) and a polymerase acidic (PA) subunits. The nuclear
export protein 1 (NS1) and NS2 are encoded from the same RNA through alternative
splicing in the infected cells. NS1 functions to inhibit the 3′-end processing of host premRNAs (19) and NS2 functions in maintaining the attachment of the RNP complex
with the inner layer of the envelope.
Biology of HA
HA plays an important role in the IAV life cycle. Two key functions of HA are
the attachment of virus to host receptors and membrane fusion during virus entry. In
3

addition, HA is one of the major viral antigens and thus a major target for host
neutralizing antibodies induced by infection and vaccination.
HA is a surface glycoprotein that presents as a trimer with three identical
monomers spiked on the virus membrane. The precursor protein (HA0) undergoes signal
peptide cleavage and N-link glycosylation, which result in a monomer with about 549
amino acid residues and a molecular mass of approximately 60 KDa (20). Each HA
monomer consists of two polypeptides, HA1 contains the receptor binding domain and
the major antigenic sites, and HA2 contains the membrane-proximal stem and fusion
peptide, which are cleaved by host cellular proteases. The cleavage of the HA precursor
is important for the virus infectivity (20). The seasonal IAV and low pathogenic avian
influenza A virus (LPAIV) usually have a mono-basic cleavage sites (e.g.
PEKQTR/GLF), and their HA proteins are cleaved by a few cellular trypsin-like
proteases, which are usually produced in the intestinal and the respiratory systems. In
contrast, the highly pathogenic avian influenza A virus (HPAIV) typically has a stretch of
basic amino acids at the cleavage site (e.g. PQRESRRKK/GLF), which can be cleaved by
common cellular proteases such as ubiquitous furin and PC6 (21). This is one of the
reasons why, compared with the LPAV, the HPAIV has the potential to infect multiple
tissues in the body and therefore causes systemic rather than localized infections.
The initial step of IAV infection is the binding of the HA to the sialylated glycan
receptors on host cells. The receptor binding site (RBS) located at the hypervariable
globular head of the HA is responsible for interaction with the glycan receptors. Each HA
monomer contains a RBS which forms a shallow pocket at the top of the globular head
and consists of 130-loop, a 150-loop, a 190 helix, and a 220-loop.
4

Receptors for IAV
Glycans expressed on the surface of mammalian cells play important roles in
many biological processes which include serving as recognition binding targets for a
variety of viruses, bacteria and parasites (22). Sialic acids (sias) (Figure 1), derivatives of
neuraminic acid with a nine-carbon sugar backbone, were first discovered by Gunnar
Blix (23) and then found wildly distributed on mammalian tissues in glycoproteins and
gangliosides. Sias usually occupy the terminus of glycoproteins and glycolipids as
components of oligosaccharide in the mucins. The agglutination of erythrocytes by IAV
was first reported when the erythrocytes were agglutinated in the allantoic fluid of the
infected chicken embryos (24). The receptors for the influenza viruses were found to be
sias when using erythrocytes treated with Vibrio cholerae neuraminidase (VCNA) (25).
Later, it was found that the linkage of sias to galactose and the types of sias were key
determinates for host range of IAVs (26, 27); the avian IAV prefers sias that are linked to
galactose in an α2,3 linkage (SAα2,3 Gal ) whereas the human IAV prefers sias that are
linked to galactose in a α2,6 linkage (SAα2,6 Gal ) (27, 28) (also see the section
glycosidic linkages).
Compared to wild-type Chinese hamster ovary (CHO) cells, the IAV infection of
N-linked glycoprotein deficient CHO cells was reduced, suggesting the importance of Nglycans for the entry of IAV (29). On the other hand, it was found that the N-linked
sialosides are not required for the entry of IAV since the IAV can infect CHO cells with
immature glycans that cannot be sialylated (30). It was reported that the H3N2 IAV could
infect a glycosphingolipid-deficient mouse skin fibroblast mutant cell line, suggesting
that gangliosides are not essential for the IAV entry and infection (31). The glycosylated
5

H1N1 viruses could infect sialic acid-deficient Lec2 Chinese hamster ovary cells that
express human C-type lectins, while the PR8 H1N1 strain which bears low levels of
mannose showed insufficient infection. Taken together, those studies suggest that IAV
entry and attachment can occur in a sialic acid-independent manner and the host cell
surface lectins may serve as a target for IAV. Nevertheless, the specific roles of the Nglycans and O-glycans in the process of virus-cell attachment and entry remain largely
unknown.
The following sections will discuss the terminal structures, linkage, and
substructures of sias and the roles of the structurally different sias in influenza virus
infection.
Neu5Ac and Neu5Gc
N-acetylneuraminic acid (Neu5Ac) and N-glycolylneuraminic acid (Neu5Gc) that
have modifications at the 5-carbon position are two of the most commonly found types of
sias on the mammalian cells. Neu5Ac was shown to be a common receptor for IAV
isolates from human, avian, and mammals (32). Neu5Gc has been reported to be present
in horses (26), dogs (33), pigs (34), and mice (35), but not in humans (36, 37). The loss of
Neu5Gc in humans was due to an inactivating mutation on the CMAH gene encoding the
cytidine monophosphate-N-acetylneuraminic acid hydroxylase (CMAH), which converts
Neu5Ac to Neu5Gc (38). The 92 bp deletion mutation in exon 6 of the CMAH gene,
which causes the loss of Neu5Gc and excess of Neu5Ac, was estimated to to have
happened in hominids about 2.9 million years ago (39). The loss of Neu5Gc in humans
may help explain the susceptibility or resistance of humans to certain pathogens including
influenza viruses (40). Similarly, the ferrets have been shown to lack Neu5Gc due to an
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ancient mutation in the CMAH gene shared by several members in the order of carnivora
(41). High-performance liquid chromatography, and mass spectrometry analysis of
chicken tissues suggested that chickens cannot synthesize Neu5Gc whereas the small
amount of Neu5Gc detected in eggs may come from the diet (42). Another report
suggested a low level of Neu5Gc detected in both trachea and intestines of chickens and
pigeons by high-performance liquid chromatography (43); however, the Neu5Gc glycan
could not be detected in chicken trachea by histological immunostaining (26). It is likely
that these conflicting observations on the level of Neu5Gc could be affected by the
sensitivity of the detection methods used in the experiments.
It has been suggested that Neu5Gc plays an important role in the infection of
equine origin H7N7 viruses and duck origin H3N2 viruses (44, 45). Takahashi et al (45)
showed that expression of Neu5Gc on human epithelial cancer cells reduced the
infectivity of IAV with Neu5Gc binding ability, suggesting that Neu5Gc may work as a
decoy receptor but not a functional receptor for IAV. Yang et al (33) reported that
Neu5Gc was detected in canine trachea tissues but not in chicken trachea tissues,
suggesting that the Neu5Gc may play an important role in the interspecies transmission
of avian-like H3N2 IAV from avian to canine species. Despite of these reports, the
functions of Neu5Gc as a receptor for IAV and the effects of Neu5Gc on IAV tissue and
host tropisms are not fully understood.
Other modified forms of sias
In addition to Neu5Ac and Neu5Gc, the primary Sia forms can be modified in the
Golgi and generate more than 30 variant types of sia, and those modifications include
addition of acetyl, sulfate, lactoyl, or methyl groups at different positions (46, 47). For
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example, various forms of sias with acetyl groups O-linked to carbon 4, 7, 8, or 9 were
found to differ in expression among tissues and hosts (48-50).
Influenza C virus was reported to recognize 9-O-acetylated sialic acid as a
receptor for cell attachment and entry (51). A more recent study showed that 9-Oacetylated sialic acid also serves as the receptor for influenza D viruses (52).
Glycosidic linkages
Although IAVs recognize the terminal sias as their receptor for the viral entry, the
binding specificity of IAV was found closely related to the linkage that connects the sias
with the other structure of the receptor. A number of studies have suggested that human
adapted IAV prefers SAα2,6 Gal, whereas the avian IAV prefers SAα2,3 Gal(28, 53, 54).
The discovery of the preference to α-2,3 or α-2,6 linkage was established through
the hemagglutination assays of human and animal IAVs of different host origin to
enzymatically modified erythrocytes (28). The proportion of the α-2,3 to the α-2,6
linkage of the erythrocytes varies depending on their source species and this determines
the phenotypes in the hemagglutination. The chicken erythrocytes contain a roughly an
equal number ratio of SAα2,6 Gal to SAα2,3 Gal (55), whereas the turkey and guinea pig
erythrocytes contain more SAα2,6Gal than SAα2,3Gal (56, 57). Horse erythrocytes
predominately contain SAα2,3 Gal, which makes it an ideal choice for the
hemagglutination inhibition (HAI) assay with H5 strains (26, 56).
In addition to the variations in erythrocytes from different hosts, the distribution
of α-2,3 and α-2,6 sias also varies among tissues and among hosts. By lectin staining, the
human upper respiratory track epithelium cells primarily express α-2,6 sialylated
glycans, whereas the lower respiratory track epithelium cells express both α-2,6 and α8

2,3 sialylated glycans (53, 54, 58). In contrast, duck intestines express predominantly α2,3 sialylated glycans whereas pig respiratory tract express both α2-6 and α2-3
sialylated glycans, and therefore pigs are hypothesized to be a “mixing vessel” for
human and avian IAVs (59, 60). However, it was also demonstrated that chicken and
quail intestines express both α2-3 sialylated glycans and α2-6 sialylated glycans (61).
With the development of glycomics, a wide spectrum of both α2-3 sialylated glycans
and α2-6 sialylated glycans were found on human lung, bronchus and nasopharynx by
mass spectrometry in a recent study (62). Similarly, the respiratory tissue of ferret was
found to heterogeneously expressing both α2-3 sialylated glycans and α2-6 sialylated
glycans by lectin staining and mass spectrometric analysis (63). These recent findings
suggests that the cell and tissue tropisms of IAV cannot be determined by
glycosidic linkage alone.
Substructures affect viral receptor binding
As described above, increasing evidence has shown that the binding specificity of
IAVs is more complex than the glycosidic linkages. IAVs may use a wide range of sias to
infect host cells. Modifications such as acylation, methylation, sulfation, fucosylation,
and phosphorylation can occur at different locations within the backbone structure and
thus may alter its biological functions, including the receptor for IAVs (64). In 1997,
Gambaryan et al (27) reported that the non-egg adapted human H1, H3 subtype IAV and
influenza B virus had strong binding affinity to Neu5Acα2-6Galβ1-4GlcNAc (6′SLN) but
not Neu5Acα2-6Galβ1-4Glc (6′SLN). Later, Gambaryan et al showed that duck IAVs
prefer receptors which possess a β, 1–3 linkage rather than a β, 1–4 linkage between
Neu5Acα2-3Gal-disaccharide and penultimate N-acetylhexosamine residue (GlcNAc)
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(65). Furthermore, the fucosylation and sulfation of GlcNAc had negative and low effect,
respectively, on its affinity to duck IAVs (65). Similar binding patterns were also
observed in H1, H2, H3, H4, and H11 HAs from duck IAVs(44). In contrast, gull IAVs
preferentially bind to the α, 2-3 sialic acid receptors with a fucosylated GlcNAc whereas
the chicken and mammalian IAVs preferentially bind to the SAα2,3 Gal receptors with a
sulfo group at position 6 of GlcNAc via a β, 1–4 linkage (65). Gambaryan et al (66)
reported that the H5, H6, H7, and H9 subtypes of IAVs from terrestrial poultry differ
from ancestral duck viruses by enhanced binding to fucosylated and/or SAα2,3 Gal
terminated receptors, suggesting that the 6-sulfo sialyl Lewis X is the common receptor
recognized by those IAVs from terrestrial poultry. Those studies suggested the
substructures of sialic acid terminated receptors play important roles in the receptor
binding specificity of IAVs.
Fucosylation is one of the most common modifications to N-glycans, O-glycans,
and glycolipids. Unlike duck IAVs, chicken H5N2 IAV was found preferentially to bind
to fucosylated SAα2,3Gal receptors, which were detected on the epithelial cells of
chicken trachea but absent from duck colon (67). This observation helps to explain why
chickens were not experimentally infected with viruses isolated from ducks. The equine
H3N8 IAVs were also reported to preferentially bind to Neu5Acα2-3Galβ1-4 (6-OHSO3) GlcNAcβ (Su-3′SLN) and Neu5Acα2-3Galβ1-4 (Fucα1-3)(6-O-HSO3)GlcNAcβ
(Su-SLex), suggesting equine H3N8 IAVs may originate from terrestrial poultry.
Residues at positions 222 and 227 were identified to be associated with the differences of
H5 avain IAVs binding to fucosylated α2, 3 sialic acid receptors (68). Although the HA
of duck H5N2 IAV preferentially bind to non-fucosylated SAα2,3 Gal receptors, the
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virions were able to bind to both non-fucosylated and fucosylated receptors through the
NA (68). Taken together, the glycan receptors for IAVs are far more complex than the α,
2-3 and α, 2-6 linkages and the role of substructures of sialic acid receptors for IAVs host
and tissue tropism is underrated.
Structure basis for binding specificity
The switch of their binding specificity from avian-like (SAα2,3 Gal) to humanlike (SAα2,6Gal) receptors for avian IAVs was considered to be associated with the
adaption of IAVs from avian to humans. The SAα2,3 Gal linkage has limited
conformational flexibility and forms a cone-like topology (58). Conversely, the presence
of C6-C5 bond provides additional conformational flexibility to SAα2,6 Gal linkage and
enables it to adopt an umbrella-like topology (58).
The RBS of IAV consists of four structural features, 130 loop, 150 loop, 190
helix, 220 loop, and the conserved amino acids at positions 98, 153, 183, and 195 form a
hydrogen-bonded network that serves as the basis of the binding pocket (69, 70).
The residues at positions 135, 136, 137, and 145 form major interactions with the
sias moiety of the Neu5Acα2-3Gal linkage receptors. In contrast, the residue at positions
137, 145, 190, 226, and 228 forms the predominant interactions with the sias moiety of
Neu5Acα2-6 Gal linkage receptors (58, 71).
Subtle changes of residues in the 220 loop affect the virus interactions to IAV
receptors with different glycosidic linkages. For example, the avian IAVs possess Q226
preferentially binding to SAα2,3 Gal whereas human IAVs possess L226 with referential
binding to SAα2,6 Gal receptors. The Q226 would not interact with the SAα2,6 Gal,
whereas L226 allows to wide the site and forms a hydrogen bond with the α2-6 linked
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sias (72-74). Similarly, a G225D mutation can completely switch binding specificity of
an avian H6N1 virus from SAα2,3 Gal to SAα2,6Gal (75). Residues at position 186, 187,
190, 193, and 226 were shown to interact with the Gal linked to sialic acid via a α2-3
linkage, whereas residues at position 190, 222, 225, and 226 were shown to interact with
the Gal linked to sias via a α2-6 linkage (58).
The residues at the 190 helix of the RBS can also affect the glycan binding
specificity of IAVs. For example, the pandemic strain A/New York/1/1918 differs from
the consensus avian H1N1 virus sequence by a E190D, which enables the virus to bind to
both SAα2,3 Gal and SAα2,6Gal glycans (76, 77). Recently, de Vries et al (78) reported
that three mutations (V186K/G, K193T, and G228S) switch binding preference of H7N9
IAV from avian like SAα2,3 Gal to human like SAα2,6Gal. A number of other amino
acid residues such as 189, 194, 198, 211, 216, and 222 may also affect the architecture of
the receptor-binding site and change the virus binding specificity and intensity to
sialylated glycans (79-81).
NA and viral glycan binding
The NA polypeptide chain comprises 470 amino acid residues and consists of
cytoplasmic, transmembrane, and stem domains. The NA of IAV belongs to the exosialidase family and cleaves the α-ketosidic linkage between synthetic substrates and the
terminal sialic acid residues in oligosaccharides, glycoproteins, glycolipids, or colominic
acids (82). The NA of IAV resembles a mushroom shape on the virion surface, with a
molecular mass of 60 KDa for the monomer and 240 KDa for the tetramer (82). NA is
indicated to be relevant in several stages during the IAV life cycle. First, NA helps the
attachment of the virus to airway epithelium by cleaving sias from respiratory tract
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mucins (83); second, NA plays an important role in the fusion of viral and cell
membranes as the HA and NA activity needs to be balanced to allow effective infection
(84, 85); third, NA promotes the budding of newly formed virions by cleaving sias from
cell surfaces and thus preventing their aggregation (84).
Although the functions of two surface glycoproteins HA and NA are to some
extent contradictory, sialic acid binding activity was also reported for the NA protein.
Laver et al (86) first reported that the NA of subtype N9 subtype of NA has
hemagglutination activity and antibody to either HA or NA alone was incapable of
inhibiting hemagglutination by the virus. Later, Webster et al (87) suggested that the
hemagglutinin activity of N9 was associated with a second Neu5Ac binding site away
from the catalytic site. Exchange of amino acids in the loops at positions 368-370 and
positions 399-403 of N9 into those corresponding positions at the N2 by site-directed
mutagenesis made N2 acquire the hemagglutination activity as shown by N9 (88).
Furthermore, it was suggested that the haemadsorbing of N9 is not sensitive to the
neuraminidase activity of N9 because the erythrocytes agglutinated by N9 cannot be
released by N9 neuraminidase activity (89). Similarly, N1 of A/FPV/Rostock/34 virus
(H7N1) expressed in SF9 cells showed hemadsorption activity cannot be blocked by 2deoxy-2,3-dehydro-N-acetylneuraminic acid, suggested that the N1 has a receptor
binding site distinct from the catalytic site (90). The haemagglutinating activity of N1
was abolished when the amino acids on the two loops at putative binding sites were
exchanged (90). However, the attempts to resolve the sialic acid binding site by X-ray
diffraction were not successful until 1997, when Varghese et al (91) resolved the X-ray
structure of a complex of N9 from A/tern/Australia/G70C/75 with Neu5Ac and found the
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Neu5Ac binds to N9 in the chair conformation and the residues that interact with the N9
second binding site were the most conserved among all avian strains, but not in humans
and swine strains.
Mutations near the active site can change the binding property of NA to sialic acid
receptors. Lin et al (92) reported that human H3N2 isolates circulating between 2005 to
2009 has a D151G substitution, which enables the viruses to agglutinate erythrocytes in
an oseltamivir-sensitive manner. The D151G mutation of human H3N2 viruses was later
found to enabled NA binding to both 3′ sialyllactosamine (3’SLN) and 6′
sialyllactosamine (6’SLN), with even higher affinities than the corresponding affinities of
HA to those sialosides (93). The introduction of the D151G mutation into both N1 and
N2 reduced the neuraminidase activity and enabled preferential binding to α, 2-3 sialic
acid receptors (93). Gulati et al (94) reported that the N2 of human H3N2 viruses isolated
in 2006, 2010 and 2012 could bind to SAα2,3Gal receptors. Moreover, the entry of
human H3N2 viruses isolated in 2010 and 2012 into Madin-Darby canine kidney cells
was inhibited by oseltamivir (94). Interestingly, a G147R mutation in N1 enables a HA
binding-deficient mutant to use N1 as the receptor binding protein (95). The G147R
mutation of N1 occurs at low frequencies in human pandemic and seasonal H1N1 strains
and this mutation did not impair the replicative capacity of virus in cell culture or mice
(96). Recently, Donald et al (97) reported that the N9 of human H7N9 virus has an active
haemadsorption site and can bind to sialic acid receptors, particularly human-like α
SAα2,6Gal receptors, which enhanced the overall binding affinities of human H7N9
viruses to human-like receptors. Those studies suggested that NA could play important
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roles in the virus attachment, entry, and evolution. However, the receptor binding
function of NA in IAV biology is underrated and needs further research.
Knowledge Gaps
NA as a receptor binding protein
It is widely accepted that the functions of two surface glycoproteins HA and NA
are to some extent contradictory: HA interacts with sialic acid receptors on host cells and
mediates the virus attachment and entry whereas NA cleaves the α-ketosidic linkage
between the terminal sialic acid residues and the remaining substructures. However, as
aforementioned, increasing evidence suggest that NAs, especially N1, N2 and N9, have a
receptor binding site distinct from or close to the catalytic site. Furthermore, the NA may
even have higher affinity to sias than HA, and thus could broaden the spectrum of
receptors that virus can bind to. Outstanding questions remain: 1) What is the role of NA
in the attachment and entry of IAVs? 2) What are the physical interactions between HA
and NA on the virion surface? 3) How do IAVs preserve a functional balance of HA and
NA activities and maintain a good fitness during virus evolution?
Quantification of the binding affinities between virus and glycans
Currently, the conventionally used methods to characterize the receptor binding
properties of HA/NA proteins of IAV include: agglutination of erythrocytes modified
with desialylation and resialylation (98), solid-phase enzyme-linked assays (99), glycan
microarray (100, 101), and bio-layer interferometry (102, 103). The erythrocytes are
modified by desialylation and resialylation to express a specific glycosidic linkage and
then tested with their agglutinations with viruses. For the solid-phase enzyme-linked
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assays, biotinylated glycans are adsorbed on solid-phase ELISA plates coated with
streptavidin and then viruses incubated on plates followed by detection with specific
antibodies. The bio-layer interferometry uses streptavidin sensors to capture the
biotinylated glycans followed by the binding to virus. Then the interference patterns of
the sensor surfaces are recorded in real time. The glycan microarrays that have large
number of synthetic sialosides printed onto NHS-coated glass slides were demonstrated
to be useful in characterizing binding specificity and intensity of either proteins or whole
virus particles to a large set of glycans.
However, the methodologies described above have obvious drawbacks (Table 1),
which limit their applications in global influenza surveillance. For example, the
erythrocytes agglutination assay cannot detect the binding specificity beyond the
glycosidic linkages and the substantial variability is observed among batches of RBS.
The solid-phase enzyme-linked assays and bio-layer interferometry cannot detect the
binding properties of viruses in a high-throughput manner. Moreover, the glycan
microarray and bio-layer interferometry require the purification of viruses, which is
considerably time-consuming, and therefore not suitable for use in large-scale screening.
The propagation of viruses in eggs or on cells during virus purification may introduce
mutations on the receptor binding site, leading to different results compared to the
clinical isolates. Lastly, the glycan analogues used in those arrays are not similar to those
presented on the epithelium of the respiratory tract. A high-throughput method for largescale analysis of the binding properties of IAV, which would be cost effective, simple,
highly sensitive, label free and without the need for virus purification, is needed for the
global influenza surveillance.
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Predicting the binding properties of IAV
Computational models for quantifying antigenic distance of IAV and thus for
improving influenza vaccine design have been reported by several groups (104-108). A
computational model for predicting the binding specificity and intensity of IAV will
assist in vaccine strain selection and global influenza surveillance. Studies have reported
the calculation of HA-receptor binding by integrating molecular modeling, free energy
simulation, ab initio fragment molecular orbital, and molecular dynamics (109-115).
However, those studies lack a systematic evaluation and also neglected the role of NA in
the binding properties of IAV. Moreover, it has been difficult to assess the effect of
hallmark residues on the binding properties of circulating IAVs (116). In summary, there
is an urgent need to develop an effective nucleic acid sequence-based and robust
computational prediction models for quantifying IAV binding specificity and intensity to
sialic acid receptors.
Substructures of sialic acid receptors affect tissue and host tropism
As mentioned above, the substructures of sialic acid receptors such as the linkages
between Neu5Acα2-3Gal-disaccharide and GlcNAc, and the fucosylation and sulfation
of GlcNAc affect virus binding properties as well as tissue and host tropism.
Modification of GlcNAc is always observed in O-glycans. The receptors for human IAV
in ferrets were reported to be O-linked sialylated glycans, which are predominantly
distributed in the submucosal glands. The infection of such cells facilitates the efficient
airborne transmission of virus by easily making the virus encapsulated into respiratory
droplets (117). Entry of the SAα2,3Gal binding preference IAV was reported to require
host fibronectin, suggesting that host proteins may also be involved in the receptor
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binding process of IAV, which remains largely unknown. Outstanding questions are: 1)
What is the distribution and intensity of modified sialic acid receptors among tissues and
among hosts? 2) What is the role of those substructures in the adaption and host switch of
IAVs? 3) What is the role of O-glycans in the IAV attachment and entry? 4) Besides Nglycan and O-glycan, what other kinds of host proteins are involved in the binding of
IAV to host receptors and how are they regulated?
Objectives of this Dissertation
The hemagglutinin of IAVs binding to host carbohydrate receptors is one of the
key determinants for viral host tropism. The residues forming the receptor-binding
pockets of the hemagglutinin are known to affect the receptor binding affinity and
subsequently the replication ability and transmissibility of IAV. However, most reports
have been focusing on individual receptor binding sites (i.e. residues 226 and 228) and
their impacts on two types of sialic acid receptors (i.e. avian-like receptor α 2,3-linked
sialic acid (SAα2,3Gal) and human-like receptor α 2,6-linked sialic acid (SAα2,6Gal).
There is lack of a systematic characterization of residues, especially, the synergetic
effects of these residues on receptor binding and specificity. This project proposes to
identify the mutations across the receptor binding pockets affecting receptor binding
properties by developing and applying a novel and high-throughput error-prone PCR
(epPCR)-based reverse genetic system, and to quantify and predict the receptor binding
avidity and replication ability in target cells using machine learning. The construction of
the computational model would link the virus genotype with the phenotypes such as
receptor binding and replication properties. The computational model would help to
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speed up the vaccine seed strain selection, field strain surveillance and to expand our
knowledge on natural history of IAV across hosts.
We hypothesize that 1) In vitro breeding of a diverse influenza virus variant
library by epPCR would enhance the process for generating high-yield strains; 2)
Mutations in the receptor binding sites of IAV would change the binding and replication
properties of the virus. With the use of epPCR-based reverse genetic system that we
developed, we can generate a large scale of receptor binding site mutants, from which the
high yield mutants would be selected; 3) The mutations in the HA proteins of equine
H3N8 IAV affect viral binding properties and are important in adapting virus from horse
to dogs, and dogs would have a unique set of glycan receptors determining canine
influenza virus’ host tropism; 4) Mutations in the receptor binding sites of IAV
hemagglutinin would affect the influenza vaccine-associated characteristics such as
receptor binding properties, replication, and antigenicity of the virus. There would be
specific sub-regions in the receptor binding pockets of IAV hemagglutinin determining 1)
virus binding to specific glycan receptors; 2) virus replication ability in hosts; 3) virus
antigenicity, and these regions may not be same.
The objectives of this dissertation are to: 1) Develop and validate a novel and high
throughput error-prone PCR (epPCR)-based reverse genetics system for rapid mutant
generation and phenotypic characterization; 2) Characterize the molecular mechanisms
determining high-yields and thermostability of influenza vaccines; 3) Characterize the
molecular mechanisms affecting H3N8 equine IAVs adaption to dogs; and 4) Develop
and validate a computational model for IAV glycan receptor binding specificity that can
help predict the receptor binding specificities and antigenic properties, as well as help
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quantify the vaccine yields by using genomic sequences. This model will be useful in
optimizing selection of effective (i.e. high yield and antigenically-matched) influenza
vaccine candidates directly from clinical samples. The genetic signatures to be identified
will help optimize vaccine seeds for vaccine production.
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Table 1. Comparison of methods to characterize the binding properties of HA/NA
proteins of IAV
Technique
Modified
erythrocytes

Solid-phase Glycan
ELISA
microarray

Bio-layer
interferometry

Label free
Sensitivity
Time

Yes
Low
Hours

Yes
High
Days

No
High
Days

Yes
High
Hours

Quantitative

Poor

Good

Moderate

Good

High throughput

No

No

Yes

No

Cost/Sample

Moderate

Moderate

High

High

Label free

Yes

Yes

No

Yes

Purify of virus

No

Dependsa

Yes

Yes

Real-time results

No

No

No

Yes

Reproducibility

Poor

Good

Moderate

Good

Native glycans

No

No

No

No

a. It depends on the grow efficiently of virus in chicken embryonic eggs or mammalian
cell lines.
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Figure 1.

Representative glycans structures for influenza receptors.
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CHAPTER II

ERROR-PRONE PCR-BASED MUTAGENESIS STRATEGY FOR RAPIDLY
GENERATING HIGH-YIELD INFLUENZA VACCINE CANDIDATES

Vaccination is the primary strategy for the prevention and control of influenza
outbreaks. However, the manufacture of influenza vaccine requires a high-yield seed
strain, and the conventional methods for generating such strains are time consuming. In
this study, we developed a novel method to rapidly generate high-yield candidate vaccine
strains by integrating error-prone PCR, site-directed mutagenesis strategies, and reverse
genetics. We used this method to generate seed strains for the influenza A(H1N1)pdm09
virus and produced six candidate strains. The yield of the candidate strains in eggs was up
to 64.6-fold higher than that for the wild-type strain. We used a mouse model to assess
the efficacy of two of the six candidate strains as a vaccine seed virus: both strains
provided complete protection in mice against lethal challenge, thus validating our
method. Results confirmed that the efficacy of these candidate vaccine seed strains was
not affected by the yield-optimization procedure.
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Introduction
Influenza viruses cause occasional pandemics and seasonal epidemics, thus
presenting continuous challenges to public health. Vaccination is the primary strategy
used to slow and stop transmission of the virus and to reduce the effect of the disease. A
high-yield vaccine seed strain is required for vaccine manufacturing and, thus, is key to a
successful influenza vaccination program. However, it is not uncommon that strains
recommended as influenza vaccine strains by the World Health Organization (WHO)
have low yields in chicken embryonic eggs (hereafter referred to as eggs) (118). Lowyield strains must be engineered into high-yield strains, a process that can be time
consuming and, thus, significantly delay vaccine production. Almost three months were
required for the WHO collaborative laboratories and vaccine companies to generate
suitable vaccine strains to produce vaccine against the 2009 pandemic influenza virus,
A(H1N1)pdm09 (119, 120). Without this delay, the vaccine could have lessened the
effect of the pandemic’s second wave of infection and reduced the number of associated
deaths. Thus, the ability to rapidly generate high-yield vaccine strains is a critical factor
in preventing and controlling influenza outbreaks.
Two common strategies have been used to generate influenza vaccine seed
viruses: 1) co-infection of a cell or an egg with two viruses, one with high-yield features
and another with antigenically matched hemagglutinin and neuraminidase (121, 122); and
2) reverse genetics to generate a virus with antigenically matched hemagglutinin and
neuraminidase, and internal genes from another virus as backbone, which help improve
yields (123-126). During the past decades, the co-infection method has been used widely
to generate vaccine seed viruses. The disadvantage of co-infection is that the
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reassortment events cannot be well controlled and may lead to viruses with undesired
traits (127, 128). Thus, instead of co-infection, egg adaption is often used to improve seed
virus growth in eggs (129-132). In contrast to the co-infection method, the reverse
genetics method can define the genomic constellation (123-126). However, it is difficult
to generate a high-yield seed strain if the hemagglutinin and neuraminidase are not
compatible with the other six gene segments from the backbone virus, and this method
does not readily allow for selecting different combinations of gene segments that may
result in higher yield viruses. In recent years, a recombinant technique has been used to
increase the yields of influenza vaccine candidates (133-138). These reassortants, which
have chimeric hemagglutinin or neuraminidase, had considerably more seed virus growth
in eggs or Madin-Darby canine kidney (MDCK) cells. However, these methods usually
require weeks to generate a desired strain with high yields.
In this study, we developed a novel error-prone PCR (epPCR)–based mutagenesis
approach to rapidly generate high-yield influenza vaccine strains.
Materials and Methods
Cells and viruses
MDCK cells and human embryonic kidney (293T) cells (both from American
Type Culture Collection, Manassas, VA) were used for propagation and culture of
influenza virus. The cells were maintained at 37°C with 5% CO2 in Dulbecco's Modified
Eagle Medium (GIBCO/BRL, Grand Island, NY) supplemented with 5% fetal bovine
serum (FBS) (Atlanta Biologicals, Lawrenceville, GA), penicillin–streptomycin, and
amphotericin B (GIBCO/BRL, Grand Island, NY). The wild-type strain of
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A/California/04/09 (H1N1) virus (CA/04) was used in the mutant library construction
(Figure 2); mouse-adapted CA/04 (139) was used for challenge experiments.
All viruses generated by reverse genetics were propagated in MDCK cells and
cultured at 37°C with 5% CO2 in Opti-MEM medium (GIBCO/BRL, Grand Island, NY)
supplemented with 1 µg/ml of TPCK (N-tosyl-L-phenylalanine chloromethyl ketone)–
Trypsin (Sigma-Aldrich, St. Louis, MO), penicillin–streptomycin, and amphotericin B
(GIBCO/BRL, Grand Island, NY). Virus titers were determined by 50% tissue culture
infectious dose (TCID50) in MDCK cells.
Primers
Four primers were used in this study: 1) 130loop_F, 5'-TCA TGG CCC AAT
CAT GAC TCG AAC-3'; 2) 190helix_F, 5'-TGG GGC ATT CAC CAT CCA TCT ACT3'; 3) 190helix_R, 5'-AAC ATA TGT ATC TGC ATT CTG ATA-3'; and 4) 220loop_R,
5'-TAG TGT CCA GTA ATA GTT CAT TCT-3'. Primers 130loop_F and 190helix_R
were used to amplify the sequence covering the 130-loop and 190-helix of the receptorbinding site in the hemagglutinin gene of influenza virus. Primers 190helix_F and
220loop_R were used to amplify the sequence covering the 190-helix and 220-loop of the
receptor-binding site in the hemagglutinin gene of influenza virus.
epPCR-based mutagenesis method to generate hemagglutinin mutants of influenza
virus
We used the GeneMorph II Random Mutagenesis Kit (Agilent Technologies,
Santa Clara, CA) according to the manufacturer’s instructions to perform epPCR. The
resulting products were used as primers to perform site directed mutagenesis. The epPCR
amplification mixture contained 17.75 µl of water, 5 µl of 10× buffer, 1 µl of 2.5 mM
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deoxyribonucleotide triphosphates, 1 µl of 10 µmol primer (each), 2 µl of hemagglutinin
plasmid of CA/04 (10 pg/µl), and 1 µl of Mutazyme II DNA polymerase (Agilent
Technologies, Santa Clara, CA). The parameters of the epPCR were as follows: one cycle
at 95°C for 5 min, followed by 30 cycles at 94°C for 1 min, 50°C for 1 min, and 72°C for
2 min, and then one cycle at 72°C for 10 min. Site-directed mutagenesis was performed
by using the QuikChange II Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA)
according to the manufacturer’s instructions. In brief, the PCR mixture included 36 µl of
water, 5 µl of 10× buffer, 1 µl of 2.5 mM deoxyribonucleotide triphosphates, 2 µl of
epPCR product (25 ng/µl), 2 µl of hemagglutinin plasmid (10 ng/µl), and 1 µl of PfuUltra
High-Fidelity DNA Polymerase (Agilent Technologies, Santa Clara, CA) (2.5 U/µl).
After digestion with DpnI (a restriction enzyme that only cleaves methylated DNA) at
37°C for 1 h, the PCR product (2 µl) was transfected into XL1-Blue Supercompetent
Cells (Agilent Technologies, Santa Clara, CA). The transformed cells were directly
inoculated onto LB (Luria Bertani) agar plates or into LB medium.
Generation of reassortant viruses by reverse genetics
The reassortant viruses were rescued by transfection in co-cultured 293T cells and
MDCK cells, as described elsewhere (140), using mutated hemagglutinin gene,
unmodified neuraminidase gene of CA/04, and six internal genes from influenza
A/PR/8/1934(H1N1) virus. At day 3 after transfection, the media and cells were
inoculated into 10-day-old eggs (0.2 ml/egg). Ninety-six hours after inoculation, we
collected the allantoic fluids from the eggs for viral titration.
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Genomic sequencing
Virion RNA and cDNA were prepared as previously described (140). Sequencing
was performed at the Life Sciences Core Laboratories Center at Cornell University
(Ithaca, NY) by using the automated 3730 DNA Analyzer (Applied Biosystems, Foster
City, CA), which utilizes Big Dye Terminator chemistry and AmpliTaq-FS DNA
Polymerase. Deep sequencing was performed by the Beijing Genomics Institute
(Shenzhen, China), using a MiSeq sequencer (Illumina, Shanghai, China).
Growth kinetics in MDCK cells
To determine the growth kinetics of viruses, we inoculated the MDCK cells with
influenza virus at a multiplicity of infection of 0.001 TCID50 and incubated the cells in
5% CO2 at 37°C for 1 h. The inocula were removed and washed two times with
phosphate-buffered saline (PBS). The cells were then incubated (37°C in 5% CO2) in
Opti-MEM I (GIBCO, Grand Island, NY) containing TPCK–trypsin (1 µg/ml). At
specified time points after inoculation, 200 µl of supernatants were collected, aliquoted,
and stored at ˗70°C until use. Virus titers in supernatants collected at the different time
points were determined by TCID50 in MDCK cells.
Western blot assay
The Western blot assay was used to compare the yields of the vaccine candidates
with those of the wild-type strain. The cell supernatants were lysed and then analyzed by
Western blot assay. Western blots were developed by using horseradish peroxidase–
conjugated goat anti-mouse IgG (Santa Cruz Biotechnology, Santa Cruz, CA) and an
enhanced chemiluminescence detection system (ECL GE Healthcare, Pittsburgh, PA) and
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then exposed to X-ray film. The primary antibodies used in the Western blot assay were
influenza nucleoprotein monoclonal antibodies from the Biodefense and Emerging
Infections Research Resources Repository (Manassas, VA).
Quantitative reverse transcription PCR (qRT-PCR)
qRT-PCR was used to determine the level of viral RNA in the allantoic fluid of
eggs inoculated with an influenza virus. Viral RNA (50 µl total) was isolated from 200 µl
of sample by using a Gene JET Viral RNA Purification Kit (Thermo Fisher Scientific,
Pittsburgh, PA). Influenza virus–specific Primer Uni12 (5′-AGCAAAAGCAGG-3′) and
10 µl of template RNA were used in the cDNA synthesis (total volume of 25 µl); the
cDNA synthesis was carried out using SuperScript III Reverse Transcriptase (Invitrogen,
Grand Island, NY) according to the manufacturer’s instructions. Primers 130loop_F and
190helix_R were used in the qPCR, which consisted of 5 µl of Master Mix (Applied
Biosystems, Foster City, CA), 500 nM each primer, 2 µl of target cDNA, and sufficient
diethylpyrocarbonate (DEPC)-treated water to make a volume of 10 µl. The cDNA was
amplified by 40 two-step PCR cycles (3 s at 95°C for denaturation of the DNA, 20 s at
60°C for primer annealing and extension). qPCR amplifications were measured by using
the Stratagene Mx3005P qPCR System (Agilent Technologies, Santa Clara, CA). As a
sample standard, we used the pHW 2000 plasmid vector with the hemagglutinin gene of
CA/04, which was serially diluted 10-fold to generate the standard curve. The
amplification results were shown as Log10 copies/µl.
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Total protein quantification
Viruses were purified from the allantoic fluids of 11-day-old embryonated
chicken eggs by low-speed clarification (4000 rpm, 20 min, 4 °C) followed by
ultracentrifugation through a cushion of 30%-60% sucrose in a 70Ti rotor (Beckman
Coulter, Fullerton, California) (37,500 rpm, 3 h, 4 °C). The virus band was collected and
purified through a cushion of 30% sucrose in a 70Ti rotor (37,500 rpm, 3 h, 4 °C). The
virus pellet was resuspended in 200ul PBS and the total amount of purified virion
proteins was determined by Quant-iTTM protein assay kit (Invitrogen, USA).
Mouse vaccination and challenge
To assess the antigenicity and protective efficacy of high-yield mutant viruses, we
vaccinated a group of 6-week-old female BALB/c mice (Harlan Laboratories,
Indianapolis, IN) by intramuscular administration of 128 hemagglutination (HA) units (in
50-µl volumes) of a formaldehyde-inactivated vaccine candidate, mutant number 81 (n =
10 mice) or mutant number 88 (n = 10 mice). Two weeks later, we administered a booster
vaccine. Mock-vaccinated mice (n = 10) received a volume of PBS equal to the amount
of vaccine administered to the vaccinated mice. Five mice that were not vaccinated and
not challenged served as environmental controls. Two weeks after the booster
vaccination, mice were anesthetized and challenged by intranasal inoculation with
mouse-adapted CA/04 at 10× the 50% lethal dose (LD50). Serum samples were collected
from mice before challenge and tested by using an HA inhibition (HI) assay. To
determine lung virus titers, we euthanized three mice at day 4 after challenge. Lungs were
homogenized and resuspended in 1 ml of sterile PBS, and virus titers were determined in
MDCK cells. The samples were also stained with hematoxylin and eosin stain for
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pathologic examination. The survival rate, clinical signs, and body weight of the
remaining mice were monitored for 14 days after the challenge. All animal studies were
approved by the Office of Regulatory Compliance Institutional Biosafety Committee and
the Institutional Animal Care and Use Committee of Mississippi State University.
HA and HI assays
HA and HI assays were performed by using a 0.5% suspension of turkey red
blood cells as described in the WHO Manual on Animal Influenza Diagnosis and
Surveillance
(http://www.who.int/csr/resources/publications/influenza/whocdscsrncs20025rev.pdf).
Structural modeling
Crystal structures of the hemagglutinin protein (Protein Databank [PDB]
accession nos. 3LZG, 3UBN, and 3UBQ of the A(H1N1)pdm09 virus and the binding
sites of carbohydrates 6'-Sialyl-N-acetyllactosamine (6SLN) and 3'-Sialyl-Nacetyllactosamine (3SLN) to this protein were obtained from PDB (141). Structural
simulation of amino acid mutations was performed on the hemagglutinin by using the
FoldX platform with its empirical force field (142) with crystal waters under the
following conditions: temperature of 298K, pH 7, 0.05 ion strength. Chimera (143) was
used to visualize the binding structures and measure contact distances. PoseScore, which
was designed for ranking near-native ligand–protein interacting structures (144), was
used to estimate the likeness of the protein–glycan binding avidities of the wild-type and
mutant to that of the native virus. The computational analysis of mutation effects on HA–
glycan bindings was focused on the mutants with 133 (H3 numbering) location only
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because the other mutations are not located in the receptor-binding sites of hemagglutinin
and did not modify the PoseScores of the hemagglutinin of the wild-type virus.
Accession numbers
The Crystal structures of the hemagglutinin protein were downloaded from
Protein Data bank with accession numbers: 3LZG, 3UBN, and 3UBQ.
Results
epPCR-based mutagenesis approach
In this study, we developed an epPCR-based mutagenesis strategy for generating
high-yield influenza vaccine candidates (Figure 2). In this method, the epPCR products
are used directly as primers for site-directed mutagenesis, and individual cloned plasmids
are then extracted. Viruses are rescued by using the individual selected plasmids, and the
rescued viruses are screened for a phenotype of high yield in eggs.
To validate our method, we used the hemagglutinin of CA/04 as the template to
generate high-yield vaccine candidates. We first applied epPCR to breed the regions of
receptor-binding sites: one region covered the 130 loop and 190 helix of the
hemagglutinin gene (referred to as 130loop+190helix), and the other region covered the
190 helix and 220 loop of the hemagglutinin gene (referred to as 190helix+220loop). The
epPCR products (234 bp for 130loop+190helix; 171 bp for 190helix+220loop) were
subsequently used as primers in site-directed mutagenesis.
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Figure 2.
Overall strategy for generating a hemagglutinin mutant library.
Based on this method, chicken embryonic egg–propagated seed viruses with high yield
can be selected for influenza vaccine candidate strains. The 130loop + 190helix or
190helix + 220loop in hemagglutinin gene of influenza A/California/04/09 (H1N1) virus
are amplified by error-prone PCR (epPCR) by using a GeneMorph II Random
Mutagenesis Kit (Agilent Technologies, Santa Clara, CA) (step 1). epPCR products are
then used as primers in the site-directed mutagenesis (step 2). After DpnI digestion at
37°C for 1 h (step 3), the PCR product is transformed into XL1-Blue Supercompetent
Cells (Agilent Technologies, Santa Clara, CA), and the cells are inoculated onto LB
(Luria Bertani) plates or into LB medium (step 4). The individual plasmid or plasmid
library is then extracted (step 5) and used with 6 internal genes from A/Puerto
Rico/8/1934(H1N1) and the neuraminidase gene from CA/04 to rescue viruses (step 6).
Rescued viruses are inoculated into 10-day-old chicken embryonic eggs to generate highyield vaccine seed. The steps are indicated by circled numbers in the figure.
Broad diversity of the hemagglutinin mutants generated by the epPCR-based
mutagenesis strategy
To evaluate the profile of the hemagglutinin mutant library, we sequenced a total
of 292 clones (142 for 130loop+190helix; 150 for 190helix+220loop). Of the 292 clones,
111 carried at least one amino acid mutation while maintaining the correct open-reading
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frame. Of these 111 hemagglutinin mutants, 66 were derived from the 130loop+190helix
epPCR products, and 45 were derived from the 190helix+220loop epPCR products.
Ninety-eight of these 111 hemagglutinin mutants had a single amino acid mutation, eight
had double mutations, and five had triple mutations. Except for two clones with the same
mutations, all hemagglutinin mutants carried different mutations. The mutation profile
analysis demonstrated that the mutated sites broadly spanned the entire target region from
the 130loop to the 220loop. Of note, some of these mutations (V135I，A137T, P140L，
H141Q，S146G， V155I， K156E， N159K， G173R， V176I， A189T， T200S，
K212T, I219V) were observed in the hemagglutinin gene of the A(H1N1)pdm09 virus
field strains.
To further demonstrate the diversity of the mutant library, we used nextgeneration sequencing to sequence the plasmid library generated by 130loop+190helix
epPCR products. The readings showed that 63.8% of the sequences had nucleotide
changes, and 83.9% of those led to effective amino acid mutations with correct openreading frames. The mutations were distributed among the 130loop and the 190helix at
both the nucleotide and amino acid levels (Figure 3).
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Figure 3.
Profile of 130loop+190helix hemagglutinin plasmid library sequenced by
using the Miseq sequencer (Illumina, Shanghai, China).
There were 238,961 readings in the library. Of those readings, 63.8% had mutations at
the nucleotide level (A), and 83.9% of those led to effective amino acid mutations with
correct open-reading frames (B). The mutation rate on each site demonstrates that
mutations were distributed almost across the entire 130-loop and 190-helix,
demonstrating that the plasmid library generated by this error-prone PCR strategy has a
broad diversity.
Rapid generation of higher yield strains by using the epPCR-based mutagenesis
strategy
To determine if seed strains with high yield could be directly rescued from the
111 mutants, we recovered the highest-yield viruses by transfection, inoculated them into
10-day-old eggs, and subsequently determined HA titers for comparison with the HA
titers for the wild-type virus. The wild-type virus had an HA titer of 32, and six mutants
(nos. 22, 58, 79, 81, 88, and 114) had an HA titer of at least 128 in passage one (Table 2).
Of note, the HA titers of the wild-type virus remained stable at 32 in passages two and
three, but the titers of mutant viruses number 81 and 88 increased to 512 after passage
two and three, respectively (Table 2).
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Figure 4.
Characterization of the high-yield influenza A(H1N1)pdm09 vaccine
candidates generated by using the error-prone PCR–based mutagenesis strategy.
Viruses were inoculated into Madin-Darby canine kidney cells at a multiplicity of
infection of 0.001. (A) Growth curves for wild-type (WT) and mutant viruses (nos. 22,
58, 79, 81, 88, and 144) measured by 50% tissue culture infectious dose (TCID50; values
shown below columns) at various hours after infection (hpi). (B) Western blot showing
the nucleoprotein expression level for the WT and mutant viruses (viruses shown above
columns).

Viral growth kinetics demonstrated that these six hemagglutinin mutants
replicated more efficiently than the wild-type virus in MDCK cells (Figure 4A). The peak
HA titers of these viruses reached 128–512 in MDCK cells, but the peak titer was only 32
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for the wild-type virus. Among these six mutants, numbers 22 and 81 yielded the highest
HA titer (512) in MDCK cells. The peak TCID50 of these mutants was 0.4–1.0 log10
TCID50 higher than that for wild-type virus (Figure 4A).
The Western blot assay results for cell lysate tested 72 h and 96 h after
inoculation confirmed these results. Nucleoprotein expression for the mutant viruses was
stronger than that for the wild-type strain. The nucleoprotein expression level for mutants
number 22, 58, 79, 81, 88, and 114 were 2.0-, 1.4-, 1.9-, 2.8-, 1.6-, and 1.7-fold higher,
respectively, than that for the wild-type virus (Figure 4B).

Figure 5.
Quantification of wild-type (WT) and mutant viruses propagated in eggs
as determined by using a hemagglutinin gene–specific quantitative reverse
transcription PCR method.
Results are expressed as the median (horizontal bars) RNA copy number (1 µl cDNA) ±
SD (vertical bars).
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Figure 6.
Total protein quantification of wild-type (WT) and mutant viruses that
purified from the allantoic fluids of 11-day-old embryonated chicken eggs.
Results are expressed as the median (horizontal bars) protein concentration ±SD (vertical
bars).
Consistent with our HA assay results, qPCR results for the six selected mutants
showed higher yields than those for the wild-type virus. On average, viral RNA levels in
allantoic fluid of eggs inoculated with mutants number 22, 58, 79, 81, 88 and 114 were
4.3-, 2.3-, 12.3-, 64.6-, 30.9-, and 30.9-fold (copies/µl) higher, respectively, than levels in
allantoic fluid of eggs inoculated with the wild-type strain (Figure 5). Meanwhile, total
protein concentrations of mutants number 22, 58, 79, 81, 88 and 114 were 1.90-, 2.33-,
1.99-, 2.50-, 1.30- and 1.97-fold (µg/ml) higher, respectively, than that of the wild-type
strain (Figure 6). These results further confirmed that, compared with the wild-type virus,
the six selected mutants generated by the epPCR-based mutagenesis strategy grew more
efficiently in eggs.
One-way HI assays using post-infection ferret antiserum raised against CA/04
showed that the homologous HI titers of 3,200 for CA/04 (Table 2). The heterologous HI
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titers of the six mutant viruses were 3,200 or 1,600, demonstrating that these candidates
had few antigenic differences from the wild-type strain.
Table 2. Characterization of influenza A(H1N1)pdm09 vaccine candidates
generated by using an error-prone PCR–based mutagenesis strategy
HA titera, passage no.

HI titerb, passage no.

Virus

1

2

3

1

2

3

Mutation (residue no.)c

Wild type

32

32

32

3,200

3,200

3,200

–

128

256

256

3,200

3,200

3,200

K133N (130), V178M

Mutant, d no.
22

(175)
58

128

256

128

3,200

3,200

3,200

K149E (146)

79

128

128

256

3,200

3,200

1,600

K157I (154)

81

128

128

512

1,600

1,600

1,600

K133I (130)

88

256

512

256

1,600

1,600

3,200

K157I (153), I169T
(166)

114

256

128

256

3,200

a

3,200

3,200

K212T (209)

HA, hemagglutination.
HI, hemagglutination inhibition. Titers were determined by using ferret serum (antiCA/04).
c
Mutations in the hemagglutinin protein sequence of the mutant, H3 numbering; the
residue numbers are residues in the hemagglutinin of influenza A(H1N1)pdm09 virus.
d
Reverse genetics–derived viruses were generated by using hemagglutinin of wild-type
influenza A/California/04/09 (H1N1) virus (CA/04) virus or hemagglutinin mutants
derived from error-prone PCR, neuraminidase of CA/04, and six other gene segments
(polymerases PA [polymerase acidic subunit], PB1 [polymerase basic subunit 1], and
PB2 and nucleoprotein, matrix protein, and nonstructural protein) from influenza
A/PR/8/34(H1N1) virus.
b
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High-yield vaccine candidates providing full protection against lethal challenge in
mice
To confirm that our mutagenesis approach had not affected subsequent vaccine
efficacy, we selected the two mutants with the highest HA titers (mutants no. 81 and 88)
as vaccine candidates and evaluated their efficacy in a mouse model. Serum samples
collected from vaccinated mice 2 weeks after the booster vaccine was administered
exhibited HI titers substantially higher than those for the mock-vaccinated group (Table
2). After viral challenge, virus replication (reaching levels up to 105.4TCID50/ml) was
detected in the lungs of all mock-vaccinated mice; no virus was detected in any of the
vaccinated mice (Table 3). Mice in the mutant number 81– and 88–vaccinated groups did
not lose weight, but the mock-vaccinated mice were lethargic and rapidly lost weight
(Figure 7A). All vaccinated mice survived the lethal challenge; all mock-vaccinated mice
died 7 days after challenge (Figure 7B).
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Figure 7.
Protective effect of high-yield vaccine candidates in mice challenged with
mouse-adapted influenza A/California/04/09 (H1N1) virus.
Groups of control; mock-vaccinated; and mutant number 81–, 88–vaccinated mice were
intranasally inoculated with 10×the 50% lethal dose of virus, after which their body
weights (A) and survival times (B) were monitored for 14 days. Results are shown as the
mean ± SD in each group (A).

Table 3. Pathogenesis and immunologic responses in vaccinated mice challenged
with mouse-adapted influenza A/California/04/09 (H1N1) virus
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Log10TCID50/ml, mean ± SDa

log2HI titer, mean ± SDb

81 (K133I)

Below detection limit

8.32 ± 0.70

88 (K157I, I169T)

Below detection limit

8.12 ± 0.45

5.4 ± 0.1

Below detection limit

Vaccine group
Mutant no. (mutation)

Mock
a

Groups of BALB/c mice were inoculated intranasally under light anesthesia with 10×
the 50% lethal dose of mouse-adapted CA/04 virus. Three mice from each group were
euthanized on day 4 after virus challenge, and virus titers in lungs were determined by
TCID50 (50% tissue culture infectious dose) in MDCK cells.
b
Serum samples were collected 2 weeks after the booster vaccine was administered, and
antibody response levels were measured by using the HI (hemagglutination inhibition)
assay.
Photomicrographs of hematoxylin and eosin–stained lung sections are shown in
Figure 8. Mock-vaccinated mice displayed acute, diffuse, necrotizing bronchitis and
bronchiolitis 4 days after challenge (Figure 8C). No histopathologic changes were
observed in the mice vaccinated with mutants number 81 or 88 (Figure 8A,B),
demonstrating effective protection of both vaccine candidates from the lethal mouseadapted CA/04 challenge. Thus, our results indicate that the high-yield candidate
vaccines generated by our epPCR-based mutagenesis strategy did not have altered
antigenicity and could serve as potential seed strains for the manufacture of influenza
vaccines.
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Figure 8.
Histopathologic findings in hematoxylin and eosin–stained lung samples
from vaccinated and mock-vaccinated mice challenged with mouse-adapted influenza
A(H1N1)pdm09 virus.
Four days after challenge, groups of mutant number 81–vaccinated (A), mutant number
88–vaccinated (B), and mock-vaccinated (C) mice were euthanized, and lungs were
collected for histopathologic examination; non-vaccinated, non-challenged mice served
as environmental controls (D). A, B, and D) Scale bar =100 µm; C) scale bar = 40 µm.
Receptor-binding models of improved-yield mutants
Among the six mutation sites, only mutants number 22 and 81 had residue 133
located in the receptor-binding sites of hemagglutinin (Figure 9). These crystal structures
of the bindings between the hemagglutinin of influenza A(H1N1)pdm09 and glycan
analogs 6SLN or 3SLN were used in computational mutation simulations to study the
effects of amino acid modifications on hemagglutinin-receptor bindings.
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Figure 9.
The locations of six mutations in the crystal structure of the hemagglutinin
(HA) of influenza A(H1N1)pdm09 virus.
The HA was adapted from the structural template of the HA of A(H1N1)pdm09 virus
(Protein Databank [PDB] 3LZG) interacting with glycans 6SLN (from PDB 3UBN) and
3SLN (from PDB 3UBQ). The HA protein structure is shown in light grey; receptorbinding residues on the 130-loop, 190-helix, and 220-loop are shown in gold. The
mutation location 133 is in orange to distinguish it from other non-binding site mutation
locations indicated in red (149, 157, 169, 178, and 212). Cyan indicates 6SLN and
magenta indicates 3SLN; both are superposed as their native binding poses against the
native HA structures.

As measurements of binding modifications caused by mutations, we calculated
the distances between the oxygen atom of a water molecule (which formed a hydrogen
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bond between amino acid residue 133 and glycan receptors) and the nearest atoms of
sialic acid and the distances between the oxygen atom of a water molecule and residue
133. Moreover, as a quantification of hemagglutinin–glycan binding avidities, we
obtained the PoseScore (144) for structural interactions between glycans and all wildtype and computationally mutated hemagglutinin structures (Figure 10).
When the hemagglutinin bound to 3SLN, the wild-type structure with a polar and
positively charged lysine at residue 133 had a distance of 4.57 Å to the linker water
molecule, and the whole interaction had a PoseScore of ˗6.32 (Figure 10B). The K133N
mutant had a polar, but neutral, asparagine at residue 133, which was only 2.23 Å from
the linker water molecule, and its PoseScore wass ˗7.04 (Figure 10D). The K133I mutant
had a nonpolar and neutral isoleucine at residue 133, which was 2.95 Å to the linker
water molecule, and its PoseScore was ˗6.88 (Figure 10F). These results showed that both
the contact distances and pose binding scores were decreased by substituting a charged
lysine with neutral asparagine or isoleucine. Thus, given that smaller contact distances
and lower PoseScores suggest stronger interactions between glycans and proteins,
mutations K133N and K133I could lead to increased 3SLN bindings compared with what
the wild-type strain does. These stronger hemagglutinin–3SLN bindings for mutants
number 22 and 81, compared with that for the wild type strain, may contribute to the
higher replication efficiencies of these two mutants in eggs and MDCK cells.
Of interest, the structural simulation showed that both the contact distances and
pose binding scores between hemagglutinin and 6SLN were also decreased by
substituting a charged lysine with neutral asparagine or isoleucine. When the
hemagglutinin bound to 6SLN, the wild-type structure with a polar and positively
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charged lysine at residue 133 had a distance of 4.41 Å to the linker water molecule and
the whole interaction had a PoseScore of ˗11.83 (Figure 10A). The K133N mutant had a
polar but neutral asparagine, which wass only 2.04 Å from the linker water molecule, and
its PoseScore wass ˗12.18 (Figure 10C). The K133I mutant had a nonpolar and neutral
isoleucine at residue 133, which was 2.82 Å from the linker water molecule, and its
PoseScore was ˗14.42 (Figure 10E). These results suggested that mutations K133N and
K133I could lead to stronger 6SLN bindings in mutants number 88 and 81 than in the
wild-type virus.
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Figure 10.
The three-dimensional structures of the hemagglutinin of the wild–type
(WT) influenza A/California/04/09 (H1N1) virus and mutant viruses (nos. 22 and 81)
in contact with human-like receptor analog 6SLN (panels A, C, and E) and avian-like
receptor analog 3SLN (panels B, D, and F).
The protein structures of hemagglutinin are shown in light grey; residue 133 is in orange.
The side chains of interacting residues on the receptor-binding sites are labeled with
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residue names and locations. The single letter amino acid annotations were used together
with H3 numbering for all binding residues. 6SLN is shown in cyan, and 3SLN is shown
in magenta. Red dots indicate the oxygen atoms from all water molecules that are in
contact with hemagglutinin side chains. The distances (in angstroms) between the water
molecule and the nearest atom on both the protein and ligand sides are indicated by
dashed lines. (A) WT hemagglutinin with lysine at position 133 in contact with 6SLN.
(B) WT hemagglutinin with lysine at position 133 in contact with 3SLN. (C) K133N
mutant hemagglutinin with asparagine at position 133 in contact with 6SLN. (D) K133N
mutant hemagglutinin receptor-binding sites with asparagine at position 133 in contact
with 3SLN. (E) Mution K133I at the hemagglutinin receptor-binding site with isoleucine
at position 133 in contact with 6SLN. (F) Mutant K133I with isoleucine at position 133 in
contact with 3SLN. Simulations on the hemagglutinin were performed by using the
FoldX empirical force field (142), and the structure was visualized by using Chimera
(143); PoseScore (144) was used to estimate the likeness of the WT and mutant protein–
glycan binding avidities to that of the native virus.
Discussion
Conventional site-directed mutagenesis strategies depend on virus variants that
are manually selected and usually have a single or a few mutations; egg-adaptation
strategy depends on the virus variants generated by error in natural viral RNA replication
(viral quasispecies) resulting from the lack of proofreading capacity in viral RNA
polymerase. The small pool of virus variants produced by these approaches is a
bottleneck in the process of selecting high-yield seed strains for influenza vaccine
production. Thus, we hypothesized that the in vitro breeding of a diverse influenza virus
variant library by epPCR would enhance the process for generating high-yield strains.
The epPCR method has been widely used to generate libraries of mutant proteins for
phenotype selection (145-149). By integrating epPCR, site-directed mutagenesis, and
reverse genetics, we developed a novel strategy for rapidly generating high-yield vaccine
candidates. Our data show that this strategy allows for the rapid generation of high-yield
vaccine candidates for the A(H1N1)pdm09 virus. Whole-virus inactivated vaccines
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derived from two high-yield candidates that we generated provided full protection against
lethal A(H1N1)pdm09 virus challenge in mice.
Recently, Imai and Wu also used epPCR strategy to generate influenza mutant
library for phenotype selection (150, 151). In their studies, the epPCR was used to
amplify the partial HA or whole NA genes, and the amplified fragment or gene need to
be digested with restriction enzyme and then subcloned to influenza reverse genetics
vector for virus rescuing. Unlike their approaches for generating influenza mutant library,
our strategy combined the epPCR and site mutagenesis approach efficiently, and we used
epPCR product as primers for site mutagenesis. Therefore, through two single PCRs, one
epPCR and another site mutagenesis PCR, we can target any region of influenza gene to
generate plasmid mutant library without designing any restriction enzyme site and
omitting the subcloning step. Thus, our approach developed here can be used for
efficiently generating diverse mutant libraries for phenotype selection for influenza virus
or other pathogen.
The mechanism(s) by which the mutations in the hemagglutinin gene improve
virus replication are poorly understood. Previous studies suggested that the functional
balance between receptor binding of the hemagglutinin and the receptor-releasing
property of the neuraminidase is critical for efficient replication of influenza viruses (85,
152). Mutations near the receptor-binding sites of the hemagglutinin are known to affect
the replication abilities of viruses (119, 120, 153, 154). In this study, we constructed a
hemagglutinin plasmid library targeted to the receptor-binding sites of influenza
A(H1N1)pdm09 virus. By using the cloned mutant hemagglutinin genes, we successfully
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rescued 43 viruses without subsequent egg passages. Of these 43 viruses, six mutants had
improved yields in eggs.
Among the mutations in the hemagglutinin of the six selected vaccine candidates
in our study (Table 2), mutations K157I and K212T were previously reported in the highyield A(H1N1)pdm09 vaccine strains generated in eggs (119). Identification of these two
previously reported mutations, which improved the yields of A(H1N1)pdm09 virus,
validates the effectiveness of our strategy. Our strategy is further validated by the fact
that we also found some novel sites in the hemagglutinin that improved yields without
changing virus antigenicity. For example, K133, which was found in two high-yield
mutants, is absent in the hemagglutinin of the contemporary human seasonal influenza
A(H1N1) virus and is highly conserved in both the A(H1N1)pdm09 virus and its
precursor, the hemagglutinin gene of the 1918 pandemic H1N1 influenza virus. The
K133N HA mutation was predicted to broadly change the electrostatic potentials
surrounding the receptor-binding domain (155). As shown in receptor-binding models
(Figure 10), the substitution of a positively charged lysine in position 133 by a polar
uncharged asparagine or hydrophobic isoleucine could contribute to the increase in
binding avidity and be responsible for the improved yield of these mutants in eggs and
MDCK cells.
A previous study predicted the important role of K133 and K149 in receptorbinding affinity and in the virulence of A(H1N1)pdm09 virus (156). Substitution of
K133R or K149R in “swine-like” A(H1N1)pdm09 virus reduced its pathogenicity (156).
The mutants with K133N or K149E mutations that were identified in this study have
higher yield properties and may have lower pathogenicity compared with that of the
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wide-type strain; which would ensure a safer vaccine production. In addition, two of six
selected mutants with improved yields harbor K157I mutations. It has been reported that
mutants with K157E mutations are preferred for replication of
A/California/7/2009(H1N1) virus in MDCK cells and eggs (120). Our results also
indicate that the presence of a isoleucine residue with hydrophobic site chain in position
157 of hemagglutinin improves the growth ability of the A(H1N1)pdm09 virus.
Concerns have been raised that even single amino acid substitution near receptorbinding sites may change the antigenicity of influenza viruses (157). However, mutations
near the receptor-binding sites of the hemagglutinin, such as L119I, A186D, N125D, and
D127E, have been used as seed viruses for the A(H1N1)pdm09 vaccine (120). The HI
assay results in our study indicate that the six high-yield candidate vaccine strains had
few antigenic changes from the CA/04 wild-type strain (Table 2). For example, although
K133 was recently documented to be involved in B cell epitopes recognized by
monoclonal antibodies (158-160), in our study, mutation K133N did not alter the
antibody-binding avidities of K133N mutant to anti-A(H1N1)pdm09 virus ferret serum;
this finding has also been reported elsewhere (155). Moreover, inactivated vaccines based
on two testing candidates that yielded the highest titers in eggs provided full protection
against lethal challenge in experiments with mice. These results provide further evidence
that the epPCR-based mutagenesis strategy combined with serologic assays, such as the
HI assay, could be used for rapid generation of influenza seed viruses.
In summary, we report the use of a novel epPCR-based site-directed mutagenesis
strategy to rapidly generate a diverse influenza hemagglutinin plasmid library and the
application of this method to generate high-yield candidate strains for production of
51

A(H1N1)pdm09 virus vaccine candidates. The mutations associated with high yield in
our study could facilitate a quick response to future outbreaks caused by A(H1N1)pdm09
virus and its variants. Moreover, this novel strategy could also be applied to the breeding
of other functional regions of a gene to rapidly generate diverse mutant libraries for gainof-function studies for influenza and potentially other pathogens.
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CHAPTER III
A Y161F HEMAGGLUTININ SUBSTITUTION INCREASES THERMOSTABILITY
AND IMPROVES YIELDS OF 2009 H1N1 INFLUENZA A VIRUS IN CELLS
Vaccination is the primary strategy for influenza prevention and control. Yet eggbased vaccines, the predominant production platform, have several disadvantages
including the emergence of viral antigenic variants that can be induced during egg
passage. These limitations have prompted development of cell-based vaccines which
themselves are not without issue. Most importantly, vaccine seed viruses often do not
grow efficiently in mammalian cell lines. Here we aimed to identify novel high-yield
signatures for influenza viruses in continuous Madin-Darby canine kidney (MDCK) and
Vero cells. Using influenza A(H1N1)pdm09 virus as the testing platform and an
integrating error-prone PCR strategy, we identified a Y161F mutation in the
hemagglutinin (HA) that not only enhanced the infectivity of the resultant virus by more
than 300-fold, but also increased its thermostability without changing its original
antigenic properties. Vaccine produced from the Y161F mutant fully protected mice
against wild-type A(H1N1)pdm09 lethal challenge. Compared with A(H1N1)pdm09, the
Y161F mutant had significantly higher avidity for avian-like and human-like receptor
analogs. Of note, introduction of the Y161F mutation into the HA of seasonal H3N2
influenza A virus (IAV) and canine H3N8 IAV also increased yields and thermostability
in MDCK cells and chicken embryotic eggs. Thus, residue F161 plays an important role
in determining viral growth and thermostability, which could be harnessed to optimize
IAV vaccine seed viruses.
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Introduction

Influenza A viruses (IAVs) cause seasonal outbreaks and occasional pandemic
outbreaks among humans and pose challenges to public health. The viruses responsible
for four pandemics have been characterized: one each in 1918 and 2009 caused by H1N1
IAVs, one in 1957 caused by an H2N2 IAV, and one in 1968 caused by an H3N2 IAV
(4). These pandemic outbreaks varied in impact, but each resulted in substantial mortality
in a short time. Compared with pandemic outbreaks, seasonal influenza outbreaks are
typically milder but still cause approximately 200,000 hospitalizations and 36,000 deaths
each year in the United States alone (161).
Vaccination has been the most efficient and economic strategy for preventing
influenza virus infection and controlling the spread of disease (162). Three types of virusbased influenza vaccines, inactivated vaccines, live-attenuated vaccines, and recombinant
hemagglutinin (HA), are licensed in the United States, with egg-produced vaccine being
the dominant source (127, 163). The egg-based platform for vaccine production has been
used since the 1950s (164), but it has several disadvantages: first, passage of seed viruses
in eggs can result in undesired egg-adapting mutations in the HA that can lead to changes
in viral antigenicity (165-168); second, due to reactogenicity concerns, egg grown
vaccine is contraindicated for those with egg allergies (169); and third, rapidly scaling up
egg production is not easily achievable . Cell-based vaccine production platforms do not
have the same limitations (170). All continuous cell lines, including Madin-Darby canine
kidney (MDCK) cells and African green monkey kidney–derived Vero cells, must be
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certified before being approved by regulatory authorities for use in the production of
influenza vaccines (171-173).
A high-yield vaccine seed strain is required for timely vaccine manufacture and is
thus a critical component of a successful influenza vaccination program. Unfortunately, it
is not uncommon that the vaccine strains recommended by the World Health
Organization (WHO) have less than desirable yields in eggs, cells, or both (174, 175). For
example, the 2009 H1N1 pandemic seed strain was a low-yield strain, and it required
almost 3 months for the WHO collaborative laboratories and vaccine companies to
engineer the selected strain to meet the criteria required for vaccine production. Because
of this delay, vaccine-derived immunity among the population arose after the peak of the
second wave of the 2009 H1N1 pandemic (176). Therefore, quickly generating a highyield vaccine seed virus is critical for rapid vaccine production and, thus, for effective
influenza prevention and control. Adaptation of viruses to cells by multiple passaging or
development of high-yield reassortant seeds using reverse genetics has been shown to be
an effective way to increase yield of vaccine seed viruses (177-180). In addition, other
studies have been performed to improve virus yields in cells by modifying the virus or
the cell line. For example, Suphaphiphat et al. (181) showed that mutations S186P and
L194I in the receptor binding site (RBS) of the A/California/04/09 (CA/04) H1N1 HA
increased growth of the virus by more than 10-fold in MDCK cells, and Hamamoto et al.
(182) reported that MDCK cells engineered with stable knockdown of interferon
regulatory factor 7 increased IAV yields.
Thermostability is also important for vaccine quality, especially in low-income
countries that lack the infrastructure to maintain a low and stable temperature during
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vaccine transportation (183). The reduced thermostability of live attenuated vaccine for
the 2009 H1N1 pandemic virus, may have been responsible for its restricted replication in
vaccinated persons (184). Mutations in HA protein can improve thermostability; for
example, mutations S133N, T189A, N198D, and L226Q in the RBS of influenza HA
were reported to be associated with a significant increase in thermostability of an H9 IAV
(185).
The objective of this study was to randomly introduce mutations into HA and
screen for those that improved IAV thermostability and yields in MDCK and Vero cells.
Such studies are important to optimize the preparation of cell-based influenza vaccine.
Materials and Methods
Cells and viruses
Human embryonic kidney (293T) cells, MDCK cells, and Vero cells were
purchased from American Type Culture Collection (Manassas, VA). Cells were
maintained at 37°C with 5% CO2 in Dulbecco's Modified Eagle Medium (GIBCO/BRL,
Grand Island, NY) supplemented with 5% fetal bovine serum (Atlanta Biologicals,
Lawrenceville, GA) and penicillin–streptomycin (Invitrogen, Carlsbad, CA). The HA
gene of CA/04 was cloned into the vector pHW2000 and used as template for
construction of the mutant library; mouse-adapted CA/04 (139) was used for challenge
experiments in mice. Influenza A/Texas/50/2012(H3N2) (TX/50) and
A/canine/Iowa/13628/2005 (H3N8) virus (canine-H3N8) were used to validate the
identified molecular markers.
The viruses generated by reverse genetics were propagated in MDCK cells and
cultured at 37°C with 5% CO2 in Opti-MEM medium (GIBCO/BRL, Grand Island, NY)
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supplemented with 1 µg/ml of TPCK (N-tosyl-L-phenylalanine chloromethyl ketone)Trypsin (Sigma-Aldrich, St. Louis, MO) and penicillin–streptomycin (Invitrogen,
Carlsbad, CA). Virus titers were determined by TCID50 in MDCK cells.
The viral total protein yield in eggs was tested as described by Adamo et al (133).
Briefly, 10-day-old chicken embryotic eggs were infected with an influenza virus and
then incubated at 37°C for 72 h. The allantoic fluid of the infected eggs was collected for
virus purification and quantification of protein concentrations as described below.
Extractions of RNA and plasmids
RNA was extracted by using an RNeasy Mini Kit (QIAGEN, Valencia, CA); the
plasmids used for transfection were prepared by using the GeneJET Plasmid Miniprep kit
(Thermo Scientific, Waltham, MA).
Mutant generation using epPCR-based reverse genetics strategy
The mutant library with random mutations in HA RBSs was generated by epPCR
as previously described (186). In brief, the randomly mutated short sequences (about 200
nucleotides) were used as primers in the site-directed mutagenesis with HA-pHW2000,
leading to plasmids with random mutations in the HA RBSs. This strategy can avoid the
need for a labor-intensive gene cloning process, and the HA-pHW2000 with mutations
can be used directly in generating vaccine candidates (186). One day before transfection,
293T cells and MDCK cells were co-cultured in 24-well plates, using a 20:1 ratio of
293T cells to MDCK cells. The cell cultures were transfected with 125 ng of each of
eight plasmids: a mutant HA gene, NA gene of CA/04, and 6 internal genes (PB2, PB1,
PA, NP, M, and NS) of influenza A/PR/8/1934(H1N1) virus. Transfection was done
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using TransIT-LT (Mirus, Madision, WI) according to the manufacturer’s instructions. In
brief, TransIT-LT transfection reagent was mixed with DNA at 2.5 μl /1 μg, incubated at
room temperature for 20 min, and then added to the cells. After 24 h, Opti-MEM medium
(GIBCO/BRL) supplemented with 1 µg/ml of TPCK-trypsin (Sigma-Aldrich, St. Louis,
MO) was added to the cells. After 72 h of incubation, supernatants were collected and
titrated in MDCK cells.
For phenotype comparison, we generated the wild-type reassortant virus (rg-wt)
containing the wild-type HA and NA genes from CA/04 and six internal genes from
A/Puerto Rico/8/34 (H1N1). The reassortant rg-TX/50 with HA and NA from TX/50 and
six internal genes from A/Puerto Rico/8/34 (H1N1) virus and the reassortant rg-H3N8
with HA and NA from canine-H3N8 and six internal genes from A/Puerto Rico/8/34
(H1N1) virus were also rescued by reverse genetics.
Site-directed mutagenesis
The QuikChange II Site-Directed Mutagenesis Kit (Agilent Technologies, Santa
Clara, CA) was used to create specific mutations in the HA gene. We used forward
primer 5′- CCACTTAAACTTCAAATTCCCAGCATTGAACGTG-3′ and reverse
primer 5′- CACGTTCAATGCTGGGAATTTGAAGTTTAAGTGG-3′ to generate
mutation Y161F in HA of TX/50, and we used forward primer 5′CAAAATCTGGAAGCTCTTTCCCCACATTGAATGTGAC-3′ and reverse primer 5′GTCACATTCAATGTGGGGAAAGAGCTTCCAGATTTTG-3′ to generate mutation
Y161F in HA of canine-H3N8. To ensure the absence of unwanted mutations, Eurofins
(Louisville, KY) used Sanger sequencing to completely sequence all constructs.
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Growth kinetics
To determine the growth kinetics of viruses, we inoculated the MDCK cells with
a testing virus at an MOI of 0.001 and then incubated the cells in 5% CO2 at 37°C for 1 h.
The inocula were then removed and cells washed twice with phosphate-buffered saline
(PBS). Opti-MEM I (GIBCO, Grand Island, NY) containing TPCK-trypsin (1 µg/ml) was
added to the cells, which were then incubated in 5% CO2 at 37°C. At specified time
points after inoculation, 200 µl of supernatant was collected from the incubated cells,
aliquoted, and stored at −70°C until use. Virus titers in supernatant collected at the
different time points were determined by TCID50 in MDCK cells.
Viral protein purification and protein concentration quantification
Viruses were purified from the cell supernatant or allantoic fluid by low-speed
clarification (2,482 × g, 20 min, 4°C) to remove debris and then ultracentrifuged through
a gradient of 30%–60% sucrose in a 70Ti Rotor (Beckman Coulter, Fullerton, CA)
(100,000 × g, 3 h, 4°C). The virus band was collected and purified through a cushion of
30% sucrose in a 70Ti Rotor (100,000 × g, 3 h, 4°C). The virus pellet was resuspended in
200 µl of PBS, and the total amount of purified virion protein was determined by using
the Pierce BCA Protein Assay Kit (Thermo Scientific, Rockford, IL).
HA and HI assays
HA and HI assays were performed by using 0.5% turkey erythrocytes as
described by the WHO Global Influenza Surveillance Network Manual for the
Laboratory Diagnosis and Virological Surveillance of Influenza (187). Guinea pig,
chicken, horse, turkey, and dog (beagle) erythrocytes were obtained from Lampire
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Biological Products (Everett, PA). The erythrocytes were washed three times with 1 ×
PBS (pH 7.2) and diluted to 0.5% for chicken, beagle, and turkey erythrocytes, 0.75% for
guinea pig erythrocytes, and 1% for horse erythrocytes.
Western blot analysis
The Western blot analysis was used to compare the influenza virus specific
protein yields of a wild type virus and those of a testing mutant. The monoclonal
antibody specific for influenza A virus nucleoprotein (NR-43899) and H1 (NR-42019)
were obtained through BEI Resources Repository (https://www.beiresources.org). The
Western blots were developed by using HRP conjugated anti-mouse IgG antibody
(Sigma-Aldrich, St. Louis, MO) and DAB substrate kit (Thermo Fisher Scientific,
Waltham, MA ) as manufacturer described. Bands were visualized by chemiluminescence
using ChemiDoc imaging system (Bio-Rad, Hercules, CA) and analyzed by ImageJ
(National Institutes of Health, Bethesda, MD).
Glycan microarray and data analyses
The 66 N-glycans (188) were printed on N-hydroxysuccinimide–derivatized slides
as previously described (189). All glycans were printed in replicates of 6 in a subarray,
and 8 subarrays were printed on each slide. All glycans were prepared at a concentration
of 100 µM in phosphate buffer (100 mM sodium phosphate buffer, pH 8.5). The slides
were fitted with an 8-chamber adapter (Grace Bio-Labs, Bend, OR) to separate the
subarray into individual wells for assay. Before assay, slides were rehydrated for 5 min in
TSMW buffer (20 mM Tris-HCl, 150 mM NaCl, 0.2 mM CaCl2, 0.2 mM MgCl2, and
0.05% Tween-20) and blocked for 30 min in TSMWB buffer (TSMW buffer with 1%
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BSA). Viruses were purified by sucrose density gradient ultracentrifugation and titrated
to about 1.0 ×105 HAU/ml. To 150 µl of virus, we added 15 µl of 1.0 M sodium
bicarbonate (pH 9.0) and then incubated the mixture with 25 µg of Molecular Probes
Alexa 488 Succinimidyl Esters (NHS esters) (Thermo Fisher Scientific, Inc., Waltham,
MA) for 1 h at 25°C. After overnight dialysis against a 7 KDa Slide-A-Lyzer MINI
Dialysis Devices (Thermo Fisher Scientific, Inc., Waltham, MA) to remove excess Alexa
488 dye, viruses were checked by HA assay and then bound to glycan array. Labeled
viruses were incubated on glycan microarray at 4°C for 1 h, washed, and centrifuged
briefly before being scanned with an InnoScan 1100 AL Mircroarray Scanner (Inopsys,
Toulouse, France).
Viruses-glycan receptor binding assay
Two biotinlyated glycan analogs, carbohydrates 3'-sialyl-N-acetyllactosamine
(3′SLN) representing SA2,3GA and 6'-sialyl-N-acetyllactosamine (6′SLN) representing
SA2,6GA, were purchased from GlycoTech (Gaithersburg, MD). The glycan stocks were
reconstituted at 1 mg/ml in 50% glycerol - PBS (vol/vol) solution according to the
manufacturer’s instructions and were stored at 4°C until use. The viral particles in wildtype reassortant virus bearing HA161Y (rg-wt) and a mutant virus bearing HA161F (rgY161F) were determined using a Virocyt 2100 virus counter (ViroCyt, Boulder, CO).
The kinetics buffer (PBS pH 7.4 with 0.01% bovine serum albumin and 0.002% Tween20) containing neuraminidase inhibitors (10 µM zanamivir hydrate and 20 µM
oseltamivir phosphate) was used to titrate the biotinylated glycan analogs and viruses
during the binding assay (190). Binding of viruses (at 1 pM/virus) to the biotinylated
glycan analogs was performed in an Octet RED96 biolayer interferometer equipped with
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streptavidin biosensor tips (PALL FortéBIO, Menlo Park, CA) according to the
manufacturer’s assay protocol: 1) Biosensor coating with biotinylated glycan analogs X
300 sec; 2) Virus association X 1,200 sec ; and 3) Dissociation in the kinetics buffer with
neuraminidase inhibitors X1,000 sec. The entire measurement cycle was maintained at
30°C with orbital shaking at 1,000 rpm.
Analyses of virus thermostability
Purified viruses were diluted in PBS to 128 HAU, and dispensed by 120 µl into
0.2-ml, thin-walled PCR tubes (USA Scientific, Ocala, FL). Tubes were placed in a
Gradient Veriti 96-Well Thermal Cycler #9902 (Life Technologies, Camarillo, CA). The
temperature range was set at 51.5°–63.0°С. Tubes were heated for 40 min, then
transferred to ice. Control samples containing 120 µL of virus were incubated for 40 min
at 0°С. Virus content in each sample was determined by HA assay using a 0.5%
suspension of turkey erythrocytes. Each virus sample was analyzed three times for
thermostability.
Animal experiments
We intramuscularly inoculated two groups of 6-week-old female BALB/c mice
(Harlan Laboratories, Indianapolis, IN) with 15 µg (in a 50-µl volume) of a
formaldehyde-inactivated vaccine candidate or wild-type virus (n = 10 mice/group).
Specifically, the viruses used as vaccine candidate were inactivated in 0.025% formalin at
4 °C for three days and then confirmed by three blind passages on MDCK cells. Two
weeks later, we administered a booster vaccine with the same amount of immunogen. A
group of mock-vaccinated mice (n = 10) received an equal volume of PBS. A group of
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mice serving as environmental controls (n = 5), were not vaccinated or challenged. Two
weeks after the booster vaccination, mice were anesthetized and challenged by intranasal
inoculation with mouse-adapted CA/04 (139) at 10 times the 50% lethal dose. Serum
samples were collected from mice before challenge and tested by HI assays. To
determine lung virus titers, we euthanized five mice at day 4 after challenge. Lungs (n = 3)
were homogenized and resuspended in 1 ml of sterile PBS, and virus titers were
determined in MDCK cells. The lung samples were also fixed in formalin and stained
with hematoxylin and eosin stain for pathologic examination. We monitored the clinical
signs, survival rate, and body weight of the remaining mice (n = 5) for 14 days after
challenge. The mice were euthanized on 14 days after challenge.
Biosafety and animal handling
All laboratory and animal experiments were conducted under BSL-2 conditions,
with investigators wearing appropriate protective equipment, and in compliance with
protocols approved by the Institutional Animal Care and Use Committee of Mississippi
State University.
Structural modeling
Crystal structures of the HA protein of the A(H1N1)pdm09 virus and the binding
sites of 6′SLN and 3′SLN to this protein were obtained from PDB (Protein Databank:
accession numbers 3LZG, 3UBN, and 3UBQ, respectively). Structural simulation of
amino acid mutations was performed on the HA by using the computer algorithm FoldX
(http://foldxsuite.crg.eu) with its empirical force field with crystal waters under the
following conditions: temperature of 298K, pH 7, 0.05 ion strength. The binding
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structures and measure of contact distances were visualized by using Chimera
(http://www.cgl.ucsf.edu/chimera/). PoseScore, which was designed for ranking nearnative ligand–protein interacting structures, was used to estimate the likeness of the
protein–glycan binding avidities of the wild-type and mutant viruses to that of the native
virus. PoseScore scores typically range from −100 to 100; the lower the score, the lower
the binding affinity. The computational analysis of the effect of mutation on HA–glycan
bindings was focused on the mutants with 161 (H3 numbering) location.
Genomic sequences, molecular characterization, and statistical analyses
HA sequences of IAVs were downloaded from the database of the Influenza Virus
Resource on January 30, 2017. Multiple sequence alignments were conducted by using
MUSCLE software (191). The mutations were identified by using Bioedit software (192).
Survival curves were calculated by the Kaplan-Meier method, and significance was
analyzed with the log-rank test using Graphpad Prism 5 software
(http://www.graphpad.com/scientific-software/prism/).
Results
Generation of RBS variants of CA/04 and assessment of their growth characteristics
in cells
To identify mutations associated with high-yields of CA/04/PR8 reassortant
viruses, a cDNA library carrying random mutations in the CA/04 HA RBS was generated
by epPCR and screened by Sanger sequencing. Hereafter, we will use the term rg to refer
to mutants from epPCR. For example, rg-Y161F denotes a reassortant virus from epPCR
with a Y161F mutation. Each mutated plasmid, together with the neuraminidase plasmid
of CA/04 and internal genes (PB2, PB1, PA, NP, M, NS) plasmids of PR8, was used to
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rescue virus by a reverse genetics approach. As a result, we obtained a total of eight
mutants: rg-D130E, rg-P140T, rg-L154F-K156Q, rg-S160T, rg-Y161F, rg-K174E, rgS188I, and rg-Y201H (Table 4).
Table 4. Characterization of MDCK cell grown receptor binding site mutants
generated by error-prone PCR-based mutagenesis strategy
Mutation

a

HI

b

TCID50

c

HA titersd

rg-wt

640

5.749

Guinea
pig
4

P140T

640

5.91 ± 0.29

4

4

<2

32

4

S188I

640

5.91 ± 0.29

4

16

<2

16

4

Chicken

Horse

Turkey

Doge

8

<2

16

8

S160T

320

6.08 ± 0.29

4

2

<2

16

8

Y201H

320

6.08 ± 0.29

16

8

<2

64

16

D130E

320

6.249

16

16

<2

128

32

K174E
L154FK156Q

320

6.249

16

16

<2

64

32

640

6.249

16

4

<2

128

64

Y161F

640

8.249

256

1,024

<2

512

128

a

Viruses that carry mutations at the receptor binding site of wild-type influenza
A/California/04/09 (H1N1) virus (CA/04) were generated by using an error-prone–based
reverse genetic system. rg-wt, CA/04 mutant.
b
HI, hemagglutination inhibition. Titers were determined by using ferret serum (antiCA/04).
c
TCID50, 50% tissue culture infectious dose. The virus titers were determined by TCID50
assay in MDCK cells.
d
HA,hemagglutination assays against types of red blood cells were performed using
standard procedures.
e
Beagle.
Analysis of viral growth kinetics showed that replication efficiencies of these 8
mutants varied greatly in MDCK cells. Among the mutants, rg-D130E, rg-K174E, rgL154F-K156Q, and rg-Y161F increased virus titers compared with the wild-type
reassortant virus rg-wt. Mutants rg-S160T, rg-P140T, rg-S188I, and rgY201H grew to
similar titers as did rg-wt (Table 4). Among all mutants, rg-Y161F had the highest virus
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titer at 8.249 log (50% tissue culture infectious dose [TCID50]), which was >300-fold
higher than that of the wild-type virus in MDCK cells. To assess the stability for the
mutation, the rg-Y161F mutant was passaged on MDCK cells for three times. The rgY161F mutant at the third passage was sequenced to confirm no additional mutations
across HA, NA and six internal gene segments.
To determine if the mutations at the RBS altered HA antigenicity, we subjected
the panel of eight RBS CA/04 mutants to a hemagglutination inhibition (HI) assay, using
ferret antisera against CA/04. Both turkey and guinea pig erythrocytes were used in the
HI assays, and the results were identical. In summary, the HI titers of four reverse genetic
variants, rg-Y161F, rg-L154F-K156Q, and rg-P140T, were equivalent to that of the rg-wt
virus. The remaining four mutants, rg-D130E, rg-K174E, rg-S160T, and rg-Y201H, had
2-fold lower HI titers compared with that of the rg-wt. Thus, all of the RBS mutants were
antigenically similar to the parental CA/04 virus despite the presence of an altered virus
growth property. Due to its preferred growth and unaltered antigenic characteristics, rgY161F was selected as a candidate vaccine virus for further studies.
In addition, we compared the HI titers for the vaccine candidate rg-Y161F and the
wild type of CA/04 against a panel of 18 human sera. Results showed that there were no
more than 2-fold change between the HI titers of rg-Y161F and those of CA/04 wild type
virus (Table 5), confirming that mutation Y161F did not alter the antigenicity of CA/04
virus.
Table 5. Serological responses of wild type and 161F mutant against a panel of
human sera using HI assays.
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Seraa

rg-wt

rg-Y161F
HI titerb
AJP125
80
40
AJP126
80
80
AJP128
40
40
AJP225
160
160
AJP226
160
160
AJP228
20
20
CAJP251
160
160
CAJP252
160
160
CAJP261
80
80
CAJP262
80
80
CAJP271
80
80
CAJP272
80
40
CAJP281
80
80
CAJP282
160
80
CAJP291
160
160
CAJP292
160
160
CAJP301
80
80
CAJP302
160
80
a
panel of 18 human sera randomly collected from a vaccine efficacy study.
b
HI, hemagglutination inhibition. Titers were determined by using turkey red blood cells
under standard procedures.
Growth properties of rg-Y161F
To evaluate the replication efficiencies of rg-Y161F, we characterized its growth
kinetics alongside rg-wt in MDCK and Vero cells. We infected cells with viruses at a
multiplicity of infection (MOI) of 0.001 (MDCK cell infection) or 0.01 (Vero cell
infection) and determined the growth kinetics of the viruses for up to 96 h in MDCK cells
and 120 h in Vero cells. In MDCK cells, the virus titers of rg-Y161F reached 108.66
TCID50/ml at 72 h after infections, >300-fold higher than the highest virus titer from rgwt (Figure 11A). In Vero cells, the titers of rg-Y161F reached 10 8.25 TCID50/ml at 96 h
after infections, a titer >100–fold higher than the highest virus titer from rg-wt (Figure
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11B). The total viral protein of rg-Y161F in cells reached a mean titer of 1236.2 µg/ml,
2.07-fold higher than that of wild-type CA/04 (p = 0.008) (Figure 11C). These results
suggest that mutation Y161F facilitates the replication efficiency of CA/04 in MDCK and
Vero cells.

Figure 11.
Growth properties of wild-type (WT) and Y161F mutant viruses.
In Madin-Darby canine kidney cells (A) and Vero cells (B). Each data point represents
the mean virus yield (log10 TCID50/ml) from three individually infected wells ± the
standard deviation. TCID50, 50% tissue culture infectious dose. Total protein of viruses
propagated in Madin-Darby canine kidney cells (C) and 10-day-old embryonated chicken
eggs (D). Viruses were purified from cell supernatant or allantoic fluid by low-speed
clarification and then subjected to sucrose density-gradient centrifugation. The virus band
was collected and purified through a cushion of 30% sucrose. The virus pellet was
resuspended in 200 µl of phosphate-buffered saline, and the total amount of purified
virion proteins was determined by using a Pierce BCA Protein Assay Kit (Thermo
Scientific, Rockford, lL).
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Impact of HA RBS mutations on virus binding to erythrocytes
We next wanted to explore possible mechanisms for the increased yields of rgY161F by examining its interaction with host receptors. Due to their unique glycan
receptor profiles (i.e., types and distributions of alpha-2,3-linked sialic acid on galactose
[SA2,3GA] and alpha-2,3-linked sialic acid on galactose [SA2,6GA]), erythrocytes from
various hosts have often been used to characterize receptor binding properties for
influenza viruses through hemagglutination assays (HA assays). We used erythrocytes
from guinea pig, chicken, horse, turkey, and dog (beagle) to compare the glycan profiles
of the full panel of eight mutants. As shown in Table 4, all mutants and the wild-type (rgwt) virus agglutinated erythrocytes from guinea pig, chicken, turkey, and beagle to
different extents, but they did not agglutinate those from horse. The eight mutants could
be separated into three groups: 1) those with increased HA titer against guinea pig,
chicken, turkey, and beagle erythrocytes (rg-D130E, rg-K174E, and rg-Y161F mutants);
2) those with an hemagglutination pattern similar to that for wild-type virus (rg-S160T,
rg-P140T, and rgS188I mutants); and 3) those that had increased HA titer against guinea
pig, turkey, and beagle erythrocytes but no change in HA titers against chicken
erythrocytes (rg-L154F-K156Q and rg-Y201H mutants). Among the eight mutants, it was
striking that rg-Y161F had the highest HA titers (range, 128–1,024 HA units [HAU]) to
erythrocytes from guinea pig, chicken, turkey, and beagle.
Effect of Y161F mutation on the receptor binding
To further explore the molecular mechanisms of the rg-Y161F high-growth yield
phenotype, we characterized its receptor binding profile by using an N-linked glycan
isoform microarray. The microarray consisted of 66 chemoenzymatically synthesized and
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purified N-glycans (188) (Figure 12). As shown in Figure 13, both rg-wt and rg-Y161F
bound predominantly to N-glycans terminating with Neu5Ac. The rg-wt virus showed
binding to α2,6-Neu5Ac–linked glycans (N0x3, N113, NN144, N213, N223, and N244),
whereas the Y161F mutant showed a preference for binding to α2,3-Neu5Ac–linked
glycans (N0x2, N112, N122, N134, N212, N222, N234, N0x5, N115, N125, N155,
N215, N225, and N255) and relatively weaker binding to α2,6-Neu5Ac–linked glycans.
Neither rg-wt or rg-Y161F were observed with noticeable binding toward α2,6-Neu5Gc–
terminated glycans (N013G and N023G) or α2,3-Neu5Gc–terminated glycans (N012G,
N022G, N015G, and N025G) (Table 6).
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Table 6.
Glycan

Glycan-binding affinity of rg-wt and rg-Y161F
rg-Y161F

rg-WT

Mean RFU

ST

Mean RFU

ST

N000

188.492

550.5156

285

701.4905

N001

707.6438

327.5512

718

647.6747

N002

359.4128

756.848

9784

6650.103

N003

36156.92

1352.438

4101

1750.521

N004

4082.929

709.2189

2341

333.9741

N005

10568.33

3183.352

37495

3439.082

N010

2003.127

1170.928

279

368.8189

N011

-6.38956

331.721

40

193.4308

N012

87.85645

256.7783

1704

663.6608

N012G

1375.353

211.4849

3054

966.775

N013

7033.308

1224.56

1098

201.3879

N013G

107.0251

390.9631

1463

389.2667

N014

1060.667

220.0813

331

310.5335

N015

3314.584

813.7164

14582

2740.829

N015G

5498.216

1443.446

6669

6423.093

N020

1182.069

188.3146

236

727.8254

N021

1453.625

383.826

82

149.2909

N022

5320.906

755.8239

2670

685.0261

N022G

456.8535

325.5246

3025

711.258

N023

21654.22

1986.137

1394

579.4759

N023G

777.929

284.4424

1682

3332.606

N024

3212.351

829.6893

2533

999.7127

N025

6335.249

937.4352

15833

2407.865

N025G

239.6085

152.6565

2612

530.023

N026

249.1928

95.88622

730

267.9652

N030

178.9077

112.3649

94

140.3139

N031

3563.777

1083.908

1032

533.767

N032

3998.267

339.778

3654

2067.069

N033

13274.31

1664.171

3113

721.1124

N034

1472.794

365.1906

2500

917.1672

N035

13330.22

1665.253

18559

2067.877

N040

1218.809

624.9239

698

412.6959

N041

1258.743

180.6654

801

394.284

N042

830.6428

292.9735

2392

871.2684

N043

7586.005

1134.389

4347

3866.418

N044

-142.1677

239.8647

980

615.5946

N045

3739.49

395.2908

22341

2375.834
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Table 6 (continued)
Glycan

rg-Y161F

rg-WT

N049

2231.554

687.8912

2637

1119.127

N050

75.07733

225.1201

396

349.6206

N051

619.7873

326.0887

519

288.3692

N052

2450.396

237.1405

5243

2329.654

N053

6280.938

757.6721

6048

464.0661

N054

1621.351

439.9279

2405

718.5867

N055

6367.197

492.0465

21395

5372.608

N110

4210.72

1093.158

1929

583.4338

N111

1177.276

309.5498

1606

391.5552

N112

1388.132

213.1503

5276

1010.739

N113

4657.989

805.3834

1835

300.0338

N114

691.6699

180.6393

1747

680.6205

N115

2158.074

594.1063

15231

1578.711

N122

1047.888

740.8103

2926

1313.506

N123

1057.472

141.4559

836

395.9283

N124

1431.261

359.1119

1960

306.9908

N125

2273.086

228.571

9348

1251.171

N133

11023.59

486.8432

17598

3034.698

N134

5560.515

573.4557

15579

2390.632

N135

5995.005

1074.86

12655

1902.752

N144

4792.17

971.6005

2658

615.2907

N145

7766.51

2068.815

14714

1666.691

N155

6670.701

615.475

14761

3575.685

N210

6141.964

1427.767

9351

2169.871

N211

4458.315

465.7474

7704

1117.586

N212

3717.126

690.5637

3216

531.5538

N213

5090.882

717.456

2059

535.9692

N214

1314.652

147.5842

2649

833.5652

N215

4864.053

702.9951

15558

3083.07

N222

4202.733

760.8467

12091

2769.343

N223

5563.709

1585.746

6272

417.2571

N224

929.681

425.931

1595

737.1837

N225

2763.485

272.7199

6804

844.0257

N233

5712.267

564.436

9637

1302.378

N234

5375.217

327.8162

11365

2309.938

N235

4597.289

1014.55

25374

12768.65

N244

9734.495

2026.691

10064

1478.048
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Table 6 (continued)
Glycan
N245

rg-Y161F

rg-WT

7924.652

1231.199

12093

1442.352

N255

5079.7

759.0126

10519

4117.714

N6000

122.999

253.1477

987

644.012

N6030

1057.472

327.948

2049

706.8542

N6211

2848.146

475.4761

3637

1002.466

N6212

9988.479

1237.444

15156

3172.203

NC1

1191.653

418.669

1632

423.1982

NC2

142.1677

150.9403

720

287.198

PC

2309.826

262.7612

1980

500.1264

SG3LNnT

5250.621

1317.346

6814

1574.936

LNnT

1544.676

394.8941

2180

907.6503
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Figure 12.
Structures of chemoenzymatically synthesized N-linked glycans on the
isoform microarray.
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Figure 13.
Receptor binding specificity of wild-type and Y161F hemagglutinin 1
mutant viruses analyzed by glycan microarray analysis.
A–D represent different categories of glycans: A, alpha-2,3 sialic acid glycans; B, alpha2,6 sialic acid glycans; C, alpha-2,3 and alpha-2,6 acid glycans; D, non–sialic acid
glycans. Vertical bars denote the fluorescent binding signal intensity. The signal for the
marker on the array was derived from the reaction between the anti-Human IgG, Cy3
(0.01 mg/ml) and anti-Human IgG, Alexa647 (0.01 mg/ml), which serve as a positive
control in glycan microarray.
To confirm the binding profiles revealed by glycan array, we performed glycan
binding assays to characterize the dynamics and avidity of virus binding to two glycan
analogs, 3′SLN and 6′SLN. The representative binding plots for each glycan analog are
shown in Figure 14A and Figure 14B. Both rg-wt and rg-Y161F showed strong binding
to 6’SLN, although rg-Y161F exhibited relatively weaker binding affinity than rg-wt
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(<1.2 fold, Figure 14B). Conversely, rg-Y161F showed much stronger binding to 3′SLN;
whereas rg-wt had no detectable binding at the same 3′SLN concentration range tested
(Figure 14D). These results confirmed the glycan array profiles that the Y161F mutation
in HA dramatically increased binding affinity to 3'SLN while retaining strong binding
affinity to 6'SLN.
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Figure 14.
Glycan binding specificity of virus by Bio-Layer Interferometry
(fortéBIO, Menlo Park, CA).
A, B) Representative binding curve of H1N1 CA WT and Y161F toward alpha 2,6–
linked sialic acid (SA2,6GA) and alpha 2,3–linked sialic acid (SA2,3GA) receptor,
respectively. The streptavidin-coated biosensors were first preloaded with biotin-labeled
sialic acid receptors, followed by the 1 pM each virus binding for 1,200 seconds in a
standard kinetic buffer with neuraminidase inhibitors (zanamivir hydrate and oseltamivir
phosphate). C, D) Sialic acid receptor concentrations were titrated from 0.1 to 5 µg/ml
(SA2,6GA) or 0.2 to 5 µg/ml (SA2,3GA) when loading with the biotin-labeled receptors.
Each individual concentration was performed three times independently, and the binding
response unit (nm) was recorded at the 1,196 second time point (4 seconds before the
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start of dissociation).Three-dimensional structures of the hemagglutinin of wild-type
(HA-WT) influenza A/California/04/09 (H1N1) virus and mutant viruse (HA-161F) in
contact with avian-like receptor analog carbohydrate 3'-sialyl-N-acetyllactosamine
(3′SLN) (E) and human-like receptor avian 6'-sialyl-N-acetyllactosamine (6′SLN) (F). G)
The calculated PoseScore for viruses.
Structural mechanism of increased rg-Y161F binding to 3'SLN and 6'SLN
Crystal structure modeling was performed to characterize the effect of the Y161F
mutation on binding affinity between HA and two testing glycan analogs, 3'SLN (Figure
14E) and 6'SLN (Figure 14F). For 3'SLN, the PoseScore of the wild-type CA/04 HA was
5.99, whereas that for the Y161F HA was −6.63. For 6'SLN, the PoseScores for wild-type
CA/04 HA and the Y161F mutant were 2.06 and −11.89, respectively (Figure 14G).
These results suggest that the Y161F mutation leads to increased binding of CA/04 to
3'SLN and 6'SLN.
Effect of the Y161F mutation on replication efficiency of other IAVs
To understand the naturally occurring molecular polymorphisms at residue 161 of
HA, we compared a total of 59,016 HA sequences covering all 18 documented HA
subtypes (H1–H18) of IAVs. The results showed that Y161 is conserved in H1–H5, H8,
H9, H11, H13, H14, and H16 IAV subtypes, whereas F161 is conserved in H7, H10,
H12, and H15 IAV subtypes (Figure 15A). Phylogenetically, H7, H10, and H15 are
group 2 HAs, and H12 is a group 1 HA (Figure 15B).
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Figure 15.
Effect of 161F mutation on growth and thermostability of influenza A
virus
(A) Sequence alignment of hemagglutinin 1 (HA1) from 18 different influenza A virus
HA subtypes (H1–H18). Residues 161 (H3 numbering) are indicated by vertical
rectangle. (B) Y161 is conserved in subtypes H1–H5, H8, H9, H11, H13, H14, and H16.
F161 is conserved in subtypes H7, H10, H12, and H15. Each residue is numbered
according to the H3 HA numbering. C) Growth properties of canine subtype H3N8
influenza virus (cH3N8) and its hemagglutinin 1 (HA1) F161 mutant virus (cH3N8
Y161F) and of (D) influenza A/Puerto Rico/8/34 (H1N1) virus (PR8) and its HA1 F161
mutant virus (PR8 Y161F) in Madin-Darby canine kidney cells. Each data point
represents the mean virus yield (log10 TCID50/ml) from three individually infected wells
± the standard deviation. E) Effect of 161F mutation (H1N1 161) on the thermostability
of influenza A/California/04/09 (H1N1) virus (H1N1 WT). F) Effect of 161F mutation
(H3N8 161F) on the thermostability of influenza A/canine/Iowa/13628/2005 (H3N8)
virus (H3N8). The viruses with equal HA titers were incubated at the indicated
temperatures for 40 minutes and then titers were determined. TCID50, 50% tissue culture
infectious dose.
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To test whether theY161F mutation would increase growth yields in IAVs other
than CA/04, we generated 161F mutants for two additional strains: TX/50 and canineH3N8. Analysis of growth kinetics in MDCK cells at an MOI of 0.001 showed that the
TX/50 161F mutant generated viral titers of 103.17, 105.92, 107.20, and 107.00 TCID50/ml at
12, 24, 48, and 72 h, respectively. This finding compared with 102.33, 105.25, 107.08, and
107.00 TCID50/ml at 12, 24, 48, and 72 h, respectively, for the wild type TX/50 virus. The
TX/50 161F mutant in MDCK cells generated a mean total viral protein titer of 882.2
mg/ml, 1.15-fold higher than that for the TX/50 wild-type virus (Figure 11C). When
subjected to ferret antisera in an HI assay, the TX/50 wild-type virus and 161F mutant
both had mean HI titers of 1:1280.
Analysis of growth kinetics in MDCK cells at an MOI of 0.001 showed that the
161F mutant of canine-H3N8 had the highest titer (107.249TCID50/ml) at 72 h after
infection; this titer was about 10-fold higher than that generated by the canine-H3N8
wild-type virus (Figure 15C). The mean HI titers of wt and rg canine-H3N8 to ferret
antisera was 640 and 533, respectively. The total viral protein of the canine-H3N8 161F
mutant reached a mean titer of 777.2 µg/ml, which was 1.85-fold higher than that of
canine-H3N8 wild-type virus (p = 0.02) (Figure 11C). We further compared influenza
virus specific protein yields by Western blot analysis using NP specific monoclonal
antibody, and results showed that the Y161F mutation increased the influenza specific
NP protein yields for rg-CA/04, rg-Tex/50, and rg-H3N8 by 42%, 18%, and 20%,
respectively. By using H1 specific monoclonal antibody, results showed that the Y161F
mutation increased the HA protein yields for rg-CA/04 by 39% (Figure 16).
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The results suggest that the Y161F mutant can enhance replication efficiency but
does not change the antigenicity of TX/12 and canine-H3N8 viruses.

Figure 16.
Western blot showing the NP and HA protein expression level for the wild
type and mutant viruses. The bands were analyzed by ImageJ software.
Effect of the Y161F mutation on replication efficiency of IAVs in eggs
While we were able to show an elevated growth phenotype of HAY161F
containing viruses in cells, we next sought to determine its impact on egg growth. To do
this we quantified the total protein yields of wt and Y161F mutant H1N1, H3N2, and
H3N8 IAVs in eggs. The total viral protein of the rg-Y161F mutant reached a mean titer
of 1,460.2 µg/ml, 1.22-fold higher than that of wild-type CA/04. Similarly, for TX/50, the
Y161F mutation conferred a 1.23-fold increase in total viral protein (1,589.2 µg/ml). The
total viral protein of the canine-H3N8 Y161F mutant reached a mean titer of 1,824.2
µg/ml, 1.45 fold higher than that of wild-type canine-H3N8 (Figure 11D). Thus, the
Y161F mutation also increased viral replication efficiency of three H1N1, H3N2, and
H3N8 IAVs tested in eggs.
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Impact of the Y161F mutation on viral thermostability
Another desirable property of an influenza vaccine virus is an increased stability.
To determine whether the Y161F mutation correlated with changes in viral
thermostability, purified viruses were diluted to 128 HAU/50 µl and incubated at a series
of high temperatures (51.5°–65°C) for 40 min, and the integrity of the HA protein was
then detected by an HA assay using 0.5% turkey erythrocytes. The CA/04 rg-wt virus
showed a precipitous drop in HA titer (from 128 to 2 HAUs) after 40 min of incubation at
55.7°C. In contrast, rg-Y161F maintained an HA titer of 64 HAU at 55.7°C which did not
drop until 59.5°C. The mutant virus maintained an HA titer of 2 HAU even at 61.4°C.
The rg-wt virus completely lost its hemagglutination ability at 55.7°C (Figure 15E).
Similar phenotypes were observed in the 161F mutants for canine-H3N8. The canineH3N8 Y161F mutant had an HA titer of 16 HAU when incubated at 57.6°C for 40 min;
this titer was 8-fold higher than that of wild-type H3N8 virus (Figure 15F). For TX/50,
the wild-type and Y161F viruses maintained titers of 8 HAU and 16 HAU, respectively,
at 61.4°C (data not shown). Taken together, the results show that the Y161F mutation
conferred higher viral temperature stability on viruses.
High-yield vaccine candidate protected mice against lethal challenge
Although we had shown that the Y161F mutation had no impact on HAI titers, we
wanted to directly confirm that there was not an associated loss in vaccine efficacy. To
do this we prepared inactivated whole virus vaccines from rg-wt and rg-Y161F CA/04
viruses and evaluated their efficacy in a mouse model. Mice were administered vaccine
or PBS (as a mock vaccine, and 2 weeks later we collected blood samples for testing. All
vaccinated mice had seroconverted and their HI titers were substantially higher than those
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of the mock-vaccinated mice (Table 7); mice vaccinated with rg-wt vaccine and rgY161F vaccine had log2(HI) titers of 7.65 ± 0.57 and 7.32 ± 0, respectively. The
heterologous HI titers were indistinguishable (p = 0.3739) from homologous titers, again
demonstrating the antigenic similarly of wt and mutant viruses.
Table 7. Immunologic and pathogenic responses in mice challenged with mouseadapted influenza A/California/04/09 (H1N1)

Vaccine
group

Log10TCID50/ml,
mean ± SDa

Log2HI titer, mean ±
SDb

log2HI titer,
mean ± SDc

WT

Below detection limit

7.65 ± 0.57

7.32±0

Mutant

Below detection limit

7.32±0

7.32±0

5.28 ± 0.14

Below detection
limit

Below detection
limit

PBSd

a

Groups of BALB/c mice were inoculated intranasally with 10× the 50% lethal dose of
mouse-adapted CA/04 virus under light anesthesia. Three mice from each group were
euthanized on day 4 after virus challenge, and virus titers in lungs were determined by
TCID50 (50% tissue culture infectious dose) in MDCK cells.
b
Serum samples were collected before challenge, and antibody response levels against the
wild-type (WT) virus were measured by using the hemagglutination inhibition (HI) assay.
c
Serum samples were collected before challenge, and antibody response levels against the
immunogen mutant were measured by using the HI assay.
d
PBS, phosphate-buffered saline mick-infection.

Following challenge, a high level of virus replication (up to 105.45 TCID50) was
observed in mock-vaccinated mice, but no virus was detected in mice vaccinated with rgwt or rg-Y161F derived vaccine. Mock-vaccinated mice exhibited signs of inactivity and
lethargy, had ruffled hair, and rapidly lost weight following challenge (Figure 17A). In
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contrast, mice vaccinated with rg-wt or rg-Y161F derived vaccines did not exhibit any
detectable clinical signs. All vaccinated mice survived, but by post-challenge day 6, all
mock-vaccinated mice (n = 5) had lost 25% of their pre-experiment body weight and
were euthanized (Figure 17B).
Results from histopathologic analyses showed that mice immunized with rg-wt or
rg-Y161F derived vaccine had no apparent pathologic changes (Figure 17C and Figure
17D). However, the mock-vaccinated mice exhibited severe bronchiolitis, and their
bronchioles showed necrosis and some attenuated regenerative epithelial cells along the
basement membrane (Figure 17E).
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Figure 17.
Weight loss and survival among vaccinated mice challenged with a lethal
dose (LD) of influenza A/California/04/09 (H1N1) virus (CA/04).
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Mice were vaccinated with wild-type (WT) or Y161F (Mutant) virus vaccine or mockvaccinated with phosphate-buffered saline (PBS) and then challenged with 10 LD50 of
mouse-adapted CA/04 by intranasal inoculation and monitored daily for 2 weeks. A)
Percent change in body weight; each point represents the mean body weight of 5 mice per
group. B) Percent surviving mice after challenge. ***, p<0.0001 for PBS group versus
WT group, as calculated by GraphPad Prism 5 software
(http://www.graphpad.com/scientific-software/prism/). Histopathologic changes in
hematoxylin and eosin–stained lung samples from groups of mice vaccinated with rgCA/04 wild-type (WT) (C) or rg-CA/04 161F (Mutant) (D) virus vaccine; mockvaccinated with phosphate buffered saline (E); or serving as controls (F). Samples were
collected 4 days after vaccinated and mock-vaccinated mice were challenged with 10
LD50 of mouse-adapted influenza A/California/04/09 (H1N1) virus. Magnification ×200.

In summary, our results from experiments in mice suggest that the Y161F
mutation in HA did not alter the viral antigenicity of CA/04 or efficiency of the vaccine
in mice.
Discussion
An effective influenza vaccination is dependent on a number of factors, not the
least of which are high yielding and stable vaccine viruses. A high yield of virus is
critical to vaccine manufacturing, and thermostability of viral antigens is critical for
vaccine shelf life which can be compromised during transportation and storage. In this
study we screened a group of randomly generated CA/04 mutants carrying substitutions
at the HA RBS. While a number of these mutants displayed enhanced features, one,
containing an Y161F change, had increased thermostability and the highest viral yields.
This mutation was also able to impart these properties on a seasonal H3N2 and a canine
H3N8 virus showing that the effect was not subtype-specific. Compared to those on
CA/04, the effects of Y161F on the seasonal H3N2 and canine H3N8 viruses we tested
were relatively less effective. One possible explanation is that, unlike the CA04 wild type
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virus which replicates poorly in MDCK cells (105.75 TCID50/ml at 72 h), TX/50 and
canine-H3N8 wild type viruses have a high replication efficiency with 107.20 TCID50/ml
and 106.50 TCID50/mL at 72 h, respectively. Furthermore, the Y161F mutation did not
change the antigenicity of the H1N1, H3N2, and H3N8 viruses tested. Animal
experiments further showed that the Y161F change in CA/04 did not have measurable
impact on the efficacy of inactivated whole-virus vaccines containing it. These results
highlight the application potential of the HA 161F signature in influenza vaccine
manufacture.
The initial step in viral infection is the binding of HA to the sialic acid receptors
on the epithelial cell surface (193). This interaction is mediated by the RBS which is
located at the globular head of the HA and consists of the 130 and 220 loops and the 190
helix. Mutations at the RBS have long been known to affect the yield of a vaccine strain
which was our rationale for targeting it. For example, mutation L194P increased the yield
of an A/England/611/07 (H3N2) 6 + 2 reassortant virus (153), and single or double
mutations at 191 (194 in H3), 197 (200), 222 (225), and 223 (226) increased replication
of A/California/7/09 (H1N1) in eggs (120). Mutations at residue 186 and 194 in the HA
of an A(H1N1)pdm09 virus have also been shown to improve viral titers in MDCK cells
and eggs (181). Avian virus yields can also be improved by targeting the RBS and the
double mutation of N133D/G198E in the HA have been reported to increase H7N9 viral
yields (194). The challenge of targeting the RBS for improving virus yields is that some
mutations which lead to improved growth also alter antigenicity. For example, mutation
G144E was shown to increase the yield of B/Victoria/504/2000, but the antigenic
properties of the virus were also changed (154). Single amino acid changes at positions
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119 (122 in H3), 153 (156), 154 (157), and 186 (189) could increase the yield of
A/California/7/09 (H1N1) in eggs, but mutations at residues 153 (156 in H3), 154 (157),
and 155 (158) drastically altered viral antigenicity (119).
The natural plasticity of the RBS for accepting substitutions was highlighted by
Yasugi et al. (195). These authors used Roche 454 sequencing to directly sequence nasal
specimens from three patients infected with A(H1N1)pdm09 virus. They found the virus’
HAs showed high levels of amino acid diversity, with polymorphisms ranging from 3.45–
8.59% for a K119N substitution, 1.01–4.99% for a N125D substitution, 0.74–21.49% for
a D222G substitution, and 2.39-4.64% for a Q223R substitution (195). The percentages
of the K119N, N125D, D222G, and Q223R mutations reached up to 60.4%, 96.7%, 85%,
and 95.8%, respectively, after egg adaptation of the primary specimens (195). Similarly,
mutations K119N and D222G were also found in the high-yield, egg-adapted
A(H1N1)pdm09 virus vaccine strain NIBRG-121xp, and a Q223R mutation was found in
another high-yield, egg-adapted A(H1N1)pdm09 strain NYMC-181A (119). These
findings demonstrate that selection or generation of an HA variant, especially in RBS of
HA, can in some cases be rapidly achieved. However, the genetic features for high-yield
property are still not fully understood and generation of high-yielding viruses using
classical virologic techniques is sometimes more challenging. In this study we therefore
opted for a random mutagenesis approach which generated eight mutants, of which four
(D130E, K174E, L154F-K156Q, Y161F) increased viral yields in cells without changing
antigenic properties (Table 4). Among these mutants, Y161F had the largest increase in
viral replication efficiencies in both MDCK and Vero cells (Figure 11).
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Binding to the host cell is the first step of influenza virus infection. Thus, the
presence of favorable receptors on a specific cell is one of the key factors determining
host and tissue tropisms of IAV. Most studies related to influenza receptors have
classified the sialic acid receptors into two groups on the basis of positions of the sialic
acid–galactose linkage: SA2,3GA or SA2,6GA. Both SA2,3GA and SA2,6GA are
present in any single cell type, but their distributions varies based on the types of cells.
For example, SA2,3GA and SA2,6GA are present in both MDCK and Vero cells, but
SA2,3GA is considerably more abundant than SA2,6GA in both cell lines (196-198).
However, in chicken erythrocytes, SA2,6GA is more abundant than SA2,3GA (55). Thus,
an ideal high-yield vaccine candidate would have high binding affinities to both
SA2,3GA and SA2,6GA (199). This double binding was the phenotype the Y161F
mutant in multiple assays, providing a plausible explanation for the increased yields in
MDCK and Vero cells.
The HA RBS is a member of the lectin superfamily, and the specificity of RBS
contributes to the host range of IAVs. Results of our structure modeling showed that
residue 161 locates at the top of the RBS (Figure 14). Others have previously reported
that an Y161A substitution in the H5N1 HA changed the receptor binding preference
from Neu5Ac to N-glycolylneuraminic acid (Neu5Gc), however, and the mutation
Y161A did not increase virus replication efficiency on MDCK cells (200). In addition,
the results of that study showed that the Y161A mutants were best in viral replication and
plaque forming ability. Our findings suggest that the binding preference of virus is
changed by introducing the F substitution at residue 161. This substitution in CA/04
accommodates virus binding to both SA2,3GA and SA2,6GA and is responsible for the
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acquisition of specificity to SA2,3GA receptors. The Phe side chain lacks the O4
hydroxyl group present on the Tyr shortening the distance between the oxygen atom of a
water molecule and residue 161; and this potentially facilitates acquisition of the viral
specificity to SA2,3GA.
Environmental factors such as temperature and pH have been reported to affect
airborne transmission of IAV, possibly by affecting viral thermostability (201). Thus,
viral thermostability could affect the quality of and transmissibility of influenza viruses.
A T318I substitution in HA increased its stability and affected the binding property of an
reassortant H5 HA/H1N1 influenza virus (150). Thus, identification of amino acid
substitutions that increase viral thermostability would also be important risk assessment
factors for emerging IAVs, such as those of subtypes H5 and H7 (202). Moreover, in
agreement with our observations, Watanabe et al. (203) reported that HA thermostability
was correlated with viral replication and glycan receptor binding of H5N1 viruses.
However, further studies are needed to interpret the molecular mechanism of increased
HA thermostability by mutations.
In conclusion, our study shows that the mutation Y161F in the RBS of the
A(H1N1)pdm09 HA significantly increased viral yield in MDCK and Vero cells by
promoting virus binding to both SA2,3GA and SA2,6GA without altering the original
antigenicity. The results suggest that Y161F mutation in HA might have potential in
generating seed virus of high yield for cell-based influenza vaccine development and
production.
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CHAPTER IV
MUTATION W222L AT THE RECEPTOR BINDING SITE OF HEMAGGLUTININ
COULD FACILITATE VIRAL ADAPTION FROM EQUINE INFLUENZA A(H3N8)
VIRUS TO DOGS
An outbreak of respiratory disease caused by the equine-origin influenza
A(H3N8) virus was first detected in dogs in 2004 and since then, has been enzootic
among dogs. Currently, the molecular mechanisms underlying host adaption of this virus
from horses to dogs are unknown. Here, we have applied quantitative binding, growth
kinetics, and immunofluorescence analyses to elucidate these mechanisms. Our findings
suggest that a substituation of W222L in the hemagglutinin of the equine-origin A(H3N8)
virus facilitated its host adaption to dogs. This mutation increased binding avidity of the
virus specifically to receptor glycans with N-glycolylneuraminic acid (Neu5Gc) and
sialyl Lewis X (SLeX) motifs. We’ve demonstrated these motifs are abundantly located in
the submucosal glands of dog trachea. Our findings also suggest that in addition to the
type of glycosidic linkage (e.g., α 2,3-linkage or α2,6-linkage), the type of sialic acid
(Neu5Gc or 5-N-acetyl neuraminic acid) and the glycan substructure (e.g., SLeX) also
play an important role in host tropism of influenza A viruses.
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Introduction
Influenza A viruses (IAVs) can infect a wide range of species, including humans,
poultry, wild birds, pigs, horses, mink, marine mammals, and dogs (204-206). IAV was
first isolated from dogs in the United States in January 2004 during an outbreak of
respiratory disease among dogs in Florida. Epidemiologic evidence along with antigenic
characterization and genetic analyses of the isolated subtype A(H3N8) IAV suggested
that the virus had “jumped” from horses to dogs (206). The virus gained the ability to
transmit between dogs and became enzootic among dog populations in the United States.
IAV transmission from birds to humans, or even between different mammalian
hosts, is not uncommon, but such transmission is usually transient and causes only
sporadic cases or small outbreaks with limited spread. It has been postulated that the
adaption of avian IAVs to humans requires an intermediate mammalian host, such as the
pig, that harbors both avian-like receptor saccharides containing α2,3-linked sialic acidgalactose (SA2,3Gal) and human-like receptor saccharides containing α2,6-linked sialic
acid-galactose (SA2,6Gal) in the respiratory tract (207, 208). However, the glycosidic
linkages alone cannot explain interspecies transmission of IAV between mammalian
hosts or between mammalian and avian hosts. For example, receptor saccharides
containing SA2,3Gal (26, 209, 210) are predominant in the respiratory tract of dogs and
horses, but equine IAV (EIV) cannot be transmitted freely between dogs and horses, as
evidenced by the fact that the North American-lineage A(H3N8) EIV was only recently
introduced into dogs and subsequently became enzootic among them (211).
The adaption of an influenza virus to a new host usually requires mutation(s) at
one or multiple virus gene segments (212, 213). It has been suggested that the A(H3N8)
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EIV and A(H3N8) canine IAV (CIV) have minimal biological differences, and their
cross-species transmission and adaption may be mediated by subtle changes in virus
biology (214). Sequence analyses suggested that A(H3N8) CIV, compared with its
precursor North American lineage A(H3N8) EIV, had mutations N54K, N83S, W222L,
I328T, and N483T in the hemagglutinin (HA) (Table 8) and a few additional mutations in
neuraminidase and other internal gene segments (215, 216). A difference in receptor
binding between the wild-type A(H3N8) EIV (wt-eH3N8) and the wild-type A(H3N8)
CIV (wt-cH3N8) has also been suggested (217).
The molecular mechanism for how A(H3N8) IAV adapts from equine to canine
remains unclear, largely because the types of sialosides and their relative distributions
and abundance in the respiratory tract of dogs and horses have not been fully elucidated.
We aim to gain an understanding of the molecular mechanisms that enabled A(H3N8)
IAV to switch from horses to dogs and to provide insight into how this emerging IAV
adapted to a new host.
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188
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138
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134
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220 Loop

190 Loop

130 Loop

Table 8. Predominant residues at the receptor binding sites of H3N2 (canine, avian),
and H3N8 (canine, equine) influenza viruses.
Virus

Materials and Methods
Cells and viruses
MDCK, A549, and DF-1 cells were purchased from American Type Culture
Collection (Manassas, VA). The cells were maintained at 37°C with 5% CO2 in
Dulbecco's Modified Eagle Medium (GIBCO/BRL, Grand Island, NY) supplemented
with 10% fetal bovine serum (FBS; Atlanta Biologicals, Lawrenceville, GA) and
penicillin (100 units/ml)–streptomycin (100 µg/ml). Influenza viruses,
A/canine/Iowa/13628/2005(H3N8), Miami-eH3N8, and Pennsylvania-eH3N8 maintained
in our laboratory were used in the study; the viruses were propagated and titrated in the
MDCK cells to determine their TCID50.
Gene cloning, site-directed mutagenesis, and virus rescue
All gene segments of A/canine/Iowa/13628/2005(H3N8) virus were cloned into
the phw2000 vector, as previously described (218). The QuikChange II Site-Directed
Mutagenesis Kit (Agilent Technologies, Santa Clara, CA) was used to create specific
mutations in the HA gene by using the following primers: forward 5′TGGGGAAAATATGCAACAACTCATATAGAATTCTAGATGG-3′ and reverse 5′CCATCTAGAATTCTATATGAGTTGTTGCATATTTTCCCCA-3′ were used to
generate mutation K54N in HA of A/canine/Iowa/13628/2005 (H3N8) virus; forward 5′GCCCTTCAGTATGAGAATTGGGACCTCTTTATAG-3′ and reverse 5′CTATAAAGAGGTCCCAATTCTCATACTGAAGGGC-3′ were used to generate
mutation S83N in HA of A/canine/Iowa/13628/2005 (H3N8) virus; and forward 5′CGAATCTAGACCGTGGGTCAGAGGTCAATC-3′ and reverse 5′GATTGACCTCTGACCCACGGTCTAGATTCG-3′ were used to generate mutation
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L222W in HA of A/canine/Iowa/13628/2005 (H3N8) virus. In brief, the site-directed
mutagenesis PCR amplification mixture contained 38.5 µl of water, 5 µl of 10× reaction
buffer, 1 µl of 2.5 mM dNTP mix, 1.25 µl (100 ng/µl) of each primer, 2 µl (5 ng/µl) of
wild-type (wt) HA segments of A/canine/Iowa/13628/2005 (H3N8) plasmid, and 1 µl of
PfuUltra HF DNA polymerase (2.5 U/µl). The parameters of the site-directed
mutagenesis PCR were as follows: one cycle at 95°C for 30 s, followed by 16 cycles at
95°C for 30 s, 55°C for 1 min, and 68°C for 5 min. The PCR products were then digested
with DpnI at 37°C for 1 h, the PCR product (2 µl) was transfected into XL1-Blue
Supercompetent Cells (Agilent Technologies, Santa Clara, CA). The transformed cells
were directly inoculated onto Luria broth agar plates. Then the plasmids were extracted,
and the mutant viruses were rescued by plasmid-based reverse genetics methods, as
described by Hoffmann et al. (219). All the viruses were sequenced to confirm no
unwanted mutations.
Replication kinetics
To determine multistep growth curves, we infected MDCK, A549, and DF-1 cells
with viruses at a multiplicity of infection of 0.01. After 1 h of incubation at 37°C, the
cells were washed twice with warm PBS and overlaid with infection medium (OptiMEM; GIBCO/BRL, Grand Island, NY) supplied with 1 µg/ml of TPCK-treated trypsin
and penicillin (100 units/ml)–streptomycin (100 µg/ml)). Supernatants were collected at
12, 24, 48, and 72 h after infection and stored at −80°C for titration by TCID50 assay in
MDCK cells.
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Trachea collection and preparation
Trachea tissues were obtained within 2 h from adult dogs following euthanasia for
non-respiratory related illness. Whole tracheas were transported in pre-warmed wash
medium consisting of a 1:1 mixture of DMEM and Bronchial Epithelial Cell Growth
Medium (BEGM; Lonza, Walkersville, MD) supplemented with penicillin (1,000 U/ml;
Sigma, St. Louis, MO), streptomycin (500 µg/ml; Sigma, St. Louis, MO). Once in the
laboratory, tracheas were kept at 37°C in a 5% CO2 humidified incubator. Over 3 h, four
to six washes were performed by immersing the tissues in fresh, warm wash medium.
Preparation of the tracheal explants
After the washing steps, we removed the surrounding connective tissue exterior to
the tracheal cartilage, opened the tracheas, and cut them lengthwise into four strips. Each
segment was then cut into approximately 5 mm explants by Biopsy punch (IntegraMiltex,
York, PA). The explant slices were placed on a 24-well transwell plate (Corning,
Corning, NY) supplied with 200 µl of explant growth medium consisting of a 1:1 mixture
of DMEM and BEGM supplemented with penicillin (200 U/ml), streptomycin (200
µg/ml), amphotericin B (5 µg/ml; Lonza, Walkersville, MD), and a BEGM SingleQuots
Kit (Lonza, Walkersville, MD) (1 kit in 500 ml of 1:1 mixture of DMEM and BEGM).
Explants were maintained at 37°C in a 5% CO2 humidified incubator; the apical and
basal growth media were changed every four h to remove any secreted cytokines and
inflammatory mediators. Before being infected, the trachea explants were washed two
times with 2× sterile PBS. Then 200 µl of infection medium containing BEBM with 0.5%
bovine serum albumin (BSA), penicillin (200 U/ml), streptomycin (200 µg/ml), and
amphotericin B (5 µg/ml) was added into the apical chamber, and the tissue was allowed
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to equilibrate for 30 min in the incubator. After removal of the infection medium, 400
TCID50 each of wt-cH3N8, Pennsylvania-eH3N8, Miami-eH3N8, rg54N-cH3N8, rg83NcH3N8, and rg222W-cH3N8 mutants was added to the apical chamber of the well and
incubated for 1 h at 37°C. After three washes with 1× sterile PBS, 500 µl of fresh growth
medium was added to the basal chamber, and 200 µl of infection medium was added to
the apical membrane. Infection medium was removed from the apical chamber at
different timepoints, and the viral titers were determined by TCID50 assay in MDCK
cells.
Consortium for Functional Glycomics (CFG) glycan array
Viruses binding to a wide range of glycan analogs were evaluated by CFG glycan
array. Viruses were first purified through a sucrose cushion at 100,000 × g for 3 h. The
purified viruses were labeled with desiccated Alexa Fluor 488 NHS Ester (Succinimidyl
Ester; Invitrogen, Carlsbad, CA) according to the manufacturer’s instructions. After
dialysis with the Slide-A-Lyzer MINI Dialysis devices (Thermo Scientific, Rockford,
IL), the Alexa Fluor 488–labeled viruses were transferred to clean tubes and stored at 4°C
until used in glycan microarray hybridizations. In glycan hybridization, the version 5.0
glycan slides (CFG) were used as described (220). The binding image was read in a
Perkin-Elmer ProScanArray scanner and analyzed using ImaGene 6.0 image analysis
software (BioDiscovery Inc., El Segundo, CA). Relative fluorescence unit (RFU) data
were normalized by adjusting the total RFU to the same level across all experiments. A
threshold of 2,000 RFU was used to floor the samples; only glycans with at least 2,000
RFU were analyzed statistically. The Wilcoxon signed rank-sum test was used to
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compare the glycan-binding patterns among rg-wt–cH3N8, rg-54N–cH3N8, rg-83N–
cH3N8, and rg-222W–cH3N8 mutants.
N-Glycan isoform microarray
The 83 N-glycans (188) were printed on N-hydroxysuccinimide (NHS)–
derivatized slides as described previously(221). All glycans were printed in replicates of
six in a subarray, and eight subarrays were printed on each slide. All glycans were
prepared at a concentration of 100 pM in phosphate buffer (100 mM sodium phosphate
buffer, pH 8.5). The slides were fitted with an eight-chamber adapter to separate the
subarray into individual wells for assay. Before the assay, slides were rehydrated for 5
min in TSMW buffer (20 mM Tris-HCl, 150 mM NaCl, 0.2 mM CaCl2, and 0.2 mM
MgCl2, 0.05% Tween). Viruses are purified by sucrose density gradient
ultracentrifugation and titrated to about 105 hemagglutination units/ml. Then 15 µl of 1.0
M sodium bicarbonate (pH 9.0) was added to 150 µl of virus, and the virus was incubated
with 25 µg of Alexa Fluor 488 NHS Ester (Succinimidyl Ester; Invitrogen, Carlsbad, CA)
for 1 h at 25°C. After overnight dialysis to remove excess Alexa 488, viruses HA titer
were checked and then bound to glycan array. Labeled viruses were incubated on the
slide at 4°C for 1 h, washed, and centrifuged briefly before being scanned with an
InnoScan 1100 AL fluorescence imager (Innopsys, Carbonne, France).
Biolayer interferometry
Two biotinylated glycan analogs (3′SLN: Neu5Acα2-3Galβ1-4GlcNAcβ and
6′SLN: Neu5Acα2-6Galβ1-4GlcNAcβ) linked to 30-KDa polymers containing 20% mol
sugar and 5% mol biotin (GlycoTech, Gaithersburg, MD) were used to represent α2,399

linked sialic acid (3′SLN) and α2,6-linked sialic acid (6′SLN). The stock solution (1
mg/ml) was prepared in 1× PBS (v/v) according to manufacturer’s instructions.
Biotinylated glycans Neu5Acα2-3Galβ1-4(Fucα1-3)GlcNAcβ (SLeX), Neu5Gcα23Galβ1-4GlcNAcβ 3′SLN (Gc), and Neu5Gcα2-3Galβ1-4(Fucα1-3)GlcNAcβ (SLeX (Gc))
were synthesized. All glycan analogs and viruses were further diluted into the kinetics
buffer (pH 7.4; PBS solution containing 0.01% BSA and 0.002% Tween-20) with
neuraminidase inhibitors (10 µM zanamivir hydrate and 10 µM oseltamivir phosphate)
for binding analysis. The binding affinities of viruses (100 pM) to glycan analogs
(ranging from 0 to 0.5 µg/ml for 3′SLN and 6′SLN; 0 to 0.5µM for SLeX, Gc, and SLeX
(Gc)

) were determined using an Octet RED96 interferometer equipped with streptavidin

biosensors (Pall ForteBio LLC, Fremont, CA). In summary, RSL of the biosensor was
calculated at the end of a 5- to 10-min loading, and the binding signal was measured at
25°C in a 20-min association step and 20-min dissociation step, with orbital shaking at
1,000 × rpm. The response of virus binding to a certain glycan loading was recorded at
the end of the association step. The normalized response was calculated by dividing the
maximum response of each glycan. The fractional saturation of the biosensor surface was
calculated by using the Hill equation as reported by Xiong et al. (102). RSL0.5 is the
relative sugar loading on the streptavidin biosensor when the fractional saturation of the
biosensor surface equals to 0.5. Given two testing viruses and a specific glycan, a higher
binding response and a smaller value of RSL0.5 a stronger binding avidity a virus will be; given
,

two testing glycans and a specific virus, a higher binding response and a smaller value of RSL0.5,
a stronger binding avidity a virus will be.
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Detection of SLeX and Neu5Gc glycans in horse and dog trachea
Normal horse and dog tracheal tissues were fixed in 10% neutral buffered
formalin for 30 h at room temperature. The tissues were paraffin-embedded and sectioned
at 5µm and then mounted on 3-aminopropyltrethoxy-silane–coated slides (Sigma, St.
Louis, MO). The slides were then deparaffinized in xylene and rehydrated through graded
alcohols. Antigen was then retrieved using Target Retrieval Solution (Dako, Carpinteria,
CA), after which the slides were blocked by blocking reagent in 5% BSA for 1h at room
temperature and then washed three times with PBST (PBS with 0.05% Tween 20). For
detection of sialyloligosaccharides reactive with SLeX antibody, the sections were
incubated overnight at 4°C with 250 µl of Alexa Fluor 488 anti-human Sialyl Lewis X
(dimeric) Antibody (1:100, BioLegend, San Diego, CA). Sections were washed three
times each with PBST and PBS, then slides were counterstained with 4′,6-diamino-2phenylindole, dihydrochloride (DAPI; Thermo Scientific, Rockford, IL). For detection of
sialyloligosaccharides reactive with Neu5Gc, slides were incubated overnight at 4°C with
Anti-Neu5Gc antibody (1:400, BioLegend, San Diego, CA). The slides were washed
three times each in PBST and PBS and then incubated at room temperature for 1h with
Goat anti-Chicken IgY (H+L) Secondary Antibody, Alexa Fluor 594 (Thermo Scientific,
Rockford, IL) diluted 1:100 in PBS with 1% BSA. The sections were counterstained with
DAPI for 3 min at room temperature. Then, after three washes with PBS, the sections
were mounted on coverslips with ProLong Gold Antifade reagent (Thermo Scientific,
Rockford, IL) and evaluated with a fluorescence microscope (Nikon, Tokyo, Japan).
Photos were taken with a digital microscope camera (Olympus, Tokyo, Japan).
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Sequences alignment and statistical analyses
HA sequences of H3N8 (equine and canine) and H3N2 (canine and avian)
influenza virus were extracted from the influenza research database
(http://www.fludb.org). The H3N2 CIVs included 120 isolates recovered from 2006 to
2018 and the H3N8 CIVs contained 347 isolates from 2003 to 2018. The multiple
sequence alignments and the identification of the mutations were identified by using
Bioedit software (192). Analysis of variance or unpaired t test was used to compare viral
titers and binding to IAV glycan receptors.
Results
Growth Kinetics
To evaluate the effect of mutations K54N, S83N, and L222W in the HA on the
growth properties of A(H3N8) IAV, we compared the growth kinetics in canine trachea
explants for the two EIV strains (i.e., one prototype EIV, A/equine/Miami/63(H3N8)
[abbreviated as Miami-eH3N8]), and a wild type field strain of EIV,
A/equine/Pennsylvania/1/2007 (H3N8) [abbreviated as Pennsylvania-eH3N8]), wtcH3N8, and three wt-cH3N8–derived HA mutants (54N, 83N, and 222W). No significant
difference (p > 0.05) was found between infectivity titers for 54N-cH3N8 and wt-cH3N8
in canine trachea explants (Figure 18A). In contrast, the growth ability of cH3N8 in the
explant tissues was significantly hampered by mutations S83N and L222W. wt-cH3N8
reached an average titer of 105.249 50% tissue culture infective dose (TCID50)/ml at 72 h
after infection; this titer was 26.1-fold higher than that for 83N-cH3N8 (p < 0.05) and
21.5-fold higher than that for 222W-cH3N8 (p < 0.05). Of interest, titers for both MiamieH3N8 and Pennsylvania-eH3N8 in canine trachea explants were similar to those for
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222W-cH3N8 (p > 0.05). No virus infectivity was detected in the mock-infected canine
trachea explants.

Figure 18.
Growth properties of equine influenza A virus, canine influenza A virus,
and mutant viruses derived from canine influenza A viruses in canine trachea explants
(A), MDCK cells (B), A549 cells (C), and DF-1 cells (D).
Trachea explants from dogs were infected with 400 TCID50 of each virus. Cells were
infected in triplicate with each virus at a multiplicity of infection of 0.01 and incubated at
37°C. Supernatant fluids were collected at indicated time points, and the viral titers were
determined by TCID50 assay in MDCK cells. Each data point represents the mean virus
yield (log10 TCID50/ml) from three individually infected wells ± standard deviation
(vertical bars).

We further evaluated the growth properties of wt-cH3N8, three mutants, and wteH3N8 on Madin-Darby canine kidney (MDCK) cells, human lung carcinoma (A549)
cells, and chicken fibroblast (DF-1) cells. Compared with wt-cH3N8, mutants 83NcH3N8 and 222W-cH3N8 exhibited poorer growth in MDCK (Figure. 18B) and A549
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cells (Figure 18C), and 83N-cH3N8 had the poorest growth among the three mutants
tested. Of interest, similar to the results in canine trachea explants, the replication kinetics
for Miami-eH3N8 and Pennsylvania-eH3N8 in MDCK and A549 cells were similar to
those for 222W-cH3N8 (p > 0.05) (Figure 18B and 18C). In DF-1 cells, wt-cH3N8, 54NcH3N8, and 83N-cH3N8 showed limited replication ability compared with the other three
testing viruses (i.e., 222W-cH3N8, Miami-eH3N8, and Pennsylvania-eH3N8), which
reached mean titers of 104.83, 104.58, and 104.91 TCID50/ml, respectively (Figure 18D).
Receptor Binding Avidity and Specificity
To determine the glycan structures specific for CIV, we generated four reassortant
viruses using reverse genetics (rg) (rg-wt–cH3N8, rg-54N, rg-83N, and rg-222W), which
have HA from cH3N8 (wild type HA, HA with mutation K54N, HA with mutation S83N,
and HA with mutation L222W, respectively), neuraminidase from wt-cH3N8, and six
internal genes from A/PR/8/1934(H1N1), and then compared the glycan binding profiles
of these four reassortant viruses using an array of 611 glycans from the Consortium of
Functional Glycomics (CFG; http://www.functionalglycomics.org), and an array of 83 Nlinked glycan isoforms (hereafter referred to as isoform microarray). To compare the
glycan binding profiles of the CIVs with those of their precursor EIVs, we also
determined that the glycan binding profiles of the wild type EIV field strain
Pennsylvania-eH3N8 using the isoform microarray. Glycans on the CFG array have
diverse terminal structures and a variety of spacer arms; glycans on the isoform
microarray have the same base structures and spacer arms but different terminal
structures (Figure 19).
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Figure 19.
Glycan structures on the N-glycan isoform microarray.
GlcNAc, N-acetylglucosamine; Man, mannose; Gal, galactose; L-Fuc, L-fucose;
Neu5Ac, N-acetyl neuraminic acid; Neu5Gc, N-glycolylneuraminic acid.

Results from the CFG array showed that rg-wt–cH3N8 virus and all three mutants
preferred binding to glycans containing α2,3-linkage sialic acids over those containing
α2,6-linked sialic acids (Figure 20A). Binding specificity of the rg-54N–cH3N8 mutant
to some SA2,3GA-like glycans was slightly increased over that of the rg-wt–cH3N8
virus.
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Figure 20.
Binding profile of four influenza virus mutants to sialic acid glycans on
the Consortium of Functional Glycomics (http://www.functionalglycomics.org)
glycan array.
Different categories of glycans on the array are highlighted as follows: red (No. 1-92),
Neu5Acα2,3 glycans; Blue (No. 93-147), Neu5Acα2,6 glycans No. 148-153 glycans are
non-sialic acid glycans; Dashed line indicates minimum relative fluorescence units of
2,000. Vertical bars indicate standard deviation.

Consistent with results from the CFG array, results from the isoform microarray
showed that all the testing viruses bound to glycans containing branched α2,3-linked
sialic acids but not α2,6-linked sialic acids (Figure 21A-E). Of interest, the data from this
isoform microarray demonstrated that rg-wt–cH3N8 virus had stronger binding affinity to
the α2,3-linked sialic acids with core fucose than those without. For example, the binding
affinity of rg-wt–cH3N8 virus to N012 was about 7-fold less than that to N015, which is
the fucosylated form of N012; rg-wt–cH3N8 virus showed strong binding signals to both
linear (N025G) and branched (N015G) α2,3-linked, fucosylated N-glycolylneuraminic
acid (Neu5Gc) but not to linear (N022G) or branched (N012G) α2,3-linked, nonfucosylated Neu5Gc (Figure 21A). Compared with the binding signals for rg-wt–cH3N8,
the binding signals for all three mutants to the fucosylated α2,3-linked N-acetyl
neuraminic acid (Neu5Ac) or Neu5Gc were reduced to different degrees (Figure 21B-D).
In contrast, Pennsylvania-eH3N8 showed moderate binding responses to α2,3-linked
sialic acids, and the responses of the Pennsylvania-eH3N8 to α2,3-linked sialic acids with
core fucose were similar to those without (Figure 21E). Of note, the binding responses of
Pennsylvania-eH3N8 to α2,3-linked sialic acids with core fucose are much weaker than
those of rg-wt–cH3N8. The Pennsylvania-eH3N8 showed moderate or low responses to
fucosylated Neu5Gc (N015G and N025G), linear non-fucosylated Neu5Gc (N022G), and
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branched non-fucosylated Neu5Gc (N012G), which are similar to cH3N8-222W but
much weaker than those by rg-wt–cH3N8 (Figure 21E).

Figure 21.
N-glycan microarray binding profiles of canine influenza A virus (CIV)
and CIV-derived mutant viruses to representative linear and branched glycans.
A, wt–cH3N8. B, rg-54N–cH3N8. C, rg-83N–cH3N8. D, rg-222W–cH3N8. E,
Pennsylvania-eH3N8. Viruses are indicated at the top of figure panels. Data are the mean
fluorescent binding signal intensity ± standard deviation (vertical bars). F, representative
glycan structures on the isoform N-glycan microarray. N002-N122, Neu5Acα2,3 glycans;
N003-N123, Neu5Acα2,6 glycans; N005-N255, Fucosylated Neu5Acα2,3 glycans;
N12G-N22G, Neu5Gcα2,3 glycans; N015G-N025G, Fucosylated Neu5Gcα2,3 glycans.
Neu5Ac, N-acetyl neuraminic acid; Neu5Gc, N-glycolylneuraminic acid. The structure
details of all those glycans were listed in Figure 19.
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To confirm these results from glycan microarray analyses and further determine the
distinct patterns derived from three mutations in CIV, we used biolayer interferometry
analyses to quantify the binding avidity and specificity of wt-cH3N8 and the three
mutants to five glycan analogs [Neu5Acα2-3Galβ1-4GlcNAcβ (3’SLN), Neu5Acα26Galβ1-4GlcNAcβ (6’SLN), Neu5Acα2-3Galβ1-4[Fucα1-3]GlcNAcβ (SLeX),
Neu5Gcα2-3Galβ1-4GlcNAcβ (3’SLN(Gc)), and Neu5Gcα2-3Galβ1-4[Fucα13]GlcNAcβ (SLeX(Gc))] (Figure 22A). For data interpretation, wt-eH3N8 was also
included as a comparison. In agreement with glycan array analyses, these analyses
showed that all tested viruses bound to 3′SLN (Figure 22C) and SLeX glycan analogs
(Figure 22D), both of which contain α2,3-linked Neu5Ac, but not to 6′SLN (Figure 22B),
which contains α2,6-linked Neu5Ac. The rg-wt–cH3N8 showed strong binding affinity to
SLeX(Gc) and 3′SLN(Gc), two glycan analogs with α2,3-linked Neu5Gc (Figure 22E); the
Pennsylvania-eH3N8 showed decent binding responses to 3′SLN(Gc) but limited binding
responses to SLeX(Gc) (Figure 22E). Compared to Pennsylvania-eH3N8, the laboratory
adapted prototype CIV Miami-eH3N8 had much weaker binding responses to α2,3-linked
Neu5Gc (Figure 22E).
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Figure 22.
Glycan binding specificity of canine influenza A virus (CIV) and CIVderived mutant viruses
Binding of viruses to biotinylated α2,6–linked sialic acid (6′SLN), α2,3–linked sialic acid
(3′SLN), Neu5Acα2-3Galβ1-4(Fucα1-3)GlcNAcβ (SLeX), Neu5Gcα2-3Galβ1-4GlcNAcβ
3′SLN(3′SLN Gc), and Neu5Gcα2-3Galβ1-4(Fucα1-3)GlcNAcβ (SLeX (Gc)) glycan
analogs as determined by Bio-Layer Interferometry (Pall ForteBio LLC, Fremont, CA).
A, Structures of the glycan analogs. B, Normalized response of virus to 6′SLN by
dividing the maximum of wild-type (wt) virus response to 3′SLN. C, Fractional saturation
of viruses to 3′SLN. D, Fractional saturation of viruses to SLeX. E, Normalized response
of viruses to 3′SLN Gc and SLeX (Gc). Values on the y axes represent the response of
viruses to glycans after the association step. Normalized response data were determined
by dividing the maximum response to each glycan or fractional saturation of the sensor at
each relative sugar loading (RSL) at a fixed virus concentration of 100 pM. The RSL0.5 is
the relative sugar loading on the streptavidin biosensor when the fractional saturation of
the biosensor surface equals to 0.5. Given two testing viruses and a specific glycan, the
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higher binding response and the smaller value of RSL0.5, the stronger binding avidity a
virus will have; given two testing glycans and a specific virus, the higher binding
response and the smaller value of RSL0.5, the stronger binding avidity a virus will have.
To determine distinct patterns of binding among the three mutants (i.e., rg-54NcH3N8, rg-83N-cH3N8, and rg-222W-cH3N8), rg-wt–cH3N8, and Pennsylvania-eH3N8
against these testing glycan analogs, we quantified 50% relative sugar loading
concentration (RSL0.5), which is the relative sugar loading on the streptavidin biosensor
when the fractional saturation of the biosensor surface equals to 0.5. Given two testing
viruses and a specific glycan, the smaller value of RSL0.5, the stronger binding avidity a
virus will have. Results suggested that among three mutants, RSL0.5 of PennsylvaniaeH3N8 to these testing glycan analogs reassemble to those of rg-222W-cH3N8 but not to
those of the other two mutants. Specifically, for 3′SLN, rg-wt-cH3N8, rg-54N–cH3N8,
and rg-83N–cH3N8 had RSL0.5 of 0.0771, 0.4726, and 0.5194, respectively, whereas
Pennsylvania-eH3N8 and rg-222W–cH3N8 had 0.1207 and 0.3239, respectively; for
SLeX, wt-cH3N8, rg-54N–cH3N8, and rg-83N–cH3N8 had RSL0.5 of 0.0385, 0.1030, and
0.1066, respectively, whereas Pennsylvania-eH3N8, rg-222W–cH3N8 had 0.0572 and
0.0573, respectively; for SLeX(Gc), wt-cH3N8, rg-54N–cH3N8, and rg-83N–cH3N8 had
RSL0.5 of 0.1446, 0.3097, and 0.3851, respectively, whereas Pennsylvania-eH3N8 and rg222W–cH3N8 had 1.332 and 1.074, respectively. In summary, rg-222W–cH3N8 and
Pennsylvania-eH3N8 had a similar glycan binding pattern, and mutation L222W of HA
decreased binding affinities of A(H3N8) CIV to glycans with α2,3-linked, fucosylated
Neu5Gc.
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SLeX and Neu5Gc Glycan Distribution
Based on the receptor binding results, we hypothesized that α2,3-linked
fucosylated Neu5Gc is the receptor that determines the host tropism of A(H3N8) CIV,
and that α2,3-linked fucosylated Neu5Gc expression in the dog trachea would differ from
expression in horse trachea. To test this hypothesis, we used immunofluorescence to
detect SLeX and Neu5Gc in trachea from dog and horse, to determine glycan receptor
distribution. The canine submucosal glands were extensively and strongly
immunopositive, indicating high SLeX glycan expression (Figure 23A, E). Although the
highest level of SLeX glycans was mainly found in the dog submucosal glands, staining
was also present along the surface of the respiratory epithelium (Figure 23F). In contrast,
in the horse trachea, no SLeX was detected in the ciliated cells, non-ciliated cells, or
submucosal glands (Figure 23B, G). On the other hand, Neu5Gc glycans were widely
distributed in both dog and horse trachea, including the ciliated and non-ciliated epithelial
cells and submucosal glands (Figure 23A, B). These results demonstrate high expression
of of Neu5Gc in horse trachea but not SLeX, whereas dog trachea extensively expresses
both SLeX and Neu5Gc.
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Figure 23.
Immunofluorescence detection of SLeX (green) and Neu5Gc glycans (red)
in dog (panels A, C, E, F) and horse trachea (panels B, D, G).
A and E. SLeX glycans were mainly found in the epithelial cells of submucosal glands in
dogs. B. No SLeX glycans were detected in the ciliated cells, non-ciliated cells, or
submucosal glands of the horse trachea. Neu5Gc glycans were widely distributed in both
dog and horse trachea, including the ciliated and non-ciliated epithelial cells and
submucosal glands. F. Expression of SLeX on the canine surface tracheal respiratory
epithelium. G. Detection of SLeX on the horse tracheal respiratory epithelium and
submucosal glands. Original magnification ×100 (panels A, B, C, D) or ×200 (panels E,
F, G). The SLeX glycan was detected by using Alexa Fluor 488 anti-human Sialyl Lewis
X (dimeric) antibody (green), and the Neu5Gc glycans by using Alexa Fluor 594 AntiNeu5Gc antibody (red). The arrows indicate immunopositive staining.

Figure 24.
Immunofluorescence assay detection of SLeX glycans in chicken trachea.
The nuclei were stained with DAPI (blue). The SLeX glycan was detected by using Alexa
Fluor 488 anti-human Sialyl Lewis X (dimeric) antibody (green). The original
magnification was ×200.

Discussion
To understand the molecular mechanisms of the host adaption of an emerging
influenza virus, it is necessary to characterize the virus receptor binding properties and
the types and distributions of host glycan receptors, two key factors determining
successful introduction and adaption of an IAV to a new host (222). In this study, we
provide evidence supporting that A(H3N8) CIV prefers glycans with a SLeX epitope and
that SLeX was differentially distributed in the trachea of the dog versus the horse. Our
comparative analyses, combined with our previous observations (33), suggests that
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mutation W222L of HA increases the binding ability of A(H3N8) CIV to SLeX and Gc
epitopes, and that gaining the SLeX(Gc) binding ability could have facilitated the adaption
of the equine-origin A(H3N8) virus to dogs.
Since the first outbreak of A(H3N8) IAV among dogs in 2004, this virus has
become enzootic among the US dog population (216). Prior epidemiologic and genetic
studies demonstrated that this emerging A(H3N8) CIV originated in horses, and was
most closely related to the Florida sub-lineage strains (206). Interspecies transmission of
A(H3N8) EIV from horses to dogs was observed when dogs were put in close contact
with experimentally infected horses (223); however, A(H3N8) CIV–infected dogs cannot
transmit CIV to horses (224), and A(H3N8) CIV replicates inefficiently in experimentally
infected equine respiratory epithelial cells (225).This suggests that CIV and EIV are not
exchangeable between equine and canine species and A(H3N8) CIV has been well
adapted in dogs. Nevertheless, A(H3N8) EIV and CIV have similar replication abilities in
canine trachea primary cell lines (214) and similar growth patterns in MDCK cells,
canine A72 cells, Norden Laboratory feline kidney cells, ferret Mpf cells, human A549
cells, and equine EQKD cells (214). However, differences in glycan binding preferences
were observed between A(H3N8) CIV, Eurasia-lineage A(H3N8) EIV, and North
America-lineage A(H3N8) EIV. Like Collins et al. (217), we observed that, compared
with the Florida sub-lineage A(H3N8) EIV, A(H3N8) CIV had higher avidity to SLeX,
supporting that, CIV and EIV are not exchangeable between equine and canine species.
Only three mutations (K54N, S83N, and L222W) were observed between the
head of HA protein of A(H3N8) CIV and that of A(H3N8) EIV. It is plausible that one of
the mutations could facilitate virus adaption from horse to dogs. von Grotthuss and
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Rychlewski, who used computational simulation in a prior study (226), suggested that
N54K could affect the glycosylation of HA and play a role in host adaption of A(H3N8)
CIV. Our data demonstrated that mutations S83N and L222W, but not K54N, have a
significant effect on the growth properties and binding properties of A(H3N8) CIV, a
finding that does not support the hypothesis of von Grotthuss and Rychlewski (226)
(Figs. 1 and 3). It is striking that mutant cH3N8-222W has a similar growth pattern as
that of wt-eH3N8. Compared to cH3N8-222W, the mutant cH3N8-83N reduced
significantly replication abilities of A(H3N8) CIV not only in canine trachea tissues but
also in in three cell lines, including MDCK, A549, and DF-1 cells. A prior study reported
that the infection of enzootic H3N8 CIV could lead to the quasispecies in the position 83
of CIV HA, suggesting this position was likely to be associated with a viral fitness cost
(227). Of interests, further analyses of HA sequences of H3N8 CIVs showed that there
are polymorphisms at position 83 of CIV HA (1.4% N; 0.3% T; 0.3% R) (data not
shown) and that, in contrast, all H3N8 CIVs have L at position 222 compared to the
conserved W at this position for H3N8 EIVs (Table 8). This finding suggests that
mutation W222L, but not N83S, could facilitate host adaption of A(H3N8) IAV from
horses to dogs. Mutation W222L is located in the 220-loop of the HA receptor binding
site, and the importance of residues in the 220-loop in determining the receptor
specificity has been reported in other IAV subtypes (131, 228).
Previous studies demonstrated that the substructure of the carbohydrate receptors
determine influenza host range and tissue tropisms. The abundance of Neu5Gcα2,3Gal
moiety (a type of SAα2,3GA) is important for EIV to replicate in equine respiratory
epithelium cells (26) as well as for CIV to replicate in canine respiratory epithelium cells
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(209, 210). Such results were confirmed by viral binding data from the CFG array, which
showed that wt-cH3N8 and wt-eH3N8 prefer SAα2,3GA, including Neu5Gcα2,3Gal.
However, such data still cannot explain the potential host factor(s) leading to host
adaption of A(H3N8) from horses to dogs. Internal complexity of glycan structures below
the sialic acid can influence glycan interaction with HA (229, 230); thus, host adaption
cannot be understood without first understanding the glycan substructures of
NeuGcα2,3Gal. The data from the isoform microarray and biolayer interferometry
analyses demonstrated clear patterns of A(H3N8) CIV binding on a set of glycans with
fucosylated α2,3-linked glycans (Figs. 2 and 3), and, of interest, a single L222W
mutation dismissed that preference so that cH3N8-222W decreased binding to
Neu5Gcα2,3Gal with the fucosylated motif (Fig. 3). Thus, mutation W222L seems to
have increased the A(H3N8) binding preference from Neu5Gcα2,3Gal to SLeX(Gc), a
Neu5Gcα2,3Gal with a fucosylated motif. Of note, a prior study suggested that amino
acid residues at positions 222 and 227 of HA could affect IAV binding to glycans with
the SLeX motif (68).
Immunofluorescent staining further demonstrated the distribution of SLeX in the
trachea (i.e., virus entry sites) of dogs and the lack of SLeX motifs in the tracheal tissue of
horses. These results supported our hypothesis that SLeX motifs could be one of the key
factors driving host adaption of A(H3N8) EIV in dogs; specifically, host adaption to dogs
could have been driven by the presence of mutation W222L in the virus HA protein. In
addition, the distribution of SLeX motifs is not only host-specific but also tissue-specific.
SLeX glycans were primarily expressed in canine tracheal submucosal glands with some
expression noted in ciliated epithelial cells (Fig. 4). As a comparison, we probed SLeX in
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chicken trachea; results showed that, unlike in dog trachea, SLeX glycans in chicken
trachea were extensively expressed in both the ciliated epithelial cells and the submucosal
glands (Figure 24). The tracheobronchial submucosal glands play multiple roles during
infection by producing mucus to inactivate the virus, but may also be infected and thus
enhance the infection (231). The receptors for human IAV in ferrets was reported to be
O-linked sialylated glycans, which are predominantly distributed in the submucosal
glands, and the infection of such cells facilitates the efficient airborne transmission of
virus by easily making the virus encapsulated into respiratory droplets (117). The L222W
mutation was shown to increase binding of H3N8 CIV to SLeX glycans, which are
present in abundancein the submucosal glands, thereby potentially facilitating the
airborne transmission of the H3N8 CIV.
Neu5Ac and Neu5Gc are two major sialic acids present in mammalian cells; they
play important roles in the recognition of influenza virus during the initial step of viral
infection. Neu5Gc has been reported to be present in horses (26), dogs (33), pigs (34),
and mice (35), but not in humans. Of interest, although it has been reported that horse
trachea expresses 90% of the α2,3-linked Gc receptors present in horses (26), our results
demonstrate that Pennsylvania-eH3N8 binds moderately to 3′SLN(Gc), a finding that is
consistent with that in a previous study (44). However, compared with those of
Pennsylvania-eH3N8, the laboratory adapted EIV prototype strain Miami-eH3N8 showed
much weaker binding responses to 3′SLN(Gc); such low responses of Miami-eH3N8 to
3′SLN(Gc) might have been caused by the extensive passage of this virus in embryonated
chicken eggs, which lacks Neu5Gc. Suzuki et al. (26) reported the presence of Gc
glycans in equine trachea but not chicken trachea, a finding that was also observed in our
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study. Our immunofluorescence staining also showed strong signal for Neu5Gc glycans
in dog trachea (Fig. 4). The interaction of Neu5Ac or Neu5Gc glycans to the receptor
binding site of viruses could affect the host tropism of those viruses. It has been reported
that the large hydrophobic side chain of F75 of two human polyomaviruses (BK
polyomavirus and JC polyomavirus) would clash with the glycolyl hydroxyl group and
prevent binding of those two viruses to receptors terminating in Neu5Gc (232). Similarly,
the L222W mutation introduced a large hydrophobic side chain and possibly caused the
loss of binding to Neu5Gc glycans.
In this study, we only characterized the distribution and abundance of two
individual glycan motifs, SLeX and Gc, in dog and horse trachea by using
immunofluorescenct staining. One potential limitation of this study was that we were
unable to test the SLeX(Gc)-like glycans due to the unavailablity of SLeX(Gc)-specific
antibody; thus, the abundance of this type of glycan substructure in the respiratory tracts
of dogs and horses is unknown.
Like H3N8 CIV, avian H3N2 virus has been identified and is enzootic in canine
populations in Southeast Asia (233, 234); furthermore, it has been shown that avian
H3N2 virus was transmitted to the US dog population (235). A previous study suggested
that the W222L mutation of HA facilitated the viral binding affinity of H3N2 CIV to
Neu5Gc and improved its replication ability in canine trachea primary cells (33).
Interestingly, similar to W222L of HA in H3N8 CIV (Fig. 2), the W222L mutation of HA
increased binding affinities of H3N2 CIV to SLex(Gc) (33, 236).
In summary, these findings suggest that mutation W222L facilitates the host
adaption of avian-origin H3N2 and equine-origin A(H3N8) IAVs in dogs by increasing
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the virus’s ability to bind to receptors with Neu5Gc and/or SLeX, which are widely
distributed in canine trachea tissues.
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CHAPTER V
SEQUENCE BASED INFLUENZA VACCINE STRAIN SELECTION USING
SYSTEMS BIOLOGY
Introduction
Although the mechanisms remain largely unknown, the receptor binding property
of influenza A virus (IAV) is clearly one of the key factors that affect the virus host and
cell tropisms. The initial step of the IAV infection is the binding of the HA protein to the
sialylated glycans on the host cells. The HA protein forms trimers, each of the monomers
has a relatively conserved receptor binding site (RBS) that functions to engage the virus
with the sialic acid (SA) glycan receptors on the host cells. The IAV was reported to have
the ability to agglutinate erythrocytes (24), and the agglutination ability was found to be
dependent on the types of SA on host cells (25). Typically, avian IAV prefers SAs that
are linked to galactose in α2,3-linkage (SA2,3Gal) whereas human IAV binds to
galactose with a α2,6-linkage (SA2,6Gal). The binding specificity and the binding
affinity of an IAV to the glycan receptors, which can be expressed differentially on
different cells and different hosts, are two of the key factors determining the virus cell
and host tropisms.
The RBS is located at the globular head of the IAV HA protein and consists of
130-loop, 150 loop, 190 helix, and 220-loop (193). Mutations in the HA RBS are well
documented to affect IAV binding affinity and specificity to SA2,3Gal and/or SA2,6 Gal.
For example, Q226L and G228S, two mutations at the 220-loop of the HA RBS,
switched the binding specificity of both subtype H2 and subtype H3 avian IAVs from
SA2,3Gal to SA2,6Gal (237); a single mutation G225D at the 220-loop of the HA RBS
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can switch virus binding specificity of subtype H6N1 avian IAV from SA2,3 Gal to
SA2,6Gal; mutations V186G/K-K193T-G228S or V186N-N224K-G228S of the HA RBS
can switch the receptor specificity of subtype H7N9 IAV from SA2,3 Gal to SA2,6Gal
(78). On the other hand, the mutation D222G in the HA RBS of 2009 H1N1 IAV
decreased virus binding affinity to SA2,6 Gal but increased that to SA2,3 Gal (238).
In addition to virus binding affinity and virus binding specificity, the mutation on
the HA RBS can change antigenic properties and growth properties of IAV. During viral
evolution, IAV mutates its HA RBS in order to adjust virus receptor binding avidity, and
these mutations at the RBS can occasionally lead to antigenic changes of the virus (239).
For example, a single mutation, N145K, at the HA RBS of subtype H3N2 human IAV
altered both virus binding affinity and virus antigenicity (240). Mutations N145K and
Y159N in the HA RBS of subtype H3N2 swine IAV were reported to drive the antigenic
evolution in US swine (241). Mutations at positions 119, 153, 154, and 186 in the HA
RBS of the 2009 H1N1 IAV improved virus replication ability in both cells and
embryonated chicken eggs (120).
Vaccination is the primary option to counteract and reduce the impacts of
influenza outbreaks (242). A high yield vaccine seed strain is required for timely vaccine
manufacture and is thus a critical component of a successful influenza vaccine campaign.
As described above, the sequences and structures of the HA RBS of IAV affect virus
receptor binding property, virus replication efficiency, and virus antigenic properties.
However, given the sequence of HA RBS, the virus receptor binding property, virus
replication efficiency, or antigenicity these features are still difficult to be predicted as a
priori. In this study, we will integrate both bench and computational approaches to
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identify the key features determining these three key biological properties for an
influenza vaccine strain. We aim to generate a large scale of mutants using epPCR
(Chapter II), to characterize three influenza vaccine specific phenotypes (i.e., receptor
binding specificity, replication efficacy in both MDCK cells and embryonated chicken
eggs, and antigenic properties), and then to identify and validate the key genetic
signatures, including genetic features in both viruses (i.e. position and residue
compositions at RBS) and hosts (glycan substructures) by applying a machine-learning
model in these phenotypic datasets. At last, a computational model is proposed to score
the vaccine candidacy based on a query sequence of the HA RBS by integrating their
weights on those phenotypes (i.e. receptor binding specificity, replication efficacy in both
MDCK cells and embryonated chicken eggs, and antigenicity). This model can be used to
screen influenza viruses in influenza surveillance to select influenza vaccine candidates,
which shall meet the following criteria that (1) their antigenic properties are similar to the
prototype vaccine antigen; (2) their yield capability in commonly used vaccine
production platforms will meet the criteria required for vaccine manufacturing; (3) the
phenotypes are stable upon at least three passages, and; (4) they remain low pathogenic
yet efficacious (as a vaccine antigen) in humans.
Materials and Methods
Cells and viruses
Human embryonic kidney (293T) cells, Madin-Darby canine kidney (MDCK)
cells were purchased from American Type Culture Collection (Manassas, VA). Cells
were maintained at 37°C with 5% CO2 in Dulbecco's Modified Eagle Medium
(GIBCO/BRL, Grand Island, NY) supplemented with 5% fetal bovine serum (Atlanta
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Biologicals, Lawrenceville, GA) and penicillin–streptomycin (Invitrogen, Carlsbad, CA).
The HA gene of A/California/04/2009 (H1N1) (abbreviated as CA/04) was cloned into
the vector pHW2000 and used as template for construction of the mutant library.
The viruses generated by reverse genetics were propagated in MDCK cells and
cultured at 37°C with 5% CO2 in Opti-MEM medium (GIBCO/BRL, Grand Island, NY)
supplemented with 1 µg/ml of TPCK (N-tosyl-L-phenylalanine chloromethyl ketone)Trypsin (Sigma-Aldrich, St. Louis, MO) and penicillin–streptomycin (Invitrogen,
Carlsbad, CA). Virus titers were determined by TCID50 in MDCK cells.
Construction of plasmid library and rescue of mutants
The mutant plasmid library with random mutations in HA RBSs was generated by
epPCR strategy as described previously (186). Briefly, four primers were used in the
generation of HA-pHW2000 RBSs mutant library: 1) 130loop_F, 5'-TCA TGG CCC
AAT CAT GAC TCG AAC-3'; 2) 190helix_F, 5'-TGG GGC ATT CAC CAT CCA TCT
ACT-3'; 3) 190helix_R, 5'-AAC ATA TGT ATC TGC ATT CTG ATA-3'; and 4)
220loop_R, 5'-TAG TGT CCA GTA ATA GTT CAT TCT-3'. The epPCR product (2 µl)
was transfected into XL1-Blue Supercompetent Cells (Agilent Technologies, Santa Clara,
CA). The transformed cells were directly inoculated onto LB (Luria Bertani) agar plates
and the clones were propagated in 5ml LB media. The clones generated from the RBSs
mutant library was confirmed by Sanger sequencing with the sequencing primer 5’-GAA
CGT GTT ACC CAG GAG ATT-3’. Mutant viruses were rescued by plasmid based
reverse genetics with the NA genes from CA/04 and six internal genes from influenza
A/Puerto Rico/8/34 (H1N1) as described previously in Chapter I. For phenotype
comparison, we generated the wild-type reassortant virus, rg-wt, with wild-type HA and
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NA genes from CA/04 and six internal genes from influenza A/Puerto Rico/8/34 (H1N1)
virus by reverse genetics approaches.
Virus sequencing
Viral RNA (80 µl total) was isolated from 200 µl of sample by using a 5X
MagMAXTM Pathogen RNA/DNA kit (Thermo Fisher Scientific, Pittsburgh, PA)
according to the manufacture’s instruction. Influenza virus–specific primer Uni12 (5’AGCAAAAGCAGG-3’) (218) and 10 µl of each isolated RNA were used in the cDNA
synthesis (total volume of 25 µl); the cDNA synthesis was carried out using SuperScript
III Reverse Transcriptase (Invitrogen, Grand Island, NY) according to the manufacturer’s
instructions. The HA segment of mutants were amplified with the primers CA/04_HA_F,
5’-ATGAAGGCAATACTAGTAGTTCTGC-3’ and CA/04_HA_R, 5’TTAAATACATATTCTACACTGTAGAGACC-3’ by using Phusion High-Fidelity PCR
Kit (Thermo Fisher Scientific, Pittsburgh, PA) according to the manufacturer’s
instructions. The PCR products (50 µl) were purified by GeneJET PCR Purification kit
(Thermo Fisher Scientific, Pittsburgh, PA) according to the manufacturer’s instructions.
The HA sequences of mutants were confirmed by Sanger sequencing.
Evaluation of viral growth
To evaluate the effect of mutations on the growth properties of viruses, we
inoculated the MDCK cells with each testing influenza virus at a multiplicity of infection
of 0.001 TCID50 and incubated the cells in 5% CO2 at 37°C for 1 h. The inocula were
removed and cells washed two times with phosphate-buffered saline (PBS). The cells
were then incubated (37°C in 5% CO2) in Opti-MEM I (GIBCO, Grand Island, NY)
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containing TPCK–trypsin (1 µg/ml). At 48h after inoculation, 200 µl of supernatants
were collected, aliquoted, and stored at ˗70°C until use. To evaluate the growth
properties of mutants on eggs, 9-day old SPF chicken eggs were inoculated 200 TCID50
of each virus and incubated under 34 °C for 48 h. The titer of harvested viruses in both
MDCK cells and SPF chicken eggs were determined by TCID50 in MDCK cells.
Virus concentration and purification
Viruses for the glycan array analysis were purified as previously described(221).
Briefly, viruses were purified from the cell supernatant or allantoic fluid by low-speed
clarification (2,482 × g, 30 min, 4°C) to remove debris and then followed by
ultracentrifugation through a cushion of 30%–60% sucrose in a 70Ti Rotor (Beckman
Coulter, Fullerton, CA) (100,000 × g, 3 h, 4°C). The virus pellet was re-suspended in 100
µl of PBS and stored at −80°C until use.
Glycan microarray
To identify unique substructures bound specific sets of mutants, an isoform
glycan array with 75 isoform glycans were printed on N-hydroxysuccinimide (NHS)–
derivatized slides as described previously (221). The 75 glycans were selected to
represent four different unique substructures, including N-glycans, Asn-linked N-glycans,
Gangliosides, Thr-linked O-mannosyl glycans (Figure 25). The structures of these 75
glycans are shown in Figure 25. These glycans on the isoform microarray have the same
base structures and spacer arms but different terminal structures (Figure 25), whereas
glycans on the CFG (Consortium of Functional Glycomics) array have diverse terminal
structures and a variety of spacer arms.
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The isoform glycans were printed in replicates of four in a subarray, and sixteen
subarrays were printed on each slide. All glycans were prepared at a concentration of 100
pM in phosphate buffer (100 mM sodium phosphate buffer, pH 8.5). The slides were
fitted with a 16-chamber adapter to separate the subarray into individual wells for assay.
The unreacted NHS groups on the slides are blocked with 50 mM ethanolamine in 50
mM sodium borate buffer (pH 9.2) at 4 °C for 1 hour and then the slides were rinsed with
water. Before the assay, slides were rehydrated for 5 min in TSMW buffer (20 mM TrisHCl, 150 mM NaCl, 0.2 mM CaCl2, and 0.2 mM MgCl2, 0.05% Tween). Viruses are
purified by sucrose density gradient ultracentrifugation and titrated to about 32, 000
hemagglutination units/ml. Then 10 µl of 1.0 M sodium bicarbonate (pH 9.0) was added
to 80 µl of virus, and the virus was incubated with 10 µg of Alexa Fluor 488 NHS Ester
(Succinimidyl Ester; Invitrogen, Carlsbad, CA) for 1 h at 25°C. After overnight dialysis
to remove excess Alexa 488, viruses HA titer were checked and then bound to glycan
array. Labeled viruses were incubated on the slide at 4°C for 2 h, washed, and centrifuged
briefly before being scanned with an InnoScan 1100 AL fluorescence imager (Innopsys,
Carbonne, France).
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Figure 25.

The sequences of synthetic glycans on the isoform glycan microarray.

Generation of ferret antisera
Ferrets antisera were generated in 6 to 8-week-old male or female ferrets, which
were tested seronegative against CA/04 H1N1, A/Switzerland/9715293/2013 (H3N2),
and A/Hong Kong/4801/2014 (H3N2). Each ferret was inoculated intranasally with 106
TCID50 of the wild type strain or a testing mutant virus. Ferret sera were collected at 21
days post-inoculation and subjected for antigenic phenotyping using serological assays.
Antigenic phenotype determined by haemagglutination inhibition (HI) assays
Haemagglutination (HA) and HI assays were performed by using 0.5% turkey
erythrocytes as described by the WHO Global Influenza Surveillance Network Manual
for the Laboratory Diagnosis and Virological Surveillance of Influenza (187). Turkey
erythrocytes were obtained from Lampire Biological Products (Everett, PA). The turkey
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erythrocytes were washed three times with 1 × PBS (pH 7.2) before use and then diluted
to 0.5% in 1 × PBS (pH 7.2).
Biolayer interferometry
Two biotinylated glycan analogs (3′SLN: Neu5Acα2-3Galβ1-4GlcNAcβ and
6′SLN: Neu5Acα2-6Galβ1-4GlcNAcβ) linked to 30-KDa polymers containing 20% mol
sugar and 5% mol biotin (GlycoTech, Gaithersburg, MD) were used to represent α2,3linked sialic acid (3′SLN) and α2,6-linked sialic acid (6′SLN). Biotinylated glycans
Neu5Acα2-3Galβ1-4(Fucα1-3)GlcNAcβ (SLeX) were synthesized. The stock solution (1
mg/ml) was prepared in 1× PBS (v/v) according to manufacturer’s instructions. All
glycan analogs and viruses were further diluted into the kinetics buffer (pH 7.4; PBS
solution containing 0.01% BSA and 0.002% Tween-20) with neuraminidase inhibitors
(10 µM zanamivir hydrate and 10 µM oseltamivir phosphate) for binding analysis. The
binding affinities of viruses (100 pM) to glycan analogs were determined using an Octet
RED96 interferometer equipped with streptavidin biosensors (Pall ForteBio LLC,
Fremont, CA). In summary, RSL of the biosensor was calculated at the end of a 5- to 10min loading, and the binding signal was measured at 25°C in a 20-min association step
and 20-min dissociation step, with orbital shaking at 1,000 × rpm. The response of virus
binding to a certain glycan loading was recorded at the end of the association step. The
normalized response was calculated by dividing the maximum response of each glycan.
Machine learning model
The in-house machine learning method (105, 243-246) was used to identify key
sequence features determining the phenotypes described above, including receptor
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binding, antigenicity, replication efficiencies. Specifically, a multi-task sparse learning
was used to identify key features associated with these phenotypes and a quantitative
function was developed to quantify distances for each phenotype on the basis of their HA
protein sequences. Each dataset was assigned with a single task in sparse learning, and
the features were derived to determine each of these phenotypes. In addition, the features
determining receptor binding, antigenicity, virus replication efficiencies were compared
to determine 1) mutations at the HA RBS affecting virus antigenic properties; 2) the
mutations at the HA RBS increasing and decreasing the yields in cells and/or eggs; 3) the
glycan substructures (i.e. glycan motif) in the arrays associated with the yields in cells
and/or eggs; 4) the glycan substructures (i.e. glycan motif) in the arrays associated with
the mutations in the HA RBS.
Protein motifs determining virus yields and antigenicity using machine learning
In the machine-learning method, we investigated impacts of individual residues as
well as the substructure motif on the HA protein structure on the phenotypes. To evaluate
the impacts of the substructure motif on the HA protein structure, a sliding-window of
residue was used as a single feature to integrate the synergistic effects of multiple
residues in a substructure motif with neighboring residues. The sliding windows could be
either overlapped or non-overlapped, and the size of windows was optimized from a
range of 6 to 14 by maximizing the predicting performance.
Specifically, we formulated the phenotype-genotype problem as a sparse learning
model. Mathematically, the sparse learning model is a linear regression loss function that
subject to regularization. The LASSO model was adopted with a least square loss and ℓ!
norm. We considered genetic difference matrix among HA protein sequences as X,
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phenotype difference as Y, sample number as N. Then the objective of our model is to
solve:
!

𝑚𝑖𝑛 ! 𝑌 − 𝑋𝜃

!
!,

Subject to 𝜃

!

≤𝑡

Where t is a predefined regularization parameter, 𝜃 denotes the numerical weights of
individual features (either a single residue or a group of neighboring residues). Absolute
value of weight indicates the impact of mutation(s) on a specific feature to phenotypes
(e.g. receptor binding, antigenicity, and replication efficiencies). The larger the weight is,
the greater the impact would be. Positive weights indicate a potential positive impact on
the phenotype; otherwise, negative.
The prediction performance of the model was evaluated by root mean square error
(RMSE):

RMSE =

1
n

!

(y! − y! )!
!!!

A lower RMSE indicated a better prediction performance.

Glycan microarray data pre-processing and analyses.
All the glycan microarray data were normalized to [0,1] by columns (Viruses)
before any statistical analysis or machine learning analysis was performed. Specifically,
each value of binding affinity was normalized by the follow equations:
𝑁𝑜𝑟𝑚𝑎𝑙𝑖𝑧𝑒𝑑 𝑁!,! =

𝑙𝑜𝑔!" 𝑁!,! －𝑚𝑖𝑛(𝑙𝑜𝑔!" (𝑁.! ))
𝑚𝑎𝑥 𝑙𝑜𝑔!" 𝑁.!
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− 𝑚𝑖𝑛(𝑙𝑜𝑔!" 𝑁.! )

Values lower than 100 (including negative values) were set to 100 before data
normalization. A value of 2,000 was used as the minimum threshold to determine
whether a virus has bounding affinity to a glycan.

Definition of glycan substructures as glycan motifs
Based on the glycan’s terminal structures, a total of 30 glycan substructure
features were extracted as glycan motifs from glycan sequences of 75 synthetic glycans
on the isoform glycan microarray. Each glycan motif was considered as an individual
feature, and each glycan is transformed as an array (dimension n = 30) of one or multiple
glycan motifs. In the glycan motif array, each feature was coded as 1 if a specific feature
is present, otherwise, as 0.

Glycan motif identification using machine learning
Because it would be difficult to integrate the data from individual experiments,
we introduced a multi-task learning framework to overcome this challenge. Multi-task
Lasso model is a conventional multi-task sparse learning model and is frequently used in
feature selection problems. Multi-task Lasso model trained least square loss with L1/L2
mixed-norm as regularizer. It solves the following objective:
𝑚𝑖𝑛

1
𝑌 − 𝑋𝜃
𝑁

!
!

+𝛼 𝜃

!

𝜃

!,!

=

!

𝜃!

!

!!!

!,!

!
!
𝜃!,!

=
!!!

!!!

Where θ ⊂ ℝ!×! , θ! is the i-th row while θ! is the j-th column.
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Multi-task Lasso model considers each column (virus) as an individual task, and
is able to run all tasks at the same time. Each feature (glycan motif) will be assigned a
numerical weight, which indicate the impact of the corresponding features on the glycan
binding. The larger the weight is, the more important the glycan motif will be.
To identify unique glycan motifs associated with the yielding phenotypes, we divide 200
viruses into six different datasets: 1) array data with high yield egg mutants, which has a
titer >3.16 x106 TCID50/ml; 2) array data with medium yield egg mutants, which has a
titer between 3.16 x104 TCID50/ml and 3.16 x106 TCID50/ml ; 3) array data with low
yield egg mutants, which has a titer <3.16 x104 TCID50/ml ; 4) array data with high yield
cell mutants, which has a titer >1.52 x106 TCID50/ml ; 5) array data with medium yield
cell mutants, which has a titer between 1.52 x104 TCID50/ml and 1.52 x106 TCID50/ml ;
6) array data with low yield cell mutants, which has a titer <1.52x104 TCID50/ml . Then
six individual machine learning processes were performed. The glycan motifs from these
learning were compared to address the following questions: 1) what are the specific
glycan motifs responding to high yields in eggs? 2) What are the specific glycan motifs
responding to low yields in eggs? 3) What are the specific glycan motifs responding to
high yields in cells? 4) What are the specific glycan motifs responding to low yields in
cells? 5) What are the specific glycan motifs responding to high yields in both eggs and
cells? 6) What are the specific glycan motifs responding to low yields in both eggs and
cells? 7) What are the unique glycan motifs responding to the yields in eggs from those
from cells?

Prediction of vaccine candidacy
133

The vaccine candidacy could be predicted using features and their weights to be
determined by aforementioned machine learning. Given the sequences of a testing virus,
a linear scoring function is proposed to predict the difference of growth property between
the testing virus and a virus has experimental data (e.g. WT). Then the value of vaccine
candidacy (y) could be calculated by the summary of the aforementioned difference (xθ)
and value of the known virus (𝑦! ).
y = 𝑥θ + 𝑦!
To avoid potential bias, average value from multiple predictions will be more
precise.
y!"#

1
=
𝑁

!

(𝑥! 𝜃 + 𝑦! )
!!!

Public sequence data, sequence alignment, and molecular characterization
HA sequences of subtype H1 IAVs from humans (including both the seasonal
H1N1 IAVs from 1977-2009 and the 2009 H1N1 IAVs from 2009 to 2018), swine, and
avian were extracted from the Influenza Research Database (http://www.fludb.org). The
multiple sequence alignments and the identification of the mutations were identified by
using Bioedit software (192). The positions were matched those corresponding mutations
at the HA protein of subtype H3N2 IAVs.

Visualization of proteins structure
The three dimensional structure of HA protein was modeled using the HA structure
template of CA/04 (PDB: 3LZG). The mutations were visualized using Chimera
software.
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Results
Features of RBS mutant library
A total of 200 mutants, each of which carries one to three random mutations in the
HA RBS of CA/04, were rescued successfully from 826 plasmids with confirmed
mutations, and the mutations were then confirmed by Sanger sequencing. The mutations
cover the region from position 122 to 244 (H3 numbering) of HA1 of CA/04 (Figure
26A). Among those mutants, 123 mutants had one mutation, 61 mutants two mutations,
and 16 mutants three mutations (Figure 26B). There were 119 mutants carries mutation(s)
at 130-190 loop of the RBS of CA/04; 51 mutants carries mutation(s) at the 190-220 of
the RBS of CA/04; 30 mutants carries mutations covering both 130-190 and 190-220 of
the RBS of CA/04. The virus rescue did not succeed for the other 626 mutant plasmids
after three trials, and mutations at these failing plasmids include positions 134, 139, 147,
155, 168, 170, 177, 179, 180, 181, 183, 185, 191, 209 and 215, which were found highly
conserved in the receptor binding pocket (Figure 26C, D).
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Figure 26.
Features of the receptor binding site mutants of influenza A(H1N1)pdm09
virus.
A, the list of mutations on the HA receptor binding site of influenza A(H1N1)pdm09
virus. The amino acids are grouped with colors by: amino acids with positive charged
side chain (R, H, K), amino acids with negative charged side chain (D, E), amino acids
with polar uncharged side chain (S, T, N, Q), Special cases (C, U, G, P); amino acids
with hydrophobic side chain (A, I, L, M, F, W, Y, V); B, the summary of numbers of
receptor binding site mutants of CA/04. C, The locations of conserved sites in top view
(C) and side view (D) of the crystal structure of the hemagglutinin (HA) of influenza
A(H1N1)pdm09 virus. The conserved residues (dark black) on the receptor-binding sites
are labeled with residue names and locations. The single letter amino acid annotations
were used together with H3 numbering for all binding residues. The HA was adapted
from the structural template of the HA of A(H1N1)pdm09 virus (Protein Databank [PDB]
3LZG).
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Antigenicity of RBS mutants
The HI titer of each RBS mutant against the CA/04 ferret antisera was recorded
(Table 9). Four mutants (S160A S188N R220K, K172R, T200S, S206T) had a HI titer of
1:160 against the CA/04 WT ferret antisera, which was at least four-fold less comparing
to the homologous titer of CA/04 WT. Of note, the D130E, S193T, A198S mutants had a
HI titer of 1:10 against the CA/04 WT ferret antisera, suggesting significant antigenic
changes due to these mutations at the RBS. Among those mutations, residues 160, 188,
193, and 200 locate at positions overlapping RBS and antigenic site B; residue 172
locates at position overlapping RBS and antigenic site D; and residue 206 locates at
position close to antigenic site D. The mutations that could alter the antigenicity of
CA/04 H1H1 were majorly located in the antigenic site B, suggesting the
immunodominance of antigenic site B over site A of HA of CA/04 H1N1.
On the other hand, the highest HI titer for the RBS mutants was 1:1280. None of
the mutants had > 2-fold increase over the homologous HI titer.
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Table 9. Serological responses of wild type and receptor binding site mutants of
CA/04 against ferret anti-CA/04 WT sera using HI assays
HI

a

M1

b

M2

M3

HI

M1

M2

M3

10

D130E

S193T

A198S

640

D171E

160

S160A

S188N

R220K

640

K149E

160

D130E

K172R

640

A142T

160

T200S

640

L151V

160

S206T

640

L154V

320

A138S

640

H141L

320

P162Q

640

K133Q

320

S125A

D130E

640

S146C

320

D130E

A142V

640

D130E

320

K174I

640

I169F

320

S167T

640

V178L

320

H141R

640

D130E

G173R

320

K166I

640

S186T

G158R

320

E175K

640

S167T

320

H141Y

N159D

640

N150T

320

N159D

K166I

640

A142S

320

T187N

640

S186T

320

K156N

640

S167T

I169H

S193N

320

S193G

640

D130E

S146G

S165I

320

E216D

640

E238A

320

K212R

640

A189V

320

V202I

640

K166R

320

D130E

640

A142D

320

F203S

640

S188N

320

K211R

640

D190V

320

T200P

640

K157N

I169F

320

D130E

640

D130E

T187S

320

D225E

640

H141Y

320

A198S

640

K145R

320

S188N

I217V

640

A189T

320

V237I

E227K

640

I182F

320

A198T

640

I152L

320

K157T

640

K156R

320

D130E

S188N

640

S146G

320

K122N

S160T

640

K163R

320

N132D

G173R

640

K166N

320

K157I

D225G

640

S165I

A189T

V237I

K212M

E227K

I152V

K149I

L154I

E175V
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Table 9 (continued)
HI

a

M1

b

M2

320

K157I

I169T

320

D130E

G158E

320

D130E

G158E

320

D130E

F203Y

320

D130E

A189V

640

M3

HI

M1

M2

640

K157I

D225G

640

A142D

A198V

640

K172R

640

I169T

640

G173E

A142V

640

A144S

640

Q192L

640

I152V

640

D130E

640

K149I

640

E175D

640

T136S

640

S131L

640

P140T

640

K172R

640

K166I

640

S160T

640

S193I

640

L151I

640

D130E

R224K

640

A137V

640

D130E

I219L

640

A137V

640

D130E

Y201H

640

V237I

640

D130E

S165N

640

F203L

640

D130E

S210R

640

D130E

1280

K166Q

640

F203Y

1280

K172I

640

D130E

D199E

1280

P221A

640

A198V

V237L

1280

K133N

640

D199E

K214E

1280

A144G

640

N197D

D225G

1280

I182V

640

A198G

1280

K157N

640

K212N

1280

I169M

640

F213L

1280

K149T

640

F213I

1280

S146N

640

I219L

1280

K174T

640

V237L

1280

S146G

640

S188I

1280

P162S

640

R208G

1280

P140H

640

D199N

F203Y

1280

V178M

640

V237I

S165N

1280

A189D

640

K222R

1280

H141L

640

D130E

I219L

1280

K149R

640

K222T

D225G

1280

L151F

Q226V

640

S186P

K222T

1280

A144T

T187S

L164I
K166E

I219V

T244S

V237I

V204M

M3

K174R

I169N

D171G

D130E

K174R

I219R

139

E175D

D199Y

Table 9 (continued)
HI

a

M1

b

M2

M3

HI

M1

M2

640

K214E

1280

G173R

640

N197S

1280

I182T

640

A218S

1280

K145I

640

A189V

1280

S188G

640

D199E

1280

A142G

640

G205A

1280

K163E

640

A198V

1280

K163N

640

K214M

1280

E175G

640

I219L

1280

V135E

640

I219V

1280

A137E

640

K214N

1280

Q196L

640

T200A

1280

A144T

640

S160L

1280

I169M

G173E

640

A144V

1280

K133Q

P140H

640

H141R

K149E

1280

V135I

640

K133N

V178M

D225G

1280

K212M

640

A144E

K163N

I219K

1280

K212N

640

V176I

1280

I217V

640

N132D

1280

A189D

Q192L

640

K133I

1280

A189D

A218S

640

A137T

H141Q

1280

D130E

A189T

640

D130E

K212T

1280

D130E

V223C

E216D

K212D

K163N

H184N

640

M3

D199E

A218T

D225E

WT

a. HI, hemagglutination inhibition;
b. Mutations (H3 numbering) on the receptor-binding site of CA/04.
Replication efficiency of RBS mutants
We evaluated the effect of RBS mutations on the replication efficiency of 2009
pandemic H1N1 virus in both MDCK cells and SPF chicken eggs. The results suggested
14 mutants had more than 10 fold increased TCID50 titer compared to the WT in MDCK
cells. The N159D, K166I mutant reached highest TCID50 titer in MDCK cells, which is
about 100 fold higher compared to the WT. A total of 29 mutants had more than 10 fold
decrease in TCID50 titer compared to that of the WT in cells. In contrast, 33 mutants had
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more than a 10 fold increase in TCID50 titer compared to the WT in SPF chicken eggs.
The D130E, S193T, A198S mutants reached the highest TCID50 titer in SPF chicken
eggs, which is about 850 fold higher compared to the WT. A total of 19 mutants had > 10
fold decreased TCID50 titer compared to that of the WT in eggs.
Key signatures determining yields from machine learning
We applied machine learning models to identify the key signatures determining
the virus yield. The overall growth data of the RBS mutants shown in Figure 27
suggested high degree of correlation between the three samples of each mutant that grew
in both cells and eggs. Thus, we used the geometrical average value of the TCID50 titer
for each mutant in the following machine learning analysis. The results identified key
signatures at positions 122, 125, 161, 133, 166, 172, 182, 198, 214, and 218 are
responsible for increasing virus yield in chicken eggs; positions 137, 190, 206 are
responsible for decreasing virus yield in chicken eggs; residues 122, 161 were
responsible for increasing virus yield in MDCK cells; residues 137, 146, 178, 199, 200,
and 206 were responsible for decreasing virus yield in MDCK cells (Figure 28). The
structure modeling results suggested that the residues increasing the virus yield were
mainly located in the surface area of the HA trimer, while the residues responsible for
decreased virus yield were mainly located in the interior of HA trimer (Figure 29B).
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Figure 27.
Overall growth efficiency of RBS mutants in MDCK cells and SPF
chicken eggs.
The X axis represents the mutant number and the Y axis represents the log10 TCID50
titer/ml. The blue line links the geometrical average of the 3 MDCK cell grown samples
for each RBS mutant. The red line links the geometrical average of the 3 SPF chicken
egg grown samples for each RBS mutant.

142

Figure 28.
Key residues for the growth of CA/04 H1N1 in cells and eggs
A, important residues for the growth of CA/04 H1N1 in cells only; B, important residues
for the growth of CA/04 H1N1 in eggs only; C, important residues for the growth of
CA/04 H1N1 in both cells and eggs.
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Figure 29.
Key residues on the HA receptor binding site that affect the antigenicity
and yield of 2009 pandemic H1N1.
A, antigenic structure of key residues would affect the antigenicity of virus. The antigenic
sites Sa (A), Sb (B), Ca1(C), Ca2 (D), and Cb (E) are marked with red, green, blue,
purple, and yellow, respectively. The key residues that affect the antigenicity of 2009
pandemic H1N1 are marked with dark black. B, schematic surface diagram of residues
affecting the virus yield in cells and eggs. The residues that increase or decrease the virus
yield are marked with red and green, respectively. All the sequences mentioned in the
text are based on H3 numbering. The HA was adapted from the structural template of the
HA of A(H1N1)pdm09 virus (Protein Databank [PDB] 3LZG).
Glycan binding affinities of RBS mutants
The binding specificity and intensity of the RBS mutants was determined by
glycan microarray, which had 75 representative glycans and were classified into 30
features (Table 10) based on the glycan structures. The overall binding intensities of
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mutants plotted with the glycans are shown as a heat map in Figure 30. As expected, the
tested mutants showed overall strong bindings to Neu5Acα2-6Gal terminated glycans
such as: N003, N113, N213, BA-01, BA-19, BA-21, A6LNnT, M103, M303, and M030.
In addition, the tested mutants had an overall stronger preference for binding to
Neu5Acα2-6Galβ terminated Gangliosides (A6LNnT) than Neu5Acα2-6Galβ terminated
Thr-linked O-mannosyl glycans (M103). The viruses binding to N-glycans and Asnlinked N-glycans with the same terminal structures (eg. N003 and BA-01) did not differ
significantly. A higher binding response of viruses to glycans with multiple Neu5Acα26Gal terminal structures than glycans with single Neu5Acα2-6Gal terminal structure was
observed.
We examined the receptor binding profiles of the high yield mutants in both
MDCK cells and eggs to further investigate the potential role of glycan binding in the
mechanism of variations in virus yield. For example, the top two mutants (D103E,
S193T, A198S; I169F) with the highest TCID50 titer in chicken eggs were 102.93 and
102.88 fold higher than the wild type. The glycan array results suggest that both mutants
(D130E, S193T, A198S and I169F) gained the ability to bind 3’SLN and SLeX terminated
glycans. For example, the ratio of WT to 6’SLN (N003): 3’SLN (N002): SLeX (N005)
was 1:0.027:0.034. In contrast, the ratio of for the D130E, S193T, A198S and I169F
mutants were 1: 0.64:1.02 and 1: 0.33: 0.36. The results suggested a more balanced
binding ratio of α2-3 sialic acid glycans to α2-6 sialic acid glycans would significantly
increase H1N1 virus yield in eggs.
Further analysis of virus binding to non-sialic acid glycans such as N001
suggested the potential role of non-sialic acid glycans during virus infections. For
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example, the top 3 mutants (K133N; H141Y, N159D; and I182V) with highest binding
signal to N001 all had an increased TCID50 titer in MDCK cells and/or chicken eggs. The
K133N and I182V mutation increased the virus TCID50 titer in chicken eggs by 101.89 and
102.43 fold, respectively. The H141Y, N159D and I182 mutations increased virus TCID50
titer in MDCK cells by 101.75 and 101.26 fold, respectively.
We noticed that the increase of virus binding to Neu5Acα2-3Gal terminated
gangliosides may increase the virus yield. The TCID50 titers of K214E mutant were101.46
and 101.5 fold higher than the WT in MDCK cells and chicken eggs, respectively. The
glycan array binding results suggested that the K214E mutant had moderate binding
signal to A3LNnT but not to Neu5Acα2-3Gal terminated N-glycans (N002) or SLeX
glycans (N005). Additionally, the K214E mutant had increased binding to Neu5Gcα26Gal terminated glycan (N213G), which may responsible for the increase of virus yield in
MDCK cells.
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Table 10. Features of the glycans on the glycan microarray
No#
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30

Glycan features
AEAB labed core pentasaccharides
Asn linked core pentasacchrides
Thr linked core mannose
Core lactose
High-Man
GlcNAc(b1-2)
Gal(b1-4)GlcNAc
Gal(a1-3)Gal(b1-4)GlcNAc
Neu5Ac(a2-3)Gal(b1-4)GlcNAc
Neu5Ac(a2-6)Gal(b1-4)GlcNAc
Neu5Gc(a2-3)Gal(b1-4)GlcNAc
Neu5Gc(a2-6)Gal(b1-4)GlcNAc
Neu8Me(a2-3)Gal(b1-4)GlcNAc
Kdn(a2-3)Gal(b1-4)GlcNAc
Neu5Ac(a2-8)Neu5Ac(a2-3)Gal(b1-4)GlcNAc
Neu5Ac(a2-8)Neu5Ac(a2-6)Gal(b1-4)GlcNAc
GlcA(a1-6)Gal(b1-4)GlcNAc
Gal(b1-4)[Fuc(a1-3)]GlcNAc
Neu5Ac(a2-3)Gal(b1-4)[Fuc(a1-3)]GlcNAc
Neu5Ac(a2-6)Gal(b1-4)[Fuc(a1-3)]GlcNAc
Neu5Gc(a2-3)Gal(b1-4)[Fuc(a1-3)]GlcNAc
Gal(a1-4)
GalNAc(b1-3)Gal(a1-4)
Gal(b1-3)GalNAc(b1-3)Gal(a1-4)
Fuc(a1-2)Gal(b1-3)GalNAc(b1-3)Gal(a1-4)
Neu5Ac(a2-3)Gal(b1-3)GalNAc(b1-3)Gal(a1-4)
Neu5Ac(a2-3)[GalNAc(b1-4)]Gal(b1-4)Glc-AEAB
Neu5Ac(a2-8)Neu5Ac(a2-3)[GalNAc(b1-4)]Gal(b1-4)Glc-AEAB
Length
Size
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Figure 30.
Heat map illustration of binding intensity of viruses bound to glycans on
the glycan array.
The normalized binding signals were log2-transformed. Each row represents a receptor
binding site mutant of CA/04 and each column represents an individual glycans. The
linkage hierarchical clustering was performed by Hierachical Clustering Explorer 3.0 to
generate the heat map and tree structure.
Glycan substructures determining yield signatures in eggs and/or cells
We used machine learning models to investigate the weight of glycan terminal
structures on virus receptor binding properties. The results suggested that Neu5Acα23Gal, Asn linked core pentasacchrides, Core lactose, AEAB labed core pentasaccharides,
and Thr linked core mannose are the most important structure motifs determining the
overall virus binding of 2009 pandemic H1N1 virus (Figure 31).
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Figure 31.
Prediction of virus glycan binding by machine learning
The X axis represents the real value of normalized glycan binding signal; The Y axis
represents the predicted value of glycan binding signal. The red line represents the
reference axis for the prediction. The blue dots represent the binding signals from the
experiments.
Validation of the key residues in the HA RBS affecting virus antigenic properties
To further determine the effect of the D130E, S193T, and 198S mutations on the
antigenicity of CA/04 H1N1, we generated ferret antisera against this mutant and then
performed a two-way HI assay. The homologous HI titers of each D130E, S193T, and
A198S mutants had a HI titer of 1:1280, which was 8 fold higher than that of the WT.
The two-way HI assay further confirmed the significant antigenic change of the virus by
mutations D130E, S193T, and A198S.
Among 199 mutant viruses, ten mutants have at least one mutation among the
positions 130, 193, and 198 of the HA protein. To further determine the types of
mutation(s) responsible for the antigenic change, all ten mutants with mutations in 130,
193, and 198 were included in the two-way HI assay (Table 11). The results of two-way
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HI assays showed that the D130E, A198S, A198G, A198V, and A198T mutants had a HI
titer of < 2-fold change compared to that of the WT virus, suggesting a limited role for
positions 130 and 198 in virus antigenic properties. However, the S193N and S193I had
the same HI titer as the homologous titer of the WT virus. Those results suggest an
important role of S193T in affecting virus antigenicity of CA/04 H1N1.
Table 11. Serological responses of the 130, 193, and 198 mutants against ferret antiCA/04 WT and CA/04 D130E, S193T, and A198S mutant sera using HI assays
Virusesa

(CA/04 WT)b

HI (D130E, S193T,
A198S)c

WT
640
160
D130E, S193T,
10
1280
A198S
D130E G158E
320
320
A198V
S167T I169H
640
320
S193N
S193I
640
320
S193G
320
160
A198V V237L
640
160
T244S
A198G
640
160
A198S
320
160
A198T
320
320
A198V
640
320
a
Mutants generated by ep-PCR based reverse genetic approaches that contains mutations
at residue 130, 193, or 198.
b. hemagglutination inhibition titers of mutants determined by using ferret serum (antiCA/04).
c. hemagglutination inhibition titers of mutants determined by using ferret serum (antiCA/04 D130E, S193T, A198S.
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Validation of the key residues affecting receptor binding properties
To test the binding profiles of the D130E, S193T, A198S mutants, we performed
biolayer interferometry analyses to characterize the dynamics and avidity of virus binding
to five representative glycan analogs, [Neu5Acα2-3Galβ1-4GlcNAcβ (3’SLN),
Neu5Acα2-6Galβ1-4GlcNAcβ (6’SLN), Neu5Acα2-3Galβ1-4[Fucα1-3]GlcNAcβ
(SLeX), Neu5Gcα2-3Galβ1-4GlcNAcβ (3’SLN(Gc)), and Neu5Gcα2-3Galβ1-4[Fucα13]GlcNAcβ (SLeX(Gc))]. Compared to the CA/04 WT that had no detectable binding to
3′SLN (see chapter III), the D130E, S193T, A198S mutant gained binding avidity to
3’SLN (Response=2.919) and SLeX (Response=2.449). The mutant had a 1.61 fold less
binding avidity to 6’SLN (Response=1.818) compare to that of 3’SLN, suggesting that
the D130E, S193T, A198S mutations changed binding preference of CA/04 H1N1 to
3’SLN over 6’SLN (Figure 32A). For the α2-3 linked sialic acids, the mutants had a 1.19fold higher binding affinity to the 3’SLN than the SLeX. Similar to the WT, the mutant
had no detectable binding to 3’SLN(Gc) and SLeX(Gc)). These results indicated that the
D130E, S193T, A198S mutation in HA increased the binding affinity to 3'SLN and
switched the binding preference of virus to 3'SLN to 6’SLN. The structure modeling
analysis showed that positions 130, 193, and 198 locates at the globular head of RBS.
The D130E and A198S mutations might function together to change the binding avidity
and specificity of the CA/04 H1N1 (Figure 32B).
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Figure 32.
Glycan binding specificity of the D130E, S193T, A198S mutant of CA/04
by Bio-Layer Interferometry (fortéBIO, Menlo Park, CA).
A. Binding of viruses to biotinylated α2,6–linked sialic acid (6′SLN), α2,3–linked sialic
acid (3′SLN), Neu5Acα2-3Galβ1-4(Fucα1-3)GlcNAcβ (SLeX) , Neu5Gcα2-3Galβ14GlcNAcβ (3’SLN(Gc)), and Neu5Gcα2-3Galβ1-4[Fucα1-3]GlcNAcβ (SLeX(Gc))] glycan
analogs as determined by Bio-Layer Interferometry (Pall ForteBio LLC, Fremont, CA).
The streptavidin-coated biosensors were first preloaded with biotin-labeled sialic acid
receptors, followed by the 1 pM each virus binding for 1,200 seconds in a standard
kinetic buffer with neuraminidase inhibitors (zanamivir hydrate and oseltamivir
phosphate). C, D) Sialic acid receptor concentrations were titrated to 1 µg/ml (3’SLN and
6’SLN) or 1uM (SLeX) when loading with the biotin-labeled receptors. The binding
response unit (nm) was recorded at the 1,196 second time point (4 seconds before the
start of dissociation). B. Three-dimensional view of the D130E, S193T, A198S mutant of
influenza A/California/04/09 (H1N1) virus.
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Evolutionary analysis of residues 130, 193 and 198 in H1 IAVs
Sequence alignment of position 130 and 198 from sequences of avian H1N1,
1918 pandemic H1N1, and 2009 pandemic H1N1 suggested that 130E, 198T are
predominant in waterfowl H1N1 whereas the 1918 pandemic H1N1 had 130E and 198A,
and the 2009 pandemic H1N1 had 130D and 198A (Table 12). Previous studies suggested
that G225D would switch binding preference of the H1N1 and H6N1 viruses from
Neu5Acα2-3Gal to Neu5Acα2-6Gal (75, 247). In this study, we identified residues 198
and 130, which may play critical role in the host adaption of avian H1N1 virus to
humans. The 1918 pandemic H1N1 was hypothesized to originate from avian H1N1
without adaptions in mammalian hosts such as pigs. The T198A mutation may change
the binding specificity of the avian H1N1 virus from α2-3 to α2-6. Additionally, the HA
of the 2009 pandemic H1N1 which originated from the 1918 pandemic H1N1 gained a
mutation at E130D which caused a loss of binding to Neu5Acα2-3Gal. Our results
suggest a novel evolutionary pathway for the adaption of avian H1N1 in obtaining
binding specificity for humans and therefore increasing the probability of causing
pandemic outbreaks in humans.
The HA sequences of North American swine H1N1 viruses from 1977 to 2018
were analyzed since the HA of the 2009 pandemic H1N1 virus originated from the H1N1
swine North America lineage (Figure 33). The results suggest that the North American
swine H1N1 only had 130E between the years of 1977 to 2000. The 130D was observed
in 2000, and then 130D became increasingly prevalent and was predominant in the North
America swine population. Similar patterns were found in residue 193 of the North
American swine H1N1 viruses. The North American swine H1N1 only had 193T
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between the years of 1977 to 1999. The 193S was first observed in the year of 2000 and
then co-circulated with the 193T. As we observed that S193T could change the
antigenicity of the H1N1 viruses, the North American swine H1N1 may have
experienced a drastic change in antigenicity change around the years of 2001-2008. In
contrast, the sequence analysis suggested that 198A was predominant in the North
American swine H1N1 during the years of 1977-2018, suggesting that 198A was
introduced into the swine population in earlier times. Most likely, the T198A mutation
occurred before 1918 and then facilitated the outbreak of the 1918 pandemic H1N1 in
humans.

Table 12. Sequence alignment of residues 130 and 198 from avian H1N1, 1918
pandemic H1N1, and 2009 pandemic H1N1 virus.
Viruses

130

191

192

193

194

195

196

197

198

225

Binding

Waterfowl
H1N1

E

Q

Q

S

L

Y

Q

N

T

G

2,3>2,6

1918 pH1N1

E

Q

Q

S

L

Y

Q

N

A

D

2,6>2,3

2009 pH1N1

D

Q

Q

S

L

Y

Q

N

A

D

2,6

Turkey H1N1

D

Q

Q

S

L

Y

Q

N

A

D

?

The HA sequences were extracted from the Influenza Research Database
(https://www.fludb.org). Residues are numbered through H3 numbering. Residues 130
and 198 are marked with red.
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Figure 33.
Evolution of amino acid positions 130, 193, and 198 in the receptor
binding site of human seasonal/pandemic H1N1 and swine H1N1 influenza viruses.
The HA sequences of human seasonal/pandemic H1N1 and swine H1N1 influenza
viruses from 1977-2018 were extracted from the Influenza Research Database
(https://www.fludb.org). The numbers of each amino acid (Y axis) were plotted as a
function of calendar year (X axis) of isolation. Each amino acid is indicated by a different
color.

Discussion
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The HA plays important role in the biology of IAV, including mediating virus
entry through the attachment to sialic acid receptors on the host cells and serving as the
major antigen of IAV. Mutations in the RBS that locate at the globular head of the HA
has been shown to affect virus binding specificity, antigenicity, and yield. The biological
properties of an IAV such as antigenicity and growth properties are critical for the
success of influenza vaccine seed strain. In this study, we performed large scale of
mutagenesis in the RBS of the HA of 2009 pandemic H1N1 and identified critical
residues on the RBS of pandemic H1N1, which would affect virus antigenicity, yield and
binding specificity. The novel biomarkers identified in this study would help the
influenza vaccine seed strain selection and expand the knowledge of H1N1 virus
evolution and host adaption.
The RBS of HA are be highly conserved among different IAVs, especially the
same HA subtypes of avian IAVs (248). In this study, we identified that mutations on
residues 134, 139, 147, 155, 168, 170, 177, 179, 180, 181, 183, 185, 191, 209 and 215
were deleterious among those RBS mutants. For example, sequence analysis of HA from
H1-H14 IAV showed that residues 134G, 139C, 147F, 170N, 180W, and 183H were
100% conserved from H1 to H14 of IAV. The residues 181G, 185P, and 215P were
92.8% conserved from H1 to H14 of IAV except residue 181A for H12, residue 185S for
H7, and residue 215L for H13 (data not shown). Our results indicate that residue C was
conserved among all position (7, 45, 58,70, 93, 139, 278, 282, 306, 467,474, 478, and
551) in the HA of IAV from H1 to H14. Residue C (7, 45, 58,70, 93, 139, 278, 282, 306,
467,474, 478, and 551) forms the disulfide linkages, which is critical in forming the
structure of HA1. In addition, hydrophobic aromatic residues such as F and W were
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found to form the base of the RBS, which was also reported by Xu et al (72). Our study
supported that the highly conserved amino acids form the framework of the HA RBS and
that mutations at those sites reduced virus’s potency and are associated with virus fitness.
This study identified that the mutations S193T, S160A, S188N, R220K, K172R,
T200S, S206T were associated with the antigenicity of H1N1 IAV. The results suggest
the immunodominance of antigenic site B over antigenic site A for HA of CA/04 H1N1.
In a prior study, Popova et al (249) reported the immunodominance of antigenic site B
over site A for a recent seasonal H3N2 human IAV. More recently, Wang et al (250)
reported that the amino acids in the antigenic site B determine antigenic difference
between a human H3N2 variant and an ancestral seasonal H3N2 influenza virus. The
heavy glycosylation of HA1 of contemporary H3N2 human IAV masked the virus and
leading to the immunodominance of the RBS over other antigenic sites. The RBS has to
maintain its structures in order to bind sialic acid receptors and thus is exposed to the
neutralizing antibodies. However, the CA/04 HA only has one glycosylation site,
suggesting that the immunodominance of antigenic site B may not be directly associated
with the extent of glycosylation of HA.
Residue 193 is located at antigenic site B and has been reported to have a strong
antigenic impact on human H3N2 IAV(157, 251). Of note, our results suggested that
residue 193 had a strong antigenic impact on the 2009 pandemic H1N1 virus. Residue
193 showed a high level of diversity between subtypes of HA. Moreover, residue 193
was reported to be located at the epitope recognized by mouse monoclonal antibodies
(251). Those findings suggest that residue 193 plays an important role in the antigenic
changes of both human H1N1 and H3N2 IAV and thus drive viral evolution. Threonine
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differs from serine by a substitution of hydrogen to a methyl group. The substitution of S
to T at position 193 increased the bulkiness around that area, which may make it more
difficult for residue 193 to adopt an alpha-helical conformation in the 190-helix of the
RBS and therefore alter the recognition of targeting neutralizing antibodies.
This study identified 13 mutations that would improve virus replication efficiency
in both eggs and cells without changing virus antigenicity. For example, mutation N159D
improved virus yield in both MDCK cells and eggs. It has been reported that N159D
functioned together with Q226R and switched the binding preference of the 2009
pandemic H1N1 virus from Neu5Acα2-6Gal to Neu5Acα2-3Gal(252). Residue 159 is
located at the very top of the RBS. It has been reported that N159D may increase the
local negative charge at the globular head, which would decrease the affinity of binding
to the human receptor but increase affinity for the avian receptor. Therefore, residue 159
may be involved in host adaption of avian IAV to humans. Interestingly, we identified
that the K166Q HA mutation significantly improved virus yield in chicken eggs but not
in MDCK cells. Our sequence analysis suggested K166Q mutation occurred during the
2012-2013 seasons and then 166Q quickly become dominant in pandemic isolates (>99%)
after the year 2013. It has been reported that the K166Q HA mutant of the 2009
pandemic H1N1virus is antigenically similar to the wild type strain, which was also
observed in this study. Linderman et al reported that the K166 epitope is shielded by a
glycosylation site located at residue 129 that was present in swine H1N1 IAV circulating
after 1985(253). A considerable homology in the vicinity of K166 was observed between
the 1918 pandemic H1N1 and the 2009 pandemic H1N1(254). Our study supports the
observation that the selective pressure on HA was aimed to improve viral fitness and
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replication to produce a large number of progeny, rather than only avoiding the host
immune recognition.
We identified one mutant virus, which possessed the D130E, S193T, and A198S
HA mutations, had switched the binding preference of 2009 pandemic H1N1 from the
human receptor to the avian receptor. Our sequence analysis suggested that residue 130E
was conserved in duck H1N1 isolates. The D130E mutation has been shown to increase
virus replication efficiency in human lung epithelial cells and in mouse lungs (255). In
addition, North American swine H1N1 was found to have 130E only between the years
of 1977 to 2000. The 130D residue started to emerge around 2000, and then became
increasingly prevalent and now dominant in the North American swine population. Our
results support the hypothesis that the E130D mutation facilitated the emergence of the
2009 pandemic, through the mechanism of decreasing the virus binding affinity to avian
receptors. It has been widely considered that a single mutation at D225G enables virus
binding to both Neu5Acα2-6Gal to Neu5Acα2-3Gal(77, 256). Here, we report a novel
biomarker, A198T, which enables the binding of the 2009 pandemic H1N1to both
Neu5Acα2-6Gal to Neu5Acα2-3Gal. Our results suggest that the T198A mutation
changed the binding preference of avian H1N1 from Neu5Acα2-3Gal to Neu5Acα26Gal. The T198A mutation may have occurred before 1918 and played important role in
the outbreak of 1918 pandemic H1N1. Sequence analysis showed that the incidence of
225G is 13.6 fold higher than the 198T, suggesting that 198A is a better human adapted
biomarker than 225D for H1N1 IAV.
A high yield and antigenic match vaccine seed virus is critical for the success of
the influenza vaccine production. Optimization of influenza vaccine seed selections is
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urgently need in the influenza vaccine industry. Currently, the mechanisms for
determining the IAV yield remains largely unknown. Besides the virus RNP activity, the
mutations on the receptor binding site of IAVs clearly could improve the virus growth in
host cells, either by expanding the receptor targets for IAVs or by enhancing the balance
of HA and NA activity. At least four key glycan substructure features associated with
vaccine yields were elucidated from this study: 1). increasing the binding ratio of α2-3
sialic acid glycans to α2-6 sialic acid glycans to expand the binding receptor targets; 2)
increasing of binding ratio of SleX glycans to α2-6 sialic acid glycans might increase the
virus yield, especially in eggs, which may express high levels of SLeX; 3) increasing
virus binding to the non-sialic acid glycans might increase yield; 4) increasing virus
binding to Neu5Gcα2-6Gal might increase the yield in MDCK cells, which might express
α2-6 linked Gc glycans as a functional receptor for virus entry.
In summary, this study systematically evaluated the effect of mutations on the
RBS of H1N1 IAV to modulate virus antigenicity, growth, and binding properties. The
residues identified in this study, which had a great impact on virus antigenicity and
growth efficiency, would help the influenza vaccine seed strain selection. The novel
biomarkers that related to the receptor binding specificity of H1N1 IAV expanded the
knowledge of H1N1 IAV evolution and host adaptions.
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CHAPTER VI
CONCLUSIONS
The studies in this dissertation have generated following conclusions:
First, a novel method was developed and validated for rapidly producing
influenza virus mutants by using an error-prone PCR–based mutagenesis strategy. This
method targets a specific region of a gene for rapidly generating a mutant library; then
the desired mutants are selected by phenotype screening of the library. Selecting seed
virus for influenza vaccine production is time consuming, and candidate strains must be
generated rapidly, produce at high yields, and have unaltered antigenicity. This novel
method was used to develop six influenza vaccine candidates that had unaltered
antigenicity and produced yields in chicken embryonic eggs that were higher than those
produced by the wild-type strain. Animal studies using two of the candidate strains
demonstrated that both strains provided effective protection and thus could be potential
vaccine candidates. This error-prone PCR–based mutagenesis method has the potential to
increase vaccine yields and could also be applied to gain-of-function studies for influenza
virus and other pathogens.
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Second, although a promising complement to current egg-based influenza
vaccines, cell-based vaccines have one big challenge; high-yield vaccine seeds for
production. In this study, we identified a molecular signature- the Y161F mutation in
hemagglutinin (HA) that resulted in increased virus growth in Madin-Darby canine
kidney cells and Vero cells, the two commonly used cell lines in influenza vaccine
manufacturing. The Y161F mutation not only increased HA thermostability, but also
enhanced its binding affinity to α2,6 and α2,3-linked Neu5Ac. These results suggest that
a vaccine strain bearing the Y161F mutation in HA could potentially increase vaccine
yields in mammalian cell culture systems.
Third, IAVs cause a significant burden on human and animal health, and the
mechanisms for interspecies transmission of IAVs are far from being understood. The
findings from this study suggest that an equine-origin A(H3N8) IAV with the mutation
W222L at its hemagglutinin increased binding to canine-specific receptors with sialyl
Lewis X and Neu5Gc motifs and, therefore may have facilitated viral adaptation from
horses to dogs. These findings suggest that in addition to the glycosidic linkage (e.g.,
α2,3-linked and α2,6-linked), the substructure in the receptor saccharides (e.g., sialyl
Lewis X and Neu5Gc) could present an interspecies transmission barrier for IAVs and
drive viral mutations to overcome such barriers.
Fourth, we revealed the immunodominance of antigenic site B over site A for HA
of CA/04 H1N1. The residue at position193 was found to have a great impact on the
antigenicity of CA/04 H1N1. The high yield signatures identified in this dissertation
would improve the vaccine seed strain selection. This dissertation identified novel
biomarkers, residues at positions 130 and 198, which can affect the binding specificity of
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H1N1 IAV, which expanded the knowledge of the 1918 pandemic H1N1 and the 2009
pandemic H1N1 emergence and evolution.
Overall, this dissertation has systematically evaluated the effects of the receptor
binding sites of IAV on virus antigenicity, yields, and receptor binding properties and the
key signatures were identified. This novel information will be useful in understanding
influenza cell and host tropisms and in selecting effective vaccine strains in influenza
surveillance.

164

REFERENCES
1.

Hause BM, Collin EA, Liu R, Huang B, Sheng Z, Lu W, Wang D, Nelson EA, Li
F. 2014. Characterization of a novel influenza virus in cattle and Swine: proposal
for a new genus in the Orthomyxoviridae family. MBio 5:e00031-14.

2.

Hause BM, Ducatez M, Collin EA, Ran Z, Liu R, Sheng Z, Armien A, Kaplan B,
Chakravarty S, Hoppe AD, Webby RJ, Simonson RR, Li F. 2013. Isolation of a
novel swine influenza virus from Oklahoma in 2011 which is distantly related to
human influenza C viruses. PLoS Pathog 9:e1003176.

3.

Tong S, Zhu X, Li Y, Shi M, Zhang J, Bourgeois M, Yang H, Chen X, Recuenco
S, Gomez J, Chen LM, Johnson A, Tao Y, Dreyfus C, Yu W, McBride R, Carney
PJ, Gilbert AT, Chang J, Guo Z, Davis CT, Paulson JC, Stevens J, Rupprecht CE,
Holmes EC, Wilson IA, Donis RO. 2013. New world bats harbor diverse
influenza A viruses. PLoS Pathog 9:e1003657.

4.

Taubenberger JK, Morens DM. 2010. Influenza: the once and future pandemic.
Public Health Rep 125 Suppl 3:16-26.

5.

Chen W, Calvo PA, Malide D, Gibbs J, Schubert U, Bacik I, Basta S, O'Neill R,
Schickli J, Palese P, Henklein P, Bennink JR, Yewdell JW. 2001. A novel
influenza A virus mitochondrial protein that induces cell death. Nat Med 7:130612.

6.

Wise HM, Foeglein A, Sun J, Dalton RM, Patel S, Howard W, Anderson EC,
Barclay WS, Digard P. 2009. A complicated message: Identification of a novel
PB1-related protein translated from influenza A virus segment 2 mRNA. J Virol
83:8021-31.

7.

Priore SF, Kauffmann AD, Baman JR, Turner DH. 2015. The Influenza A PB1F2 and N40 Start Codons Are Contained within an RNA Pseudoknot.
Biochemistry 54:3413-5.

8.

Jagger BW, Wise HM, Kash JC, Walters KA, Wills NM, Xiao YL, Dunfee RL,
Schwartzman LM, Ozinsky A, Bell GL, Dalton RM, Lo A, Efstathiou S, Atkins
JF, Firth AE, Taubenberger JK, Digard P. 2012. An overlapping protein-coding
region in influenza A virus segment 3 modulates the host response. Science
337:199-204.
165

9.

Muramoto Y, Noda T, Kawakami E, Akkina R, Kawaoka Y. 2013. Identification
of novel influenza A virus proteins translated from PA mRNA. J Virol 87:245562.

10.

Lamb RA, Lai CJ, Choppin PW. 1981. Sequences of mRNAs derived from
genome RNA segment 7 of influenza virus: colinear and interrupted mRNAs code
for overlapping proteins. Proc Natl Acad Sci U S A 78:4170-4.

11.

Lamb RA, Choppin PW, Chanock RM, Lai CJ. 1980. Mapping of the two
overlapping genes for polypeptides NS1 and NS2 on RNA segment 8 of influenza
virus genome. Proc Natl Acad Sci U S A 77:1857-61.

12.

Kochs G, Garcia-Sastre A, Martinez-Sobrido L. 2007. Multiple anti-interferon
actions of the influenza A virus NS1 protein. J Virol 81:7011-21.

13.

Calder LJ, Wasilewski S, Berriman JA, Rosenthal PB. 2010. Structural
organization of a filamentous influenza A virus. Proc Natl Acad Sci U S A
107:10685-90.

14.

Bouvier NM, Palese P. 2008. The biology of influenza viruses. Vaccine 26 Suppl
4:D49-53.

15.

Smirnov Yu A, Kuznetsova MA, Kaverin NV. 1991. The genetic aspects of
influenza virus filamentous particle formation. Arch Virol 118:279-84.

16.

Hughey PG, Roberts PC, Holsinger LJ, Zebedee SL, Lamb RA, Compans RW.
1995. Effects of antibody to the influenza A virus M2 protein on M2 surface
expression and virus assembly. Virology 212:411-21.

17.

Bourmakina SV, Garcia-Sastre A. 2003. Reverse genetics studies on the
filamentous morphology of influenza A virus. J Gen Virol 84:517-27.

18.

Lakdawala SS, Lamirande EW, Suguitan AL, Jr., Wang W, Santos CP, Vogel L,
Matsuoka Y, Lindsley WG, Jin H, Subbarao K. 2011. Eurasian-origin gene
segments contribute to the transmissibility, aerosol release, and morphology of the
2009 pandemic H1N1 influenza virus. PLoS Pathog 7:e1002443.

19.

Nemeroff ME, Barabino SM, Li Y, Keller W, Krug RM. 1998. Influenza virus
NS1 protein interacts with the cellular 30 kDa subunit of CPSF and inhibits 3'end
formation of cellular pre-mRNAs. Mol Cell 1:991-1000.

20.

Steinhauer DA. 1999. Role of hemagglutinin cleavage for the pathogenicity of
influenza virus. Virology 258:1-20.

21.

Horimoto T, Nakayama K, Smeekens SP, Kawaoka Y. 1994. Proproteinprocessing endoproteases PC6 and furin both activate hemagglutinin of virulent
avian influenza viruses. J Virol 68:6074-8.
166

22.

Varki A, Lowe JB. 2009. Biological Roles of Glycans. In nd, Varki A, Cummings
RD, Esko JD, Freeze HH, Stanley P, Bertozzi CR, Hart GW, Etzler ME (ed),
Essentials of Glycobiology, Cold Spring Harbor (NY).

23.

Lundblad A. 2015. Gunnar Blix and his discovery of sialic acids. Fascinating
molecules in glycobiology. Ups J Med Sci 120:104-12.

24.

Hirst GK. 1941. The Agglutination of Red Cells by Allantoic Fluid of Chick
Embryos Infected with Influenza Virus. Science 94:22-3.

25.

Gottschalk A. 1957. Neuraminidase: the specific enzyme of influenza virus and
Vibrio cholerae. Biochim Biophys Acta 23:645-6.

26.

Suzuki Y, Ito T, Suzuki T, Holland RE, Jr., Chambers TM, Kiso M, Ishida H,
Kawaoka Y. 2000. Sialic acid species as a determinant of the host range of
influenza A viruses. J Virol 74:11825-31.

27.

Gambaryan AS, Tuzikov AB, Piskarev VE, Yamnikova SS, Lvov DK, Robertson
JS, Bovin NV, Matrosovich MN. 1997. Specification of receptor-binding
phenotypes of influenza virus isolates from different hosts using synthetic
sialylglycopolymers: non-egg-adapted human H1 and H3 influenza A and
influenza B viruses share a common high binding affinity for 6'-sialyl(Nacetyllactosamine). Virology 232:345-50.

28.

Rogers GN, Paulson JC. 1983. Receptor determinants of human and animal
influenza virus isolates: differences in receptor specificity of the H3
hemagglutinin based on species of origin. Virology 127:361-73.

29.

Chu VC, Whittaker GR. 2004. Influenza virus entry and infection require host cell
N-linked glycoprotein. Proc Natl Acad Sci U S A 101:18153-8.

30.

de Vries E, de Vries RP, Wienholts MJ, Floris CE, Jacobs MS, van den Heuvel A,
Rottier PJ, de Haan CA. 2012. Influenza A virus entry into cells lacking sialylated
N-glycans. Proc Natl Acad Sci U S A 109:7457-62.

31.

Ablan S, Rawat SS, Blumenthal R, Puri A. 2001. Entry of influenza virus into a
glycosphingolipid-deficient mouse skin fibroblast cell line. Arch Virol 146:222738.

32.

Higa HH, Rogers GN, Paulson JC. 1985. Influenza virus hemagglutinins
differentiate between receptor determinants bearing N-acetyl-, N-glycollyl-, and
N,O-diacetylneuraminic acids. Virology 144:279-82.

33.

Yang G, Li S, Blackmon S, Ye J, Bradley KC, Cooley J, Smith D, Hanson L,
Cardona C, Steinhauer DA, Webby R, Liao M, Wan XF. 2013. Mutation
tryptophan to leucine at position 222 of haemagglutinin could facilitate H3N2
influenza A virus infection in dogs. J Gen Virol 94:2599-608.
167

34.

Suzuki T, Horiike G, Yamazaki Y, Kawabe K, Masuda H, Miyamoto D, Matsuda
M, Nishimura SI, Yamagata T, Ito T, Kida H, Kawaoka Y, Suzuki Y. 1997.
Swine influenza virus strains recognize sialylsugar chains containing the
molecular species of sialic acid predominantly present in the swine tracheal
epithelium. FEBS Lett 404:192-6.

35.

Hedlund M, Tangvoranuntakul P, Takematsu H, Long JM, Housley GD,
Kozutsumi Y, Suzuki A, Wynshaw-Boris A, Ryan AF, Gallo RL, Varki N, Varki
A. 2007. N-glycolylneuraminic acid deficiency in mice: implications for human
biology and evolution. Mol Cell Biol 27:4340-6.

36.

Varki A. 2001. Loss of N-glycolylneuraminic acid in humans: Mechanisms,
consequences, and implications for hominid evolution. Am J Phys Anthropol
Suppl 33:54-69.

37.

Chou HH, Takematsu H, Diaz S, Iber J, Nickerson E, Wright KL, Muchmore EA,
Nelson DL, Warren ST, Varki A. 1998. A mutation in human CMP-sialic acid
hydroxylase occurred after the Homo-Pan divergence. Proc Natl Acad Sci U S A
95:11751-6.

38.

Irie A, Koyama S, Kozutsumi Y, Kawasaki T, Suzuki A. 1998. The molecular
basis for the absence of N-glycolylneuraminic acid in humans. J Biol Chem
273:15866-71.

39.

Hayakawa T, Aki I, Varki A, Satta Y, Takahata N. 2006. Fixation of the humanspecific CMP-N-acetylneuraminic acid hydroxylase pseudogene and implications
of haplotype diversity for human evolution. Genetics 172:1139-46.

40.

Springer SA, Diaz SL, Gagneux P. 2014. Parallel evolution of a self-signal:
humans and new world monkeys independently lost the cell surface sugar
Neu5Gc. Immunogenetics 66:671-4.

41.

Ng PS, Bohm R, Hartley-Tassell LE, Steen JA, Wang H, Lukowski SW,
Hawthorne PL, Trezise AE, Coloe PJ, Grimmond SM, Haselhorst T, von Itzstein
M, Paton AW, Paton JC, Jennings MP. 2014. Ferrets exclusively synthesize
Neu5Ac and express naturally humanized influenza A virus receptors. Nat
Commun 5:5750.

42.

Schauer R, Srinivasan GV, Coddeville B, Zanetta JP, Guerardel Y. 2009. Low
incidence of N-glycolylneuraminic acid in birds and reptiles and its absence in the
platypus. Carbohydr Res 344:1494-500.

43.

Liu Y, Han C, Wang X, Lin J, Ma M, Shu Y, Zhou J, Yang H, Liang Q, Guo C,
Zhu J, Wei H, Zhao J, Ma Z, Pan J. 2009. Influenza A virus receptors in the
respiratory and intestinal tracts of pigeons. Avian Pathol 38:263-6.
168

44.

Gambaryan AS, Matrosovich TY, Philipp J, Munster VJ, Fouchier RA, Cattoli G,
Capua I, Krauss SL, Webster RG, Banks J, Bovin NV, Klenk HD, Matrosovich
MN. 2012. Receptor-binding profiles of H7 subtype influenza viruses in different
host species. J Virol 86:4370-9.

45.

Takahashi T, Takano M, Kurebayashi Y, Masuda M, Kawagishi S, Takaguchi M,
Yamanaka T, Minami A, Otsubo T, Ikeda K, Suzuki T. 2014. Nglycolylneuraminic acid on human epithelial cells prevents entry of influenza A
viruses that possess N-glycolylneuraminic acid binding ability. J Virol 88:844556.

46.

Angata T, Varki A. 2002. Chemical diversity in the sialic acids and related alphaketo acids: an evolutionary perspective. Chem Rev 102:439-69.

47.

Wasik BR, Barnard KN, Parrish CR. 2016. Effects of Sialic Acid Modifications
on Virus Binding and Infection. Trends Microbiol 24:991-1001.

48.

Klein A, Krishna M, Varki NM, Varki A. 1994. 9-O-acetylated sialic acids have
widespread but selective expression: analysis using a chimeric dual-function
probe derived from influenza C hemagglutinin-esterase. Proc Natl Acad Sci U S
A 91:7782-6.

49.

Schauer R, Schmid H, Pommerencke J, Iwersen M, Kohla G. 2001. Metabolism
and role of O-acetylated sialic acids. Adv Exp Med Biol 491:325-42.

50.

Schauer R. 2004. Sialic acids: fascinating sugars in higher animals and man.
Zoology (Jena) 107:49-64.

51.

Rogers GN, Herrler G, Paulson JC, Klenk HD. 1986. Influenza C virus uses 9-Oacetyl-N-acetylneuraminic acid as a high affinity receptor determinant for
attachment to cells. J Biol Chem 261:5947-51.

52.

Song H, Qi J, Khedri Z, Diaz S, Yu H, Chen X, Varki A, Shi Y, Gao GF. 2016.
An Open Receptor-Binding Cavity of Hemagglutinin-Esterase-Fusion
Glycoprotein from Newly-Identified Influenza D Virus: Basis for Its Broad Cell
Tropism. PLoS Pathog 12:e1005411.

53.

Baum LG, Paulson JC. 1990. Sialyloligosaccharides of the respiratory epithelium
in the selection of human influenza virus receptor specificity. Acta Histochem
Suppl 40:35-8.

54.

Couceiro JN, Paulson JC, Baum LG. 1993. Influenza virus strains selectively
recognize sialyloligosaccharides on human respiratory epithelium; the role of the
host cell in selection of hemagglutinin receptor specificity. Virus Res 29:155-65.
169

55.

Aich U, Beckley N, Shriver Z, Raman R, Viswanathan K, Hobbie S, Sasisekharan
R. 2011. Glycomics-based analysis of chicken red blood cells provides insight
into the selectivity of the viral agglutination assay. FEBS J 278:1699-712.

56.

Ito T, Suzuki Y, Mitnaul L, Vines A, Kida H, Kawaoka Y. 1997. Receptor
specificity of influenza A viruses correlates with the agglutination of erythrocytes
from different animal species. Virology 227:493-9.

57.

Makkoch J, Prachayangprecha S, Payungporn S, Chieochansin T, Songserm T,
Amonsin A, Poovorawan Y. 2012. Erythrocyte binding preference of human
pandemic influenza virus a and its effect on antibody response detection. Ann Lab
Med 32:276-82.

58.

Chandrasekaran A, Srinivasan A, Raman R, Viswanathan K, Raguram S, Tumpey
TM, Sasisekharan V, Sasisekharan R. 2008. Glycan topology determines human
adaptation of avian H5N1 virus hemagglutinin. Nat Biotechnol 26:107-13.

59.

Ito T, Couceiro JN, Kelm S, Baum LG, Krauss S, Castrucci MR, Donatelli I, Kida
H, Paulson JC, Webster RG, Kawaoka Y. 1998. Molecular basis for the
generation in pigs of influenza A viruses with pandemic potential. J Virol
72:7367-73.

60.

Suzuki Y. 2005. Sialobiology of influenza: molecular mechanism of host range
variation of influenza viruses. Biol Pharm Bull 28:399-408.

61.

Guo CT, Takahashi N, Yagi H, Kato K, Takahashi T, Yi SQ, Chen Y, Ito T,
Otsuki K, Kida H, Kawaoka Y, Hidari KI, Miyamoto D, Suzuki T, Suzuki Y.
2007. The quail and chicken intestine have sialyl-galactose sugar chains
responsible for the binding of influenza A viruses to human type receptors.
Glycobiology 17:713-24.

62.

Walther T, Karamanska R, Chan RW, Chan MC, Jia N, Air G, Hopton C, Wong
MP, Dell A, Malik Peiris JS, Haslam SM, Nicholls JM. 2013. Glycomic analysis
of human respiratory tract tissues and correlation with influenza virus infection.
PLoS Pathog 9:e1003223.

63.

Jia N, Barclay WS, Roberts K, Yen HL, Chan RW, Lam AK, Air G, Peiris JS,
Dell A, Nicholls JM, Haslam SM. 2014. Glycomic characterization of respiratory
tract tissues of ferrets: implications for its use in influenza virus infection studies.
J Biol Chem 289:28489-504.

64.

Muthana SM, Campbell CT, Gildersleeve JC. 2012. Modifications of glycans:
biological significance and therapeutic opportunities. ACS Chem Biol 7:31-43.

170

65.

Gambaryan A, Yamnikova S, Lvov D, Tuzikov A, Chinarev A, Pazynina G,
Webster R, Matrosovich M, Bovin N. 2005. Receptor specificity of influenza
viruses from birds and mammals: new data on involvement of the inner fragments
of the carbohydrate chain. Virology 334:276-83.

66.

Gambaryan AS, Tuzikov AB, Pazynina GV, Desheva JA, Bovin NV,
Matrosovich MN, Klimov AI. 2008. 6-sulfo sialyl Lewis X is the common
receptor determinant recognized by H5, H6, H7 and H9 influenza viruses of
terrestrial poultry. Virol J 5:85.

67.

Hiono T, Okamatsu M, Nishihara S, Takase-Yoden S, Sakoda Y, Kida H. 2014. A
chicken influenza virus recognizes fucosylated alpha2,3 sialoglycan receptors on
the epithelial cells lining upper respiratory tracts of chickens. Virology 456457:131-8.

68.

Hiono T, Okamatsu M, Igarashi M, McBride R, de Vries RP, Peng W, Paulson
JC, Sakoda Y, Kida H. 2016. Amino acid residues at positions 222 and 227 of the
hemagglutinin together with the neuraminidase determine binding of H5 avian
influenza viruses to sialyl Lewis X. Arch Virol 161:307-16.

69.

Wilson IA, Skehel JJ, Wiley DC. 1981. Structure of the haemagglutinin
membrane glycoprotein of influenza virus at 3 A resolution. Nature 289:366-73.

70.

Weis W, Brown JH, Cusack S, Paulson JC, Skehel JJ, Wiley DC. 1988. Structure
of the influenza virus haemagglutinin complexed with its receptor, sialic acid.
Nature 333:426-31.

71.

Martin J, Wharton SA, Lin YP, Takemoto DK, Skehel JJ, Wiley DC, Steinhauer
DA. 1998. Studies of the binding properties of influenza hemagglutinin receptorsite mutants. Virology 241:101-11.

72.

Xu R, McBride R, Paulson JC, Basler CF, Wilson IA. 2010. Structure, receptor
binding, and antigenicity of influenza virus hemagglutinins from the 1957 H2N2
pandemic. J Virol 84:1715-21.

73.

Liu J, Stevens DJ, Haire LF, Walker PA, Coombs PJ, Russell RJ, Gamblin SJ,
Skehel JJ. 2009. Structures of receptor complexes formed by hemagglutinins from
the Asian Influenza pandemic of 1957. Proc Natl Acad Sci U S A 106:17175-80.

74.

Ha Y, Stevens DJ, Skehel JJ, Wiley DC. 2003. X-ray structure of the
hemagglutinin of a potential H3 avian progenitor of the 1968 Hong Kong
pandemic influenza virus. Virology 309:209-18.

171

75.

de Vries RP, Tzarum N, Peng W, Thompson AJ, Ambepitiya Wickramasinghe
IN, de la Pena ATT, van Breemen MJ, Bouwman KM, Zhu X, McBride R, Yu W,
Sanders RW, Verheije MH, Wilson IA, Paulson JC. 2017. A single mutation in
Taiwanese H6N1 influenza hemagglutinin switches binding to human-type
receptors. EMBO Mol Med 9:1314-1325.

76.

Stevens J, Blixt O, Glaser L, Taubenberger JK, Palese P, Paulson JC, Wilson IA.
2006. Glycan microarray analysis of the hemagglutinins from modern and
pandemic influenza viruses reveals different receptor specificities. J Mol Biol
355:1143-55.

77.

Glaser L, Stevens J, Zamarin D, Wilson IA, Garcia-Sastre A, Tumpey TM, Basler
CF, Taubenberger JK, Palese P. 2005. A single amino acid substitution in 1918
influenza virus hemagglutinin changes receptor binding specificity. J Virol
79:11533-6.

78.

de Vries RP, Peng W, Grant OC, Thompson AJ, Zhu X, Bouwman KM, de la
Pena ATT, van Breemen MJ, Ambepitiya Wickramasinghe IN, de Haan CAM,
Yu W, McBride R, Sanders RW, Woods RJ, Verheije MH, Wilson IA, Paulson
JC. 2017. Three mutations switch H7N9 influenza to human-type receptor
specificity. PLoS Pathog 13:e1006390.

79.

Stevens J, Blixt O, Tumpey TM, Taubenberger JK, Paulson JC, Wilson IA. 2006.
Structure and receptor specificity of the hemagglutinin from an H5N1 influenza
virus. Science 312:404-10.

80.

Stevens J, Chen LM, Carney PJ, Garten R, Foust A, Le J, Pokorny BA,
Manojkumar R, Silverman J, Devis R, Rhea K, Xu X, Bucher DJ, Paulson JC,
Cox NJ, Klimov A, Donis RO. 2010. Receptor specificity of influenza A H3N2
viruses isolated in mammalian cells and embryonated chicken eggs. J Virol
84:8287-99.

81.

Bradley KC, Galloway SE, Lasanajak Y, Song X, Heimburg-Molinaro J, Yu H,
Chen X, Talekar GR, Smith DF, Cummings RD, Steinhauer DA. 2011. Analysis
of influenza virus hemagglutinin receptor binding mutants with limited receptor
recognition properties and conditional replication characteristics. J Virol
85:12387-98.

82.

Varghese JN, Colman PM. 1991. Three-dimensional structure of the
neuraminidase of influenza virus A/Tokyo/3/67 at 2.2 A resolution. J Mol Biol
221:473-86.

83.

Matrosovich MN, Matrosovich TY, Gray T, Roberts NA, Klenk HD. 2004.
Neuraminidase is important for the initiation of influenza virus infection in human
airway epithelium. J Virol 78:12665-7.
172

84.

Wagner R, Wolff T, Herwig A, Pleschka S, Klenk HD. 2000. Interdependence of
hemagglutinin glycosylation and neuraminidase as regulators of influenza virus
growth: a study by reverse genetics. J Virol 74:6316-23.

85.

Mitnaul LJ, Matrosovich MN, Castrucci MR, Tuzikov AB, Bovin NV, Kobasa D,
Kawaoka Y. 2000. Balanced hemagglutinin and neuraminidase activities are
critical for efficient replication of influenza A virus. J Virol 74:6015-20.

86.

Laver WG, Colman PM, Webster RG, Hinshaw VS, Air GM. 1984. Influenza
virus neuraminidase with hemagglutinin activity. Virology 137:314-23.

87.

Webster RG, Air GM, Metzger DW, Colman PM, Varghese JN, Baker AT, Laver
WG. 1987. Antigenic structure and variation in an influenza virus N9
neuraminidase. J Virol 61:2910-6.

88.

Nuss JM, Air GM. 1991. Transfer of the hemagglutinin activity of influenza virus
neuraminidase subtype N9 into an N2 neuraminidase background. Virology
183:496-504.

89.

Air GM, Laver WG. 1995. Red cells bound to influenza virus N9 neuraminidase
are not released by the N9 neuraminidase activity. Virology 211:278-84.

90.

Hausmann J, Kretzschmar E, Garten W, Klenk HD. 1995. N1 neuraminidase of
influenza virus A/FPV/Rostock/34 has haemadsorbing activity. J Gen Virol 76 (
Pt 7):1719-28.

91.

Varghese JN, Colman PM, van Donkelaar A, Blick TJ, Sahasrabudhe A,
McKimm-Breschkin JL. 1997. Structural evidence for a second sialic acid binding
site in avian influenza virus neuraminidases. Proc Natl Acad Sci U S A 94:1180812.

92.

Lin YP, Gregory V, Collins P, Kloess J, Wharton S, Cattle N, Lackenby A,
Daniels R, Hay A. 2010. Neuraminidase receptor binding variants of human
influenza A(H3N2) viruses resulting from substitution of aspartic acid 151 in the
catalytic site: a role in virus attachment? J Virol 84:6769-81.

93.

Zhu X, McBride R, Nycholat CM, Yu W, Paulson JC, Wilson IA. 2012. Influenza
virus neuraminidases with reduced enzymatic activity that avidly bind sialic Acid
receptors. J Virol 86:13371-83.

94.

Gulati S, Smith DF, Cummings RD, Couch RB, Griesemer SB, St George K,
Webster RG, Air GM. 2013. Human H3N2 Influenza Viruses Isolated from 1968
To 2012 Show Varying Preference for Receptor Substructures with No Apparent
Consequences for Disease or Spread. PLoS One 8:e66325.

95.

Hooper KA, Bloom JD. 2013. A mutant influenza virus that uses an N1
neuraminidase as the receptor-binding protein. J Virol 87:12531-40.
173

96.

Hooper KA, Crowe JE, Jr., Bloom JD. 2015. Influenza viruses with receptorbinding N1 neuraminidases occur sporadically in several lineages and show no
attenuation in cell culture or mice. J Virol 89:3737-45.

97.

Benton DJ, Wharton SA, Martin SR, McCauley JW. 2017. Role of Neuraminidase
in Influenza A(H7N9) Virus Receptor Binding. J Virol 91.

98.

Carroll SM, Higa HH, Paulson JC. 1981. Different cell-surface receptor
determinants of antigenically similar influenza virus hemagglutinins. J Biol Chem
256:8357-63.

99.

Gambaryan AS, Matrosovich MN. 1992. A solid-phase enzyme-linked assay for
influenza virus receptor-binding activity. J Virol Methods 39:111-23.

100.

Fukui S, Feizi T, Galustian C, Lawson AM, Chai W. 2002. Oligosaccharide
microarrays for high-throughput detection and specificity assignments of
carbohydrate-protein interactions. Nat Biotechnol 20:1011-7.

101.

Stevens J, Blixt O, Paulson JC, Wilson IA. 2006. Glycan microarray technologies:
tools to survey host specificity of influenza viruses. Nat Rev Microbiol 4:857-64.

102.

Xiong X, Coombs PJ, Martin SR, Liu J, Xiao H, McCauley JW, Locher K,
Walker PA, Collins PJ, Kawaoka Y, Skehel JJ, Gamblin SJ. 2013. Receptor
binding by a ferret-transmissible H5 avian influenza virus. Nature 497:392-6.

103.

Petersen RL. 2017. Strategies Using Bio-Layer Interferometry Biosensor
Technology for Vaccine Research and Development. Biosensors (Basel) 7.

104.

Liao YC, Lee MS, Ko CY, Hsiung CA. 2008. Bioinformatics models for
predicting antigenic variants of influenza A/H3N2 virus. Bioinformatics 24:50512.

105.

Sun H, Yang J, Zhang T, Long LP, Jia K, Yang G, Webby RJ, Wan XF. 2013.
Using sequence data to infer the antigenicity of influenza virus. MBio 4.

106.

Steinbruck L, Klingen TR, McHardy AC. 2014. Computational prediction of
vaccine strains for human influenza A (H3N2) viruses. J Virol 88:12123-32.

107.

Neher RA, Bedford T, Daniels RS, Russell CA, Shraiman BI. 2016. Prediction,
dynamics, and visualization of antigenic phenotypes of seasonal influenza viruses.
Proc Natl Acad Sci U S A 113:E1701-9.

108.

Yao Y, Li X, Liao B, Huang L, He P, Wang F, Yang J, Sun H, Zhao Y, Yang J.
2017. Predicting influenza antigenicity from Hemagglutintin sequence data based
on a joint random forest method. Sci Rep 7:1545.
174

109.

Li M, Wang B. 2006. Computational studies of H5N1 hemagglutinin binding with
SA-alpha-2, 3-Gal and SA-alpha-2, 6-Gal. Biochem Biophys Res Commun
347:662-8.

110.

Iwata T, Fukuzawa K, Nakajima K, Aida-Hyugaji S, Mochizuki Y, Watanabe H,
Tanaka S. 2008. Theoretical analysis of binding specificity of influenza viral
hemagglutinin to avian and human receptors based on the fragment molecular
orbital method. Comput Biol Chem 32:198-211.

111.

Sawada T, Hashimoto T, Tokiwa H, Suzuki T, Nakano H, Ishida H, Kiso M,
Suzuki Y. 2008. Ab initio fragment molecular orbital studies of influenza virus
hemagglutinin-sialosaccharide complexes toward chemical clarification about the
virus host range determination. Glycoconj J 25:805-15.

112.

Das P, Li J, Royyuru AK, Zhou R. 2009. Free energy simulations reveal a double
mutant avian H5N1 virus hemagglutinin with altered receptor binding specificity.
J Comput Chem 30:1654-63.

113.

Jongkon N, Mokmak W, Chuakheaw D, Shaw PJ, Tongsima S, Sangma C. 2009.
Prediction of avian influenza A binding preference to human receptor using
conformational analysis of receptor bound to hemagglutinin. BMC Genomics 10
Suppl 3:S24.

114.

Newhouse EI, Xu D, Markwick PR, Amaro RE, Pao HC, Wu KJ, Alam M,
McCammon JA, Li WW. 2009. Mechanism of glycan receptor recognition and
specificity switch for avian, swine, and human adapted influenza virus
hemagglutinins: a molecular dynamics perspective. J Am Chem Soc 131:1743042.

115.

Cao Y, Koh X, Dong L, Du X, Wu A, Ding X, Deng H, Shu Y, Chen J, Jiang T.
2011. Rapid estimation of binding activity of influenza virus hemagglutinin to
human and avian receptors. PLoS One 6:e18664.

116.

Tharakaraman K, Raman R, Viswanathan K, Stebbins NW, Jayaraman A,
Krishnan A, Sasisekharan V, Sasisekharan R. 2013. Structural determinants for
naturally evolving H5N1 hemagglutinin to switch its receptor specificity. Cell
153:1475-85.

117.

Jayaraman A, Chandrasekaran A, Viswanathan K, Raman R, Fox JG,
Sasisekharan R. 2012. Decoding the distribution of glycan receptors for humanadapted influenza A viruses in ferret respiratory tract. PLoS One 7:e27517.

118.

Gerdil C. 2003. The annual production cycle for influenza vaccine. Vaccine
21:1776-9.
175

119.

Robertson JS, Nicolson C, Harvey R, Johnson R, Major D, Guilfoyle K, Roseby
S, Newman R, Collin R, Wallis C, Engelhardt OG, Wood JM, Le J, Manojkumar
R, Pokorny BA, Silverman J, Devis R, Bucher D, Verity E, Agius C, Camuglia S,
Ong C, Rockman S, Curtis A, Schoofs P, Zoueva O, Xie H, Li X, Lin Z, Ye Z,
Chen LM, O'Neill E, Balish A, Lipatov AS, Guo Z, Isakova I, Davis CT, Rivailler
P, Gustin KM, Belser JA, Maines TR, Tumpey TM, Xu X, Katz JM, Klimov A,
Cox NJ, Donis RO. 2011. The development of vaccine viruses against pandemic
A(H1N1) influenza. Vaccine 29:1836-43.

120.

Chen Z, Wang W, Zhou H, Suguitan AL, Jr., Shambaugh C, Kim L, Zhao J,
Kemble G, Jin H. 2010. Generation of live attenuated novel influenza virus
A/California/7/09 (H1N1) vaccines with high yield in embryonated chicken eggs.
J Virol 84:44-51.

121.

Kilbourne ED. 1969. Future influenza vaccines and the use of genetic
recombinants. Bull World Health Organ 41:643-645.

122.

Kilbourne ED, Murphy JS. 1960. Genetic studies of influenza viruses. I. Viral
morphology and growth capacity as exchangeable genetic traits. Rapid in ovo
adaptation of early passage Asian strain isolates by combination with PR8. J Exp
Med 111:387-406.

123.

Fodor E, Devenish L, Engelhardt OG, Palese P, Brownlee GG, Garcia-Sastre A.
1999. Rescue of influenza A virus from recombinant DNA. J Virol 73:9679-82.

124.

Neumann G, Watanabe T, Ito H, Watanabe S, Goto H, Gao P, Hughes M, Perez
DR, Donis R, Hoffmann E, Hobom G, Kawaoka Y. 1999. Generation of influenza
A viruses entirely from cloned cDNAs. Proc Natl Acad Sci U S A 96:9345-50.

125.

Nicolson C, Major D, Wood JM, Robertson JS. 2005. Generation of influenza
vaccine viruses on Vero cells by reverse genetics: an H5N1 candidate vaccine
strain produced under a quality system. Vaccine 23:2943-52.

126.

Horimoto T, Murakami S, Muramoto Y, Yamada S, Fujii K, Kiso M, IwatsukiHorimoto K, Kino Y, Kawaoka Y. 2007. Enhanced growth of seed viruses for
H5N1 influenza vaccines. Virology 366:23-7.

127.

Fulvini AA, Ramanunninair M, Le J, Pokorny BA, Arroyo JM, Silverman J,
Devis R, Bucher D. 2011. Gene constellation of influenza A virus reassortants
with high growth phenotype prepared as seed candidates for vaccine production.
PLoS One 6:e20823.

128.

Ottmann M, Duchamp MB, Casalegno JS, Frobert E, Moules V, Ferraris O,
Valette M, Escuret V, Lina B. 2010. Novel influenza A(H1N1) 2009 in vitro
reassortant viruses with oseltamivir resistance. Antivir Ther 15:721-6.
176

129.

Gambaryan AS, Robertson JS, Matrosovich MN. 1999. Effects of egg-adaptation
on the receptor-binding properties of human influenza A and B viruses. Virology
258:232-9.

130.

Robertson JS, Bootman JS, Newman R, Oxford JS, Daniels RS, Webster RG,
Schild GC. 1987. Structural changes in the haemagglutinin which accompany egg
adaptation of an influenza A(H1N1) virus. Virology 160:31-7.

131.

Rogers GN, Paulson JC, Daniels RS, Skehel JJ, Wilson IA, Wiley DC. 1983.
Single amino acid substitutions in influenza haemagglutinin change receptor
binding specificity. Nature 304:76-8.

132.

Widjaja L, Ilyushina N, Webster RG, Webby RJ. 2006. Molecular changes
associated with adaptation of human influenza A virus in embryonated chicken
eggs. Virology 350:137-45.

133.

Adamo JE, Liu T, Schmeisser F, Ye Z. 2009. Optimizing viral protein yield of
influenza virus strain A/Vietnam/1203/2004 by modification of the neuraminidase
gene. J Virol 83:4023-9.

134.

Harvey R, Guilfoyle KA, Roseby S, Robertson JS, Engelhardt OG. 2011.
Improved antigen yield in pandemic H1N1 (2009) candidate vaccine viruses with
chimeric hemagglutinin molecules. J Virol 85:6086-90.

135.

Harvey R, Nicolson C, Johnson RE, Guilfoyle KA, Major DL, Robertson JS,
Engelhardt OG. 2010. Improved haemagglutinin antigen content in H5N1
candidate vaccine viruses with chimeric haemagglutinin molecules. Vaccine
28:8008-14.

136.

Pan W, Dong Z, Meng W, Zhang W, Li T, Li C, Zhang B, Chen L. 2012.
Improvement of influenza vaccine strain A/Vietnam/1194/2004 (H5N1) growth
with the neuraminidase packaging sequence from A/Puerto Rico/8/34. Hum
Vaccin Immunother 8:252-9.

137.

Jing X, Phy K, Li X, Ye Z. 2012. Increased hemagglutinin content in a reassortant
2009 pandemic H1N1 influenza virus with chimeric neuraminidase containing
donor A/Puerto Rico/8/34 virus transmembrane and stalk domains. Vaccine
30:4144-52.

138.

Gomila RC, Suphaphiphat P, Judge C, Spencer T, Ferrari A, Wen Y, Palladino G,
Dormitzer PR, Mason PW. 2013. Improving influenza virus backbones by
including terminal regions of MDCK-adapted strains on hemagglutinin and
neuraminidase gene segments. Vaccine 31:4736-43.

139.

Ilyushina NA, Khalenkov AM, Seiler JP, Forrest HL, Bovin NV, Marjuki H,
Barman S, Webster RG, Webby RJ. 2010. Adaptation of pandemic H1N1
influenza viruses in mice. J Virol 84:8607-16.
177

140.

Ye J, Sorrell EM, Cai Y, Shao H, Xu K, Pena L, Hickman D, Song H, Angel M,
Medina RA, Manicassamy B, Garcia-Sastre A, Perez DR. 2010. Variations in the
hemagglutinin of the 2009 H1N1 pandemic virus: potential for strains with altered
virulence phenotype? PLoS Pathog 6:e1001145.

141.

Xu R, Krause JC, McBride R, Paulson JC, Crowe JE, Jr., Wilson IA. 2013. A
recurring motif for antibody recognition of the receptor-binding site of influenza
hemagglutinin. Nat Struct Mol Biol 20:363-70.

142.

Schymkowitz JW, Rousseau F, Martins IC, Ferkinghoff-Borg J, Stricher F,
Serrano L. 2005. Prediction of water and metal binding sites and their affinities by
using the Fold-X force field. Proc Natl Acad Sci U S A 102:10147-52.

143.

Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC,
Ferrin TE. 2004. UCSF Chimera--a visualization system for exploratory research
and analysis. J Comput Chem 25:1605-12.

144.

Fan H, Schneidman-Duhovny D, Irwin JJ, Dong G, Shoichet BK, Sali A. 2011.
Statistical potential for modeling and ranking of protein-ligand interactions. J
Chem Inf Model 51:3078-92.

145.

Cherry JR, Lamsa MH, Schneider P, Vind J, Svendsen A, Jones A, Pedersen AH.
1999. Directed evolution of a fungal peroxidase. Nat Biotechnol 17:379-84.

146.

Cirino PC, K. M. Mayer, and D. Umeno. . 2003. Generating mutant libraries
using error-prone PCR. Methods Mol Biol 231:3-9.

147.

Daugherty PS, Chen G, Iverson BL, Georgiou G. 2000. Quantitative analysis of
the effect of the mutation frequency on the affinity maturation of single chain Fv
antibodies. Proc Natl Acad Sci U S A 97:2029-34.

148.

Wan L, Twitchett MB, Eltis LD, Mauk AG, Smith M. 1998. In vitro evolution of
horse heart myoglobin to increase peroxidase activity. Proc Natl Acad Sci U S A
95:12825-31.

149.

Zang H, Irimia A, Choi JY, Angel KC, Loukachevitch LV, Egli M, Guengerich
FP. 2006. Efficient and high fidelity incorporation of dCTP opposite 7,8-dihydro8-oxodeoxyguanosine by Sulfolobus solfataricus DNA polymerase Dpo4. J Biol
Chem 281:2358-72.

150.

Imai M, Watanabe T, Hatta M, Das SC, Ozawa M, Shinya K, Zhong G, Hanson
A, Katsura H, Watanabe S, Li C, Kawakami E, Yamada S, Kiso M, Suzuki Y,
Maher EA, Neumann G, Kawaoka Y. 2012. Experimental adaptation of an
influenza H5 HA confers respiratory droplet transmission to a reassortant H5
HA/H1N1 virus in ferrets. Nature 486:420-8.
178

151.

Wu NC, Young AP, Dandekar S, Wijersuriya H, Al-Mawsawi LQ, Wu TT, Sun
R. 2013. Systematic identification of H274Y compensatory mutations in influenza
A virus neuraminidase by high-throughput screening. J Virol 87:1193-9.

152.

Wagner R, Matrosovich M, Klenk HD. 2002. Functional balance between
haemagglutinin and neuraminidase in influenza virus infections. Rev Med Virol
12:159-66.

153.

Hartgroves LC, Koudstaal W, McLeod C, Moncorge O, Thompson CI, Ellis J,
Bull C, Havenga MJ, Goudsmit J, Barclay WS. 2010. Rapid generation of a wellmatched vaccine seed from a modern influenza A virus primary isolate without
recourse to eggs. Vaccine 28:2973-9.

154.

Lugovtsev VY, Vodeiko GM, Levandowski RA. 2005. Mutational pattern of
influenza B viruses adapted to high growth replication in embryonated eggs.
Virus Res 109:149-57.

155.

Li Y, Myers JL, Bostick DL, Sullivan CB, Madara J, Linderman SL, Liu Q,
Carter DM, Wrammert J, Esposito S, Principi N, Plotkin JB, Ross TM, Ahmed R,
Wilson PC, Hensley SE. 2013. Immune history shapes specificity of pandemic
H1N1 influenza antibody responses. J Exp Med 210:1493-500.

156.

Meroz D, Yoon SW, Ducatez MF, Fabrizio TP, Webby RJ, Hertz T, Ben-Tal N.
2011. Putative amino acid determinants of the emergence of the 2009 influenza A
(H1N1) virus in the human population. Proc Natl Acad Sci U S A 108:13522-7.

157.

Koel BF, Burke DF, Bestebroer TM, van der Vliet S, Zondag GC, Vervaet G,
Skepner E, Lewis NS, Spronken MI, Russell CA, Eropkin MY, Hurt AC, Barr IG,
de Jong JC, Rimmelzwaan GF, Osterhaus AD, Fouchier RA, Smith DJ. 2013.
Substitutions near the receptor binding site determine major antigenic change
during influenza virus evolution. Science 342:976-9.

158.

O'Donnell CD, Vogel L, Wright A, Das SR, Wrammert J, Li GM, McCausland
M, Zheng NY, Yewdell JW, Ahmed R, Wilson PC, Subbarao K. 2012. Antibody
pressure by a human monoclonal antibody targeting the 2009 pandemic H1N1
virus hemagglutinin drives the emergence of a virus with increased virulence in
mice. MBio 3.

159.

Krause JC, Tsibane T, Tumpey TM, Huffman CJ, Basler CF, Crowe JE, Jr. 2011.
A broadly neutralizing human monoclonal antibody that recognizes a conserved,
novel epitope on the globular head of the influenza H1N1 virus hemagglutinin. J
Virol 85:10905-8.

179

160.

Whittle JR, Zhang R, Khurana S, King LR, Manischewitz J, Golding H,
Dormitzer PR, Haynes BF, Walter EB, Moody MA, Kepler TB, Liao HX,
Harrison SC. 2011. Broadly neutralizing human antibody that recognizes the
receptor-binding pocket of influenza virus hemagglutinin. Proc Natl Acad Sci U S
A 108:14216-21.

161.

Thompson WW, Shay DK, Weintraub E, Brammer L, Bridges CB, Cox NJ,
Fukuda K. 2004. Influenza-associated hospitalizations in the United States.
JAMA 292:1333-40.

162.

Muennig PA, Khan K. 2001. Cost-effectiveness of vaccination versus treatment
of influenza in healthy adolescents and adults. Clin Infect Dis 33:1879-85.

163.

Lambert LC, Fauci AS. 2010. Influenza vaccines for the future. N Engl J Med
363:2036-44.

164.

Milian E, Kamen AA. 2015. Current and emerging cell culture manufacturing
technologies for influenza vaccines. Biomed Res Int 2015:504831.

165.

Gambaryan AS, Marinina VP, Tuzikov AB, Bovin NV, Rudneva IA, Sinitsyn
BV, Shilov AA, Matrosovich MN. 1998. Effects of host-dependent glycosylation
of hemagglutinin on receptor-binding properties on H1N1 human influenza A
virus grown in MDCK cells and in embryonated eggs. Virology 247:170-7.

166.

Katz JM, Naeve CW, Webster RG. 1987. Host cell-mediated variation in H3N2
influenza viruses. Virology 156:386-95.

167.

Meyer WJ, Wood JM, Major D, Robertson JS, Webster RG, Katz JM. 1993.
Influence of host cell-mediated variation on the international surveillance of
influenza A (H3N2) viruses. Virology 196:130-7.

168.

Schild GC, Oxford JS, de Jong JC, Webster RG. 1983. Evidence for host-cell
selection of influenza virus antigenic variants. Nature 303:706-9.

169.

Davies R, Pepys J. 1976. Egg allergy, influenza vaccine, and immunoglobulin E
antibody. J Allergy Clin Immunol 57:373-83.

170.

Perdue ML, Arnold F, Li S, Donabedian A, Cioce V, Warf T, Huebner R. 2011.
The future of cell culture-based influenza vaccine production. Expert Rev
Vaccines 10:1183-94.

171.

Chu C, Lugovtsev V, Golding H, Betenbaugh M, Shiloach J. 2009. Conversion of
MDCK cell line to suspension culture by transfecting with human siat7e gene and
its application for influenza virus production. Proc Natl Acad Sci U S A
106:14802-7.
180

172.

Halperin SA, Smith B, Mabrouk T, Germain M, Trepanier P, Hassell T, Treanor
J, Gauthier R, Mills EL. 2002. Safety and immunogenicity of a trivalent,
inactivated, mammalian cell culture-derived influenza vaccine in healthy adults,
seniors, and children. Vaccine 20:1240-7.

173.

Kistner O, Barrett PN, Mundt W, Reiter M, Schober-Bendixen S, Dorner F. 1998.
Development of a mammalian cell (Vero) derived candidate influenza virus
vaccine. Vaccine 16:960-8.

174.

Lau SC, Scholtissek C. 1995. Abortive infection of Vero cells by an influenza A
virus (FPV). Virology 212:225-31.

175.

Nakamura K, Homma M. 1981. Protein synthesis in Vero cells abortively infected
with influenza B virus. J Gen Virol 56:199-202.

176.

Rambhia KJ, Watson M, Sell TK, Waldhorn R, Toner E. 2010. Mass vaccination
for the 2009 H1N1 pandemic: approaches, challenges, and recommendations.
Biosecur Bioterror 8:321-30.

177.

Cobbin JC, Verity EE, Gilbertson BP, Rockman SP, Brown LE. 2013. The source
of the PB1 gene in influenza vaccine reassortants selectively alters the
hemagglutinin content of the resulting seed virus. J Virol 87:5577-85.

178.

Hoffmann E, Krauss S, Perez D, Webby R, Webster RG. 2002. Eight-plasmid
system for rapid generation of influenza virus vaccines. Vaccine 20:3165-70.

179.

Hu W, Zhang H, Han Q, Li L, Chen Y, Xia N, Chen Z, Shu Y, Xu K, Sun B.
2015. A Vero-cell-adapted vaccine donor strain of influenza A virus generated by
serial passages. Vaccine 33:374-81.

180.

Liu M, Liu CG, Zhang Y, Shi WL, Wang W, Liu YY. 2012. Efficacy of a highyield attenuated vaccine strain wholly derived from avian influenza viruses by use
of reverse genetics. Vet Microbiol 161:43-8.

181.

Suphaphiphat P, Franti M, Hekele A, Lilja A, Spencer T, Settembre E, Palmer G,
Crotta S, Tuccino AB, Keiner B, Trusheim H, Balabanis K, Sackal M, Rothfeder
M, Mandl CW, Dormitzer PR, Mason PW. 2010. Mutations at positions 186 and
194 in the HA gene of the 2009 H1N1 pandemic influenza virus improve
replication in cell culture and eggs. Virol J 7:157.

182.

Hamamoto I, Takaku H, Tashiro M, Yamamoto N. 2013. High yield production
of influenza virus in Madin Darby canine kidney (MDCK) cells with stable
knockdown of IRF7. PLoS One 8:e59892.

183.

Brandau DT, Jones LS, Wiethoff CM, Rexroad J, Middaugh CR. 2003. Thermal
stability of vaccines. J Pharm Sci 92:218-31.
181

184.

O'Donnell CD, Vogel L, Matsuoka Y, Jin H, Subbarao K. 2014. The matrix gene
segment destabilizes the acid and thermal stability of the hemagglutinin of
pandemic live attenuated influenza virus vaccines. J Virol 88:12374-84.

185.

Rudneva IA, Timofeeva TA, Ignatieva AV, Shilov AA, Ilyushina NA. 2016.
Effects of hemagglutinin amino acid substitutions in H9 influenza A virus escape
mutants. Arch Virol doi:10.1007/s00705-016-3038-x.

186.

Ye J, Wen F, Xu Y, Zhao N, Long L, Sun H, Yang J, Cooley J, Todd Pharr G,
Webby R, Wan XF. 2015. Error-prone pcr-based mutagenesis strategy for rapidly
generating high-yield influenza vaccine candidates. Virology 482:234-43.

187.

Organization WH. 2011. Manual for the laboratory diagnosis and virological
surveillance of influenza. Geneva : World Health Organization,

188.

Li L, Liu Y, Ma C, Qu J, Calderon AD, Wu B, Wei N, Wang X, Guo Y, Xiao Z,
Song J, Sugiarto G, Li Y, Yu H, Chen X, Wang PG. 2015. Efficient
Chemoenzymatic Synthesis of an N-glycan Isomer Library. Chem Sci 6:56525661.

189.

Wu Z, Liu Y, Ma C, Li L, Bai J, Byrd-Leotis L, Lasanajak Y, Guo Y, Wen L, Zhu
H, Song J, Li Y, Steinhauer DA, Smith DF, Zhao B, Chen X, Guan W, Wang PG.
2016. Identification of the binding roles of terminal and internal glycan epitopes
using enzymatically synthesized N-glycans containing tandem epitopes. Org
Biomol Chem 14:11106-11116.

190.

Xiong X, Martin SR, Haire LF, Wharton SA, Daniels RS, Bennett MS, McCauley
JW, Collins PJ, Walker PA, Skehel JJ, Gamblin SJ. 2013. Receptor binding by an
H7N9 influenza virus from humans. Nature 499:496-9.

191.

Edgar RC. 2004. MUSCLE: multiple sequence alignment with high accuracy and
high throughput. Nucleic Acids Res 32:1792-7.

192.

Hall TA. 1999. BioEdit: a user-friendly biological sequence alignment editor and
analysis program for Windows 95/98/NT. Nucleic Acids Symposium Series
41:95-98.

193.

Skehel JJ, Wiley DC. 2000. Receptor binding and membrane fusion in virus
entry: the influenza hemagglutinin. Annu Rev Biochem 69:531-69.

194.

Chen Z, Baz M, Lu J, Paskel M, Santos C, Subbarao K, Jin H, Matsuoka Y. 2014.
Development of a high-yield live attenuated H7N9 influenza virus vaccine that
provides protection against homologous and heterologous H7 wild-type viruses in
ferrets. J Virol 88:7016-23.
182

195.

Yasugi M, Nakamura S, Daidoji T, Kawashita N, Ramadhany R, Yang CS,
Yasunaga T, Iida T, Horii T, Ikuta K, Takahashi K, Nakaya T. 2012. Frequency
of D222G and Q223R hemagglutinin mutants of pandemic (H1N1) 2009
influenza virus in Japan between 2009 and 2010. PLoS One 7:e30946.

196.

Govorkova EA, Murti G, Meignier B, de Taisne C, Webster RG. 1996. African
green monkey kidney (Vero) cells provide an alternative host cell system for
influenza A and B viruses. J Virol 70:5519-24.

197.

Ito T, Suzuki Y, Takada A, Kawamoto A, Otsuki K, Masuda H, Yamada M,
Suzuki T, Kida H, Kawaoka Y. 1997. Differences in sialic acid-galactose linkages
in the chicken egg amnion and allantois influence human influenza virus receptor
specificity and variant selection. J Virol 71:3357-62.

198.

Seo SH, Goloubeva O, Webby R, Webster RG. 2001. Characterization of a
porcine lung epithelial cell line suitable for influenza virus studies. J Virol
75:9517-25.

199.

Chen Z, Zhou H, Kim L, Jin H. 2012. The receptor binding specificity of the live
attenuated influenza H2 and H6 vaccine viruses contributes to vaccine
immunogenicity and protection in ferrets. J Virol 86:2780-6.

200.

Wang M, Tscherne DM, McCullough C, Caffrey M, Garcia-Sastre A, Rong L.
2012. Residue Y161 of influenza virus hemagglutinin is involved in viral
recognition of sialylated complexes from different hosts. J Virol 86:4455-62.

201.

Pica N, Bouvier NM. 2012. Environmental factors affecting the transmission of
respiratory viruses. Curr Opin Virol 2:90-5.

202.

Schrauwen EJ, Fouchier RA. 2014. Host adaptation and transmission of influenza
A viruses in mammals. Emerg Microbes Infect 3:e9.

203.

Watanabe Y, Arai Y, Daidoji T, Kawashita N, Ibrahim MS, El-Gendy Eel D,
Hiramatsu H, Kubota-Koketsu R, Takagi T, Murata T, Takahashi K, Okuno Y,
Nakaya T, Suzuki Y, Ikuta K. 2015. Characterization of H5N1 influenza virus
variants with hemagglutinin mutations isolated from patients. MBio 6.

204.

Morens DM, Taubenberger JK. 2010. Historical thoughts on influenza viral
ecosystems, or behold a pale horse, dead dogs, failing fowl, and sick swine.
Influenza Other Respir Viruses 4:327-37.

205.

Anthony SJ, St Leger JA, Pugliares K, Ip HS, Chan JM, Carpenter ZW,
Navarrete-Macias I, Sanchez-Leon M, Saliki JT, Pedersen J, Karesh W, Daszak P,
Rabadan R, Rowles T, Lipkin WI. 2012. Emergence of fatal avian influenza in
New England harbor seals. MBio 3:e00166-12.
183

206.

Crawford PC, Dubovi EJ, Castleman WL, Stephenson I, Gibbs EP, Chen L, Smith
C, Hill RC, Ferro P, Pompey J, Bright RA, Medina MJ, Johnson CM, Olsen CW,
Cox NJ, Klimov AI, Katz JM, Donis RO. 2005. Transmission of equine influenza
virus to dogs. Science 310:482-5.

207.

Webby RJ, Webster RG. 2001. Emergence of influenza A viruses. Philos Trans R
Soc Lond B Biol Sci 356:1817-28.

208.

Webster RG, Govorkova EA. 2014. Continuing challenges in influenza. Ann N Y
Acad Sci 1323:115-39.

209.

Ning ZY, Wu XT, Cheng YF, Qi WB, An YF, Wang H, Zhang GH, Li SJ. 2012.
Tissue distribution of sialic acid-linked influenza virus receptors in beagle dogs. J
Vet Sci 13:219-22.

210.

Daly JM, Blunden AS, Macrae S, Miller J, Bowman SJ, Kolodziejek J, Nowotny
N, Smith KC. 2008. Transmission of equine influenza virus to English foxhounds.
Emerg Infect Dis 14:461-4.

211.

Gibbs EP, Anderson TC. 2010. Equine and canine influenza: a review of current
events. Anim Health Res Rev 11:43-51.

212.

Ince WL, Gueye-Mbaye A, Bennink JR, Yewdell JW. 2013. Reassortment
complements spontaneous mutation in influenza A virus NP and M1 genes to
accelerate adaptation to a new host. J Virol 87:4330-8.

213.

Manz B, Schwemmle M, Brunotte L. 2013. Adaptation of avian influenza A virus
polymerase in mammals to overcome the host species barrier. J Virol 87:7200-9.

214.

Feng KH, Gonzalez G, Deng L, Yu H, Tse VL, Huang L, Huang K, Wasik BR,
Zhou B, Wentworth DE, Holmes EC, Chen X, Varki A, Murcia PR, Parrish CR.
2015. Equine and Canine Influenza H3N8 Viruses Show Minimal Biological
Differences Despite Phylogenetic Divergence. J Virol 89:6860-73.

215.

Rivailler P, Perry IA, Jang Y, Davis CT, Chen LM, Dubovi EJ, Donis RO. 2010.
Evolution of canine and equine influenza (H3N8) viruses co-circulating between
2005 and 2008. Virology 408:71-9.

216.

Payungporn S, Crawford PC, Kouo TS, Chen LM, Pompey J, Castleman WL,
Dubovi EJ, Katz JM, Donis RO. 2008. Influenza A virus (H3N8) in dogs with
respiratory disease, Florida. Emerg Infect Dis 14:902-8.

217.

Collins PJ, Vachieri SG, Haire LF, Ogrodowicz RW, Martin SR, Walker PA,
Xiong X, Gamblin SJ, Skehel JJ. 2014. Recent evolution of equine influenza and
the origin of canine influenza. Proc Natl Acad Sci U S A 111:11175-80.
184

218.

Hoffmann E, Stech J, Guan Y, Webster RG, Perez DR. 2001. Universal primer set
for the full-length amplification of all influenza A viruses. Arch Virol 146:227589.

219.

Hoffmann E, Neumann G, Kawaoka Y, Hobom G, Webster RG. 2000. A DNA
transfection system for generation of influenza A virus from eight plasmids. Proc
Natl Acad Sci U S A 97:6108-13.

220.

Bradley KC, Jones CA, Tompkins SM, Tripp RA, Russell RJ, Gramer MR,
Heimburg-Molinaro J, Smith DF, Cummings RD, Steinhauer DA. 2011.
Comparison of the receptor binding properties of contemporary swine isolates and
early human pandemic H1N1 isolates (Novel 2009 H1N1). Virology 413:169-82.

221.

Wen F, Li L, Zhao N, Chiang MJ, Xie H, Cooley J, Webby R, Wang PG, Wan
XF. 2017. A Y161F Hemagglutinin Substitution Increases Thermostability and
Improves Yields of 2009 H1N1 influenza A Virus in Cells. J Virol
doi:10.1128/JVI.01621-17.

222.

de Graaf M, Fouchier RA. 2014. Role of receptor binding specificity in influenza
A virus transmission and pathogenesis. EMBO J 33:823-41.

223.

Yamanaka T, Nemoto M, Tsujimura K, Kondo T, Matsumura T. 2009.
Interspecies transmission of equine influenza virus (H3N8) to dogs by close
contact with experimentally infected horses. Vet Microbiol 139:351-5.

224.

Yamanaka T, Nemoto M, Bannai H, Tsujimura K, Kondo T, Matsumura T,
Muranaka M, Ueno T, Kinoshita Y, Niwa H, Hidari KI, Suzuki T. 2012. No
evidence of horizontal infection in horses kept in close contact with dogs
experimentally infected with canine influenza A virus (H3N8). Acta Vet Scand
54:25.

225.

Quintana AM, Hussey SB, Burr EC, Pecoraro HL, Annis KM, Rao S, Landolt
GA. 2011. Evaluation of infectivity of a canine lineage H3N8 influenza A virus in
ponies and in primary equine respiratory epithelial cells. Am J Vet Res 72:1071-8.

226.

von Grotthuss M, Rychlewski L. 2006. Influenza mutation from equine to canine.
Science 311:1241-2; author reply 1241-2.

227.

Hoelzer K, Murcia PR, Baillie GJ, Wood JL, Metzger SM, Osterrieder N, Dubovi
EJ, Holmes EC, Parrish CR. 2010. Intrahost evolutionary dynamics of canine
influenza virus in naive and partially immune dogs. J Virol 84:5329-35.

228.

Gamblin SJ, Haire LF, Russell RJ, Stevens DJ, Xiao B, Ha Y, Vasisht N,
Steinhauer DA, Daniels RS, Elliot A, Wiley DC, Skehel JJ. 2004. The structure
and receptor binding properties of the 1918 influenza hemagglutinin. Science
303:1838-42.
185

229.

Nycholat CM, McBride R, Ekiert DC, Xu R, Rangarajan J, Peng W, Razi N,
Gilbert M, Wakarchuk W, Wilson IA, Paulson JC. 2012. Recognition of sialylated
poly-N-acetyllactosamine chains on N- and O-linked glycans by human and avian
influenza A virus hemagglutinins. Angew Chem Int Ed Engl 51:4860-3.

230.

Ji Y, White YJ, Hadden JA, Grant OC, Woods RJ. 2017. New insights into
influenza A specificity: an evolution of paradigms. Curr Opin Struct Biol 44:219231.

231.

van Riel D, Munster VJ, de Wit E, Rimmelzwaan GF, Fouchier RA, Osterhaus
AD, Kuiken T. 2007. Human and avian influenza viruses target different cells in
the lower respiratory tract of humans and other mammals. Am J Pathol 171:121523.

232.

Stehle T, Khan ZM. 2014. Rules and exceptions: sialic acid variants and their role
in determining viral tropism. J Virol 88:7696-9.

233.

Song D, Kang B, Lee C, Jung K, Ha G, Kang D, Park S, Park B, Oh J. 2008.
Transmission of avian influenza virus (H3N2) to dogs. Emerg Infect Dis 14:7416.

234.

Wang H, Jia K, Qi W, Zhang M, Sun L, Liang H, Du G, Tan L, Shao Z, Ye J, Sun
L, Cao Z, Chen Y, Zhou P, Su S, Li S. 2013. Genetic characterization of avianorigin H3N2 canine influenza viruses isolated from Guangdong during 20062012. Virus Genes 46:558-62.

235.

Voorhees IEH, Glaser AL, Toohey-Kurth K, Newbury S, Dalziel BD, Dubovi EJ,
Poulsen K, Leutenegger C, Willgert KJE, Brisbane-Cohen L, Richardson-Lopez J,
Holmes EC, Parrish CR. 2017. Spread of Canine Influenza A(H3N2) Virus,
United States. Emerg Infect Dis 23.

236.

Pulit-Penaloza JA, Simpson N, Yang H, Creager HM, Jones J, Carney P, Belser
JA, Yang G, Chang J, Zeng H, Thor S, Jang Y, Killian ML, Jenkins-Moore M,
Janas-Martindale A, Dubovi E, Wentworth DE, Stevens J, Tumpey TM, Davis
CT, Maines TR. 2017. Assessment of Molecular, Antigenic, and Pathological
Features of Canine Influenza A(H3N2) Viruses That Emerged in the United
States. J Infect Dis 216:S499-S507.

237.

Matrosovich M, Tuzikov A, Bovin N, Gambaryan A, Klimov A, Castrucci MR,
Donatelli I, Kawaoka Y. 2000. Early alterations of the receptor-binding properties
of H1, H2, and H3 avian influenza virus hemagglutinins after their introduction
into mammals. J Virol 74:8502-12.

238.

Belser JA, Jayaraman A, Raman R, Pappas C, Zeng H, Cox NJ, Katz JM,
Sasisekharan R, Tumpey TM. 2011. Effect of D222G mutation in the
hemagglutinin protein on receptor binding, pathogenesis and transmissibility of
the 2009 pandemic H1N1 influenza virus. PLoS One 6:e25091.
186

239.

Hensley SE, Das SR, Bailey AL, Schmidt LM, Hickman HD, Jayaraman A,
Viswanathan K, Raman R, Sasisekharan R, Bennink JR, Yewdell JW. 2009.
Hemagglutinin receptor binding avidity drives influenza A virus antigenic drift.
Science 326:734-6.

240.

Li Y, Bostick DL, Sullivan CB, Myers JL, Griesemer SB, Stgeorge K, Plotkin JB,
Hensley SE. 2013. Single hemagglutinin mutations that alter both antigenicity and
receptor binding avidity influence influenza virus antigenic clustering. J Virol
87:9904-10.

241.

Lewis NS, Anderson TK, Kitikoon P, Skepner E, Burke DF, Vincent AL. 2014.
Substitutions near the hemagglutinin receptor-binding site determine the antigenic
evolution of influenza A H3N2 viruses in U.S. swine. J Virol 88:4752-63.

242.

Harper SA, Fukuda K, Uyeki TM, Cox NJ, Bridges CB. 2004. Prevention and
control of influenza: recommendations of the Advisory Committee on
Immunization Practices (ACIP). MMWR Recomm Rep 53:1-40.

243.

Cai Z, Ducatez MF, Yang J, Zhang T, Long LP, Boon AC, Webby RJ, Wan XF.
2012. Identifying antigenicity-associated sites in highly pathogenic H5N1
influenza virus hemagglutinin by using sparse learning. J Mol Biol 422:145-55.

244.

Yang J, Zhang T, Wan XF. 2014. Sequence-based antigenic change prediction by
a sparse learning method incorporating co-evolutionary information. PLoS One
9:e106660.

245.

Han L, Zhang Y, Wan XF, Zhang T. 2016. Generalized Hierarchical Sparse
Model for Arbitrary-Order Interactive Antigenic Sites Identification in Flu Virus
Data. KDD 2016:865-874.

246.

Han L, Li L, Wen F, Zhong L, Zhang T, Wan XF. 2018. Graph-Guided MultiTask Sparse Learning Model: a Method for Identifying Antigenic Variants of
Influenza A(H3N2) Virus. Bioinformatics doi:10.1093/bioinformatics/bty457.

247.

Xu R, McBride R, Nycholat CM, Paulson JC, Wilson IA. 2012. Structural
characterization of the hemagglutinin receptor specificity from the 2009 H1N1
influenza pandemic. J Virol 86:982-90.

248.

Matrosovich MN, Gambaryan AS, Teneberg S, Piskarev VE, Yamnikova SS,
Lvov DK, Robertson JS, Karlsson KA. 1997. Avian influenza A viruses differ
from human viruses by recognition of sialyloligosaccharides and gangliosides and
by a higher conservation of the HA receptor-binding site. Virology 233:224-34.

249.

Popova L, Smith K, West AH, Wilson PC, James JA, Thompson LF, Air GM.
2012. Immunodominance of antigenic site B over site A of hemagglutinin of
recent H3N2 influenza viruses. PLoS One 7:e41895.
187

250.

Wang X, Ilyushina NA, Lugovtsev VY, Bovin NV, Couzens LK, Gao J, Donnelly
RP, Eichelberger MC, Wan H. 2017. Amino Acids in Hemagglutinin Antigenic
Site B Determine Antigenic and Receptor Binding Differences between
A(H3N2)v and Ancestral Seasonal H3N2 Influenza Viruses. J Virol 91.

251.

Lee MS, Chen JS. 2004. Predicting antigenic variants of influenza A/H3N2
viruses. Emerg Infect Dis 10:1385-90.

252.

He L, Jiang K, Wu Q, Duan Z, Xu H, Liu J, Cui Z, Gu M, Wang X, Liu X, Liu X.
2014. Two amino acid substitutions in the haemagglutinin of the 2009 pandemic
H1N1 virus decrease direct-contact transmission in guinea pigs. J Gen Virol
95:2612-7.

253.

Linderman SL, Chambers BS, Zost SJ, Parkhouse K, Li Y, Herrmann C, Ellebedy
AH, Carter DM, Andrews SF, Zheng NY, Huang M, Huang Y, Strauss D, Shaz
BH, Hodinka RL, Reyes-Teran G, Ross TM, Wilson PC, Ahmed R, Bloom JD,
Hensley SE. 2014. Potential antigenic explanation for atypical H1N1 infections
among middle-aged adults during the 2013-2014 influenza season. Proc Natl
Acad Sci U S A 111:15798-803.

254.

Xu R, Ekiert DC, Krause JC, Hai R, Crowe JE, Jr., Wilson IA. 2010. Structural
basis of preexisting immunity to the 2009 H1N1 pandemic influenza virus.
Science 328:357-60.

255.

Wormann X, Lesch M, Welke RW, Okonechnikov K, Abdurishid M, Sieben C,
Geissner A, Brinkmann V, Kastner M, Karner A, Zhu R, Hinterdorfer P, Anish C,
Seeberger PH, Herrmann A, Meyer TF, Karlas A. 2016. Genetic characterization
of an adapted pandemic 2009 H1N1 influenza virus that reveals improved
replication rates in human lung epithelial cells. Virology 492:118-29.

256.

Zhang W, Shi Y, Qi J, Gao F, Li Q, Fan Z, Yan J, Gao GF. 2013. Molecular basis
of the receptor binding specificity switch of the hemagglutinins from both the
1918 and 2009 pandemic influenza A viruses by a D225G substitution. J Virol
87:5949-58.

188

